BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bang Y, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang Y. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet 2010;376:687-97. [DOI: 10.1016/s0140-6736(10)61121-x] [Cited by in Crossref: 3820] [Cited by in F6Publishing: 2177] [Article Influence: 318.3] [Reference Citation Analysis]
Number Citing Articles
1 Martín-Richard M, Carmona-Bayonas A, Custodio AB, Gallego J, Jiménez-Fonseca P, Reina JJ, Richart P, Rivera F, Alsina M, Sastre J. SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019). Clin Transl Oncol 2020;22:236-44. [PMID: 31989475 DOI: 10.1007/s12094-019-02259-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
2 Svensson MC, Borg D, Zhang C, Hedner C, Nodin B, Uhlén M, Mardinoglu A, Leandersson K, Jirström K. Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival. Front Oncol 2019;9:136. [PMID: 30931254 DOI: 10.3389/fonc.2019.00136] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
3 Creemers A, Ter Veer E, de Waal L, Lodder P, Hooijer GKJ, van Grieken NCT, Bijlsma MF, Meijer SL, van Oijen MGH, van Laarhoven HWM. Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis. Sci Rep 2017;7:3135. [PMID: 28600510 DOI: 10.1038/s41598-017-03304-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
4 Nakamichi N, Tsujiura M, Matsui T, Yamamoto T, Yoshioka A, Hiramoto H, Ouchi Y, Ishimoto T, Kosuga T, Mochizuki S, Nakashima S, Bamba M, Masuyama M, Otsuji E. The therapeutic strategy for advanced gastric cancer with pyloric stenosis and liver metastasis; successfully treated by gastro-jejunal bypass and chemotherapy first, followed by curative R0 resection. Surg Case Rep 2021;7:6. [PMID: 33409765 DOI: 10.1186/s40792-020-00979-7] [Reference Citation Analysis]
5 Shimazu K, Fukuda K, Yoshida T, Inoue M, Shibata H. High circulating tumor cell concentrations in a specific subtype of gastric cancer with diffuse bone metastasis at diagnosis. World J Gastroenterol 2016; 22(26): 6083-6088 [PMID: 27468200 DOI: 10.3748/wjg.v22.i26.6083] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Isharwal S, Huang H, Nanjangud G, Audenet F, Chen YB, Gopalan A, Fine SW, Tickoo SK, Lee BH, Iyer G, Chadalavada K, Rosenberg JE, Bajorin DF, Herr HW, Donat SM, Dalbagni G, Bochner BH, Solit DB, Reuter VE, Al-Ahmadie HA. Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Hum Pathol 2018;77:63-9. [PMID: 29601842 DOI: 10.1016/j.humpath.2018.03.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
7 Yee EK, Coburn NG, Zuk V, Davis LE, Mahar AL, Liu Y, Gupta V, Darling G, Hallet J. Geographic impact on access to care and survival for non-curative esophagogastric cancer: a population-based study. Gastric Cancer 2021;24:790-9. [PMID: 33550518 DOI: 10.1007/s10120-021-01157-w] [Reference Citation Analysis]
8 Klempner SJ, Bhangoo MS, Luu HY, Kim ST, Chao J, Kim KM, Lee J. Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy. J Gastrointest Oncol 2018;9:1198-206. [PMID: 30603142 DOI: 10.21037/jgo.2018.09.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Nelson B. Buying time in gastric cancer. Cancer Cytopathol 2010;118:414. [PMID: 21240994 DOI: 10.1002/cncy.20129] [Reference Citation Analysis]
10 Halmos B, Jia Y, Bokar JA, Fu P, Adelstein DJ, Juergens R, Rodal MB, Dowlati A. A Phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer. Invest New Drugs 2013;31:1244-50. [PMID: 23553066 DOI: 10.1007/s10637-013-9945-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
11 Angerilli V, Galuppini F, Businello G, Dal Santo L, Savarino E, Realdon S, Guzzardo V, Nicolè L, Lazzarin V, Lonardi S, Loupakis F, Fassan M. MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. Biomedicines 2021;9:318. [PMID: 33801049 DOI: 10.3390/biomedicines9030318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Sun Z, Liu C, Jiang WG, Ye L. Deregulated bone morphogenetic proteins and their receptors are associated with disease progression of gastric cancer. Comput Struct Biotechnol J 2020;18:177-88. [PMID: 31988704 DOI: 10.1016/j.csbj.2019.12.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
13 Kaltsidis H, Mansoor W, Park JH, Song HY, Edwards DW, Laasch HU. Oesophageal stenting: Status quo and future challenges. Br J Radiol 2018;91:20170935. [PMID: 29888981 DOI: 10.1259/bjr.20170935] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Boku N, Muro K, Machida N, Hashigaki S, Kimura N, Suzuki M, Lechuga M, Miyata Y. Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer. Invest New Drugs. 2014;32:261-270. [PMID: 23665950 DOI: 10.1007/s10637-013-9948-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
15 Zou K, Yang S, Zheng L, Yang C, Xiong B. Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review. BMC Cancer 2016;16:737. [PMID: 27633381 DOI: 10.1186/s12885-016-2772-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
16 Ko BK, Lee SY, Lee YH, Hwang IS, Persson H, Rockberg J, Borrebaeck C, Park D, Kim KT, Uhlen M, Lee JS. Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer. Mol Oncol 2015;9:398-408. [PMID: 25306393 DOI: 10.1016/j.molonc.2014.09.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
17 Oono Y, Kuwata T, Takashima K, Shinmura K, Hori K, Yoda Y, Ikematsu H, Shitara K, Kinoshita T, Yano T. Human epidermal growth factor receptor 2-, epidermal growth factor receptor-, and mesenchymal epithelial transition factor-positive sites of gastric cancer using surgical samples. Gastric Cancer 2019;22:335-43. [PMID: 29951752 DOI: 10.1007/s10120-018-0853-7] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Kang Y, Chen L, Ryu M, Oh D, Oh SC, Chung HC, Lee K, Omori T, Shitara K, Sakuramoto S, Chung I, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen J, Bai L, Oh S, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(21)00692-6] [Reference Citation Analysis]
19 Shen J, Kong W, Wu Y, Ren H, Wei J, Yang Y, Yang Y, Yu L, Guan W, Liu B. Plasma mRNA as liquid biopsy predicts chemo-sensitivity in advanced gastric cancer patients. J Cancer 2017;8:434-42. [PMID: 28261345 DOI: 10.7150/jca.17369] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
20 Klempner SJ, Maron SB, Chase L, Lomnicki S, Wainberg ZA, Catenacci DVT. Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis. Oncologist 2019;24:475-82. [PMID: 30470690 DOI: 10.1634/theoncologist.2018-0602] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
21 Baniak N, Senger JL, Ahmed S, Kanthan SC, Kanthan R. Gastric biomarkers: a global review. World J Surg Oncol. 2016;14:212. [PMID: 27514667 DOI: 10.1186/s12957-016-0969-3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 9.2] [Reference Citation Analysis]
22 Murphy A, Kelly RJ. From molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancer. Gastroenterol Res Pract 2015;2015:896560. [PMID: 25784931 DOI: 10.1155/2015/896560] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
23 Chen XZ, Zhang WH, Chen HN, Liu JP, He D, Liu Y, Liu K, Chen XL, Mo XM, Zhou ZG, Hu JK. Associations between serum CA724 and HER2 overexpression among stage II-III resectable gastric cancer patients: an observational study. Oncotarget 2016;7:23647-57. [PMID: 27027339 DOI: 10.18632/oncotarget.8145] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
24 Chae YK, Arya A, Chiec L, Shah H, Rosenberg A, Patel S, Raparia K, Choi J, Wainwright DA, Villaflor V. Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy? Oncotarget. 2017;8:100863-100898. [PMID: 29246028 DOI: 10.18632/oncotarget.19809] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
25 Hashimoto T, Kurokawa Y, Wada N, Takahashi T, Miyazaki Y, Tanaka K, Makino T, Yamasaki M, Nakajima K, Mori M, Doki Y. Clinical significance of chromatin remodeling factor CHD5 expression in gastric cancer. Oncol Lett 2020;19:1066-73. [PMID: 31897220 DOI: 10.3892/ol.2019.11138] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Zhu GJ, Xu CW, Fang MY, Zhang YP, Li Y. Detection of Her-2/neu expression in gastric cancer: Quantitative PCR versus immunohistochemistry. Exp Ther Med 2014;8:1501-7. [PMID: 25289049 DOI: 10.3892/etm.2014.1982] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
27 Zhou X, Wang Y, Shan B, Han J, Zhu H, Lv Y, Fan X, Sang M, Liu XD, Liu W. The downregulation of miR-200c/141 promotes ZEB1/2 expression and gastric cancer progression. Med Oncol. 2015;32:428. [PMID: 25502084 DOI: 10.1007/s12032-014-0428-3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
28 Lee SW, Lee T, Sul HJ, Park KC, Park J. Differences in Somatic Mutation Profiles between Korean Gastric Cancer and Gastric Adenoma Patients. J Clin Med 2021;10:2038. [PMID: 34068652 DOI: 10.3390/jcm10092038] [Reference Citation Analysis]
29 Patil PS, Mehta SA, Mohandas KM. Over-expression of HER2 in Indian patients with gastric cancer. Indian J Gastroenterol 2013;32:350. [PMID: 23111642 DOI: 10.1007/s12664-012-0279-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
30 Nam S. Cancer Transcriptome Dataset Analysis: Comparing Methods of Pathway and Gene Regulatory Network-Based Cluster Identification. OMICS 2017;21:217-24. [PMID: 28388297 DOI: 10.1089/omi.2016.0169] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
31 Peterson A, Jiang Q, Chu XP. Commentary: Potential Therapeutic Consequences of an Acid-Sensing Ion Channel 1a-Blocking Antibody. Front Pharmacol 2019;10:954. [PMID: 31544902 DOI: 10.3389/fphar.2019.00954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Damasceno EA, Carneiro FP, Magalhães AV, Carneiro Mde V, Takano GH, Vianna LM, Seidler HB, Castro TM, Muniz-Junqueira MI, Amorim RF, Ferreira VM, Motoyama AB. IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status. J Cancer Res Clin Oncol 2014;140:2163-8. [PMID: 25323937 DOI: 10.1007/s00432-014-1850-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
33 Javle M, Smyth EC, Chau I. Ramucirumab: successfully targeting angiogenesis in gastric cancer. Clin Cancer Res 2014;20:5875-81. [PMID: 25281695 DOI: 10.1158/1078-0432.CCR-14-1071] [Cited by in Crossref: 41] [Cited by in F6Publishing: 22] [Article Influence: 5.1] [Reference Citation Analysis]
34 Nam S. Databases and tools for constructing signal transduction networks in cancer. BMB Rep 2017;50:12-9. [PMID: 27502015 DOI: 10.5483/bmbrep.2017.50.1.135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
35 Weinberg BA, Xiu J, Hwang JJ, Shields AF, Salem ME, Marshall JL. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. Oncologist 2018;23:1171-7. [PMID: 29703766 DOI: 10.1634/theoncologist.2018-0034] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
36 Katona BW, Rustgi AK. Gastric Cancer Genomics: Advances and Future Directions. Cell Mol Gastroenterol Hepatol. 2017;3:211-217. [PMID: 28275688 DOI: 10.1016/j.jcmgh.2017.01.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 7.4] [Reference Citation Analysis]
37 Bai ZG, Zhang ZT. A systematic review and meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer. Onco Targets Ther 2018;11:7077-87. [PMID: 30410364 DOI: 10.2147/OTT.S169484] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
38 Davern M, Donlon NE, Power R, Hayes C, King R, Dunne MR, Reynolds JV. The tumour immune microenvironment in oesophageal cancer. Br J Cancer 2021;125:479-94. [PMID: 33903730 DOI: 10.1038/s41416-021-01331-y] [Reference Citation Analysis]
39 Yang G, Jian L, Lin X, Zhu A, Wen G. Bioinformatics Analysis of Potential Key Genes in Trastuzumab-Resistant Gastric Cancer. Dis Markers 2019;2019:1372571. [PMID: 31949544 DOI: 10.1155/2019/1372571] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
40 Al-Batran SE, Moorahrend E, Maintz C, Goetze TO, Hempel D, Thuss-Patience P, Gaillard VE, Hegewisch-Becker S. Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. Oncologist 2020;25:e1181-7. [PMID: 32311799 DOI: 10.1634/theoncologist.2020-0109] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
41 Boekhout AH, Beijnen JH, Schellens JH. Trastuzumab. Oncologist 2011;16:800-10. [PMID: 21632460 DOI: 10.1634/theoncologist.2010-0035] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
42 Horinouchi T, Yoshida N, Matsumoto C, Hara Y, Toihata T, Iwatsuki M, Baba Y, Miyamoto Y, Baba H. Human Epidermal Growth Factor Receptor 2-positive Primary Adenocarcinoma in the Cervical Oesophagus: A Case Report. In Vivo 2021;35:2297-303. [PMID: 34182509 DOI: 10.21873/invivo.12503] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Yokoyama D, Hisamori S, Deguchi Y, Nishigori T, Okabe H, Kanaya S, Manaka D, Kadokawa Y, Hata H, Minamiguchi S, Tsunoda S, Obama K, Sakai Y. PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma. Sci Rep 2021;11:9013. [PMID: 33907203 DOI: 10.1038/s41598-021-88331-3] [Reference Citation Analysis]
44 Cavaliere A, Merz V, Casalino S, Zecchetto C, Simionato F, Salt HL, Contarelli S, Santoro R, Melisi D. Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer. J Gastric Cancer 2019;19:375-92. [PMID: 31897341 DOI: 10.5230/jgc.2019.19.e39] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
45 Haas M, Büttner M, Rau TT, Fietkau R, Grabenbauer GG, Distel LV. Inflammation in gastric adenocarcinoma of the cardia: how do EBV infection, Her2 amplification and cancer progression influence tumor-infiltrating lymphocytes? Virchows Arch. 2011;458:403-411. [PMID: 21359545 DOI: 10.1007/s00428-011-1058-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
46 Bando H, Rubinstein L, Harris P, Yoshino T, Doi T, Ohtsu A, Welch J, Takebe N. Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials. Gastric Cancer 2017;20:481-8. [PMID: 27510411 DOI: 10.1007/s10120-016-0629-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Cappuzzo F, Cho YG, Sacconi A, Alì G, Siclari O, Incarbone M, Destro A, Terracciano L, Fontanini G, Marchetti A, Roncalli M, Varella-Garcia M. p95HER2 truncated form in resected non-small cell lung cancer. J Thorac Oncol 2012;7:520-7. [PMID: 22307009 DOI: 10.1097/JTO.0b013e318249e13f] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
48 He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, Shen ZY, Liu Q. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol 2013; 19(14): 2171-2178 [PMID: 23599643 DOI: 10.3748/wjg.v19.i14.2171] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 56] [Article Influence: 5.7] [Reference Citation Analysis]
49 Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 2011;8:492-503. [DOI: 10.1038/nrclinonc.2011.45] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 9.8] [Reference Citation Analysis]
50 Di Maio M, Perrone F, Conte P. Real-World Evidence in Oncology: Opportunities and Limitations. Oncologist 2020;25:e746-52. [PMID: 31872939 DOI: 10.1634/theoncologist.2019-0647] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
51 Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Brägelmann J, Seiwert T. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011;12:9-46. [PMID: 21543897 DOI: 10.4161/cbt.12.1.15747] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 6.0] [Reference Citation Analysis]
52 Takahama T, Takeda M, Nishina S, Nakagawa K. A case of severe cerebral embolism after chemotherapy for HER2-positive gastric cancer. BMC Res Notes 2015;8:100. [PMID: 25885256 DOI: 10.1186/s13104-015-1059-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
53 Pasini F, Fraccon AP, Modena Y, Bencivenga M, Giacopuzzi S, La Russa F, Gusella M, de Manzoni G. Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new? Gastric Cancer 2017;20:31-42. [PMID: 27568322 DOI: 10.1007/s10120-016-0626-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
54 Lordick F. [Novel pharmaceutical treatment approaches for gastric cancer]. Pathologe 2017;38:87-92. [PMID: 28220199 DOI: 10.1007/s00292-017-0272-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
55 Zhang DS, Jin Y, Luo HY, Wang ZQ, Qiu MZ, Wang FH, Li YH, Xu RH. Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study. Br J Cancer. 2015;112:266-270. [PMID: 25474247 DOI: 10.1038/bjc.2014.607] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
56 Rahman R, Asombang AW, Ibdah JA. Characteristics of gastric cancer in Asia. World J Gastroenterol. 2014;20:4483-4490. [PMID: 24782601 DOI: 10.3748/wjg.v.i16.4483] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Ieni A, Cardia R, Pizzimenti C, Zeppa P, Tuccari G. HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies. J Pers Med 2020;10:E10. [PMID: 32098203 DOI: 10.3390/jpm10010010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Nagaraja AK, Kikuchi O, Bass AJ. Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma. Cancer Discov 2019;9:1656-72. [PMID: 31727671 DOI: 10.1158/2159-8290.CD-19-0487] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
59 Qiu MZ, Xu RH. The progress of targeted therapy in advanced gastric cancer. Biomark Res. 2013;1:32. [PMID: 24330856 DOI: 10.1186/2050-7771-1-32] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
60 Cong X, Zhang Y, Zhu Z, Li S, Yin X, Zhai Z, Zhang Y, Xue Y. CD66b+ neutrophils and α-SMA+ fibroblasts predict clinical outcomes and benefits from postoperative chemotherapy in gastric adenocarcinoma. Cancer Med 2020;9:2761-73. [PMID: 32096331 DOI: 10.1002/cam4.2939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
61 Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res 2018;10:239-48. [PMID: 29445300 DOI: 10.2147/CMAR.S149619] [Cited by in Crossref: 339] [Cited by in F6Publishing: 218] [Article Influence: 84.8] [Reference Citation Analysis]
62 Hashimoto T, Kurokawa Y, Mori M, Doki Y. Update on the Treatment of Gastric Cancer. JMA J 2018;1:40-9. [PMID: 33748521 DOI: 10.31662/jmaj.2018-0006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
63 Shitara K, Mizota A, Matsuo K, Sato Y, Kondo C, Takahari D, Ura T, Tajika M, Muro K. Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis. Gastric Cancer. 2013;16:48-55. [PMID: 22362376 DOI: 10.1007/s10120-012-0143-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
64 Beer A, Taghizadeh H, Schiefer AI, Puhr HC, Karner AK, Jomrich G, Schoppmann SF, Kain R, Preusser M, Ilhan-Mutlu A. PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study. Pathol Oncol Res 2020;26:2225-35. [PMID: 32372174 DOI: 10.1007/s12253-020-00814-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Mao L, Sun AJ, Wu JZ, Tang JH. Involvement of microRNAs in HER2 signaling and trastuzumab treatment. Tumour Biol 2016. [PMID: 27734339 DOI: 10.1007/s13277-016-5405-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
66 Kim ST, Banks KC, Pectasides E, Kim SY, Kim K, Lanman RB, Talasaz A, An J, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Park SH, Park JO, Park YS, Lim HY, Kim NKD, Park W, Lee H, Bass AJ, Kim K, Kang WK, Lee J. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients. Ann Oncol. 2018;29:1037-1048. [PMID: 29409051 DOI: 10.1093/annonc/mdy034] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 15.0] [Reference Citation Analysis]
67 Behrens HM, Warneke VS, Böger C, Garbrecht N, Jüttner E, Klapper W, Mathiak M, Oschlies I, Rudolph U, Stuhlmann-Laeisz C. Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off rule. Cancer Med. 2015;4:235-244. [PMID: 25515030 DOI: 10.1002/cam4.365] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
68 Koo DH, Ryu MH, Lee MY, Chae H, Kim EJ, Moon MS, Kang YK. Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2-Targeted Agent in the Real-World Setting. Cancer Res Treat 2021;53:436-44. [PMID: 33070558 DOI: 10.4143/crt.2020.725] [Reference Citation Analysis]
69 Seo HS, Song KY, Jung YJ, Park SM, Jeon HM, Kim W, Chin HM, Kim JJ, Kim SK, Chun KH, Kim JG, Lee JH, Lee HH, Kim DJ, Yoo HM, Kim CH, Kim EY, Park CH; Catholic Gastric Cancer Study Group (CGCSG). Radical Gastrectomy After Chemotherapy May Prolong Survival in Stage IV Gastric Cancer: A Korean Multi-institutional Analysis. World J Surg. 2018;42:3286-3293. [PMID: 29717344 DOI: 10.1007/s00268-018-4635-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
70 Kinugasa H, Nouso K, Tanaka T, Miyahara K, Morimoto Y, Dohi C, Matsubara T, Okada H, Yamamoto K. Droplet digital PCR measurement of HER2 in patients with gastric cancer. Br J Cancer 2015;112:1652-5. [PMID: 25897674 DOI: 10.1038/bjc.2015.129] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
71 Monte AA, Vasiliou V, Heard KJ. Omics Screening for Pharmaceutical Efficacy and Safety in Clinical Practice. J Pharmacogenomics Pharmacoproteomics 2012;S5:001. [PMID: 23264882 DOI: 10.4172/2153-0645.s5-001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
72 Moro H, Hattori N, Nakamura Y, Kimura K, Imai T, Maeda M, Yashiro M, Ushijima T. Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways. Gastric Cancer 2020;23:105-15. [PMID: 31555951 DOI: 10.1007/s10120-019-01010-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
73 Rubenstein JH, Shaheen NJ. Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. Gastroenterology. 2015;149:302-17.e1. [PMID: 25957861 DOI: 10.1053/j.gastro.2015.04.053] [Cited by in Crossref: 182] [Cited by in F6Publishing: 175] [Article Influence: 26.0] [Reference Citation Analysis]
74 Gaur P, Kim MP, Dunkin BJ. Esophageal cancer: Recent advances in screening, targeted therapy, and management. J Carcinog 2014;13:11. [PMID: 25395880 DOI: 10.4103/1477-3163.143720] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
75 Singh D, Dheer D, Samykutty A, Shankar R. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development. J Control Release 2021;340:1-34. [PMID: 34673122 DOI: 10.1016/j.jconrel.2021.10.006] [Reference Citation Analysis]
76 Ramos MFKP, Pereira MA, de Castria TB, Ribeiro RRE, Cardili L, de Mello ES, Zilberstein B, Ribeiro-júnior U, Cecconello I. Remnant gastric cancer: a neglected group with high potential for immunotherapy. J Cancer Res Clin Oncol 2020;146:3373-83. [DOI: 10.1007/s00432-020-03322-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Halabi S, Li C, Luo S. Developing and Validating Risk Assessment Models of Clinical Outcomes in Modern Oncology. JCO Precis Oncol 2019;3. [PMID: 31840130 DOI: 10.1200/PO.19.00068] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
78 Yu Z, Jiang X, Qin L, Deng H, Wang J, Ren W, Li H, Zhao L, Liu H, Yan H, Shi W, Wang Q, Luo C, Long B, Zhou H, Sun H, Jiao Z. A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. Oncogene 2021;40:1027-42. [PMID: 33323973 DOI: 10.1038/s41388-020-01572-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
79 Gowryshankar A, Nagaraja V, Eslick GD. HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis. J Gastrointest Oncol. 2014;5:25-35. [PMID: 24490040 DOI: 10.3978/j.issn.2078-6891.2013.039] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
80 Bornschein J, Nielitz J, Drozdov I, Selgrad M, Wex T, Jechorek D, Link A, Vieth M, Malfertheiner P. Expression of aurora kinase A correlates with the Wnt-modulator RACGAP1 in gastric cancer. Cancer Med 2016;5:516-26. [PMID: 26778597 DOI: 10.1002/cam4.610] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
81 Yu S, Wang Y, Peng K, Lyu M, Liu F, Liu T. Establishment of a Prognostic Signature of Stromal/Immune-Related Genes for Gastric Adenocarcinoma Based on ESTIMATE Algorithm. Front Cell Dev Biol 2021;9:752023. [PMID: 34900998 DOI: 10.3389/fcell.2021.752023] [Reference Citation Analysis]
82 Tajirika T, Tokumaru Y, Taniguchi K, Sugito N, Matsuhashi N, Futamura M, Yanagihara K, Akao Y, Yoshida K. DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells. Int J Mol Sci 2018;19:E2005. [PMID: 29987267 DOI: 10.3390/ijms19072005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
83 Röcken C, Behrens HM, Böger C, Krüger S. Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort. J Clin Pathol 2016;69:70-5. [PMID: 26251521 DOI: 10.1136/jclinpath-2015-202980] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
84 Zhao W, Wang M, Wang C, Liu Y, Liu H, Luo S. RACGAP1 is transcriptionally regulated by E2F3, and its depletion leads to mitotic catastrophe in esophageal squamous cell carcinoma. Ann Transl Med 2020;8:950. [PMID: 32953750 DOI: 10.21037/atm-20-2901] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Dobsch P, Michels B, Müller-Schilling M, Kandulski A. [Therapeutic regimens using monoclonal antibodies in gastroenterology]. Internist (Berl) 2019;60:1043-58. [PMID: 31501913 DOI: 10.1007/s00108-019-00682-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
86 Wang Y, Jiang Z, Xu C, Wang H, Tan L, Su J, Wang X, Jiang D, Hou Y, Song Q. Increased MET gene copy number negatively affects the survival of esophageal squamous cell carcinoma patients. BMC Cancer 2019;19:240. [PMID: 30885149 DOI: 10.1186/s12885-019-5450-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 Bose K, Franck C, Müller MN, Canbay A, Link A, Venerito M. Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions. Gastroenterol Res Pract 2017;2017:5651903. [PMID: 28785280 DOI: 10.1155/2017/5651903] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
88 Metzger ML, Behrens HM, Böger C, Haag J, Krüger S, Röcken C. MET in gastric cancer--discarding a 10% cutoff rule. Histopathology 2016;68:241-53. [PMID: 26033401 DOI: 10.1111/his.12745] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
89 Namikawa T, Ishida N, Tsuda S, Fujisawa K, Munekage E, Iwabu J, Munekage M, Uemura S, Tsujii S, Maeda H, Kitagawa H, Kobayashi M, Hanazaki K. Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab. Surg Case Rep 2018;4:71. [PMID: 29978335 DOI: 10.1186/s40792-018-0479-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
90 Konopka K, Micek A, Ochenduszko S, Streb J, Potocki P, Kwinta Ł, Wysocki PJ. Combined Neutrophil-to-Lymphocyte and Platelet-Volume-to-Platelet Ratio (NLR and PVPR Score) Represents a Novel Prognostic Factor in Advanced Gastric Cancer Patients. J Clin Med 2021;10:3902. [PMID: 34501353 DOI: 10.3390/jcm10173902] [Reference Citation Analysis]
91 Pai SM, Huang KH, Chen MH, Fang WL, Chao Y, Lo SS, Li AF, Wu CW, Shyr YM. Cardia Gastric Cancer Is Associated With Increased PIK3CA Amplifications and HER2 Expression Than Noncardia Gastric Cancer According to Lauren Classification. Front Oncol 2021;11:632609. [PMID: 34168977 DOI: 10.3389/fonc.2021.632609] [Reference Citation Analysis]
92 Hsu C, Shen YC, Cheng CC, Cheng AL, Hu FC, Yeh KH. Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression. Gastric Cancer. 2012;15:265-280. [PMID: 22576708 DOI: 10.1007/s10120-012-0151-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
93 Kwon MJ, Kim RN, Song K, Jeon S, Jeong HM, Kim JS, Han J, Hong S, Oh E, Choi JS, An J, Pollack JR, Choi YL, Park CK, Shin YK. Genes co-amplified with ERBB2 or MET as novel potential cancer-promoting genes in gastric cancer. Oncotarget 2017;8:92209-26. [PMID: 29190909 DOI: 10.18632/oncotarget.21150] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
94 Fujikuni N, Tanabe K, Hattori M, Yamamoto Y, Tazawa H, Toyota K, Tokumoto N, Hotta R, Yanagawa S, Saeki Y, Sugiyama Y, Ikeda M, Shishida M, Fukuda T, Okano K, Nishihara M, Ohdan H; on behalf of Hiroshima Surgical study group of Clinical Oncology (HiSCO). Distal Gastrectomy for Symptomatic Stage IV Gastric Cancer Contributes to Prognosis with Acceptable Safety Compared to Gastrojejunostomy. Cancers 2022;14:388. [DOI: 10.3390/cancers14020388] [Reference Citation Analysis]
95 Ciesielski M, Szajewski M, Walczak J, Pęksa R, Lenckowski R, Supeł M, Zieliński J, Kruszewski WJ. Impact of chromosome 17 centromere copy number increase on patient survival and human epidermal growth factor receptor 2 expression in gastric adenocarcinoma. Oncol Lett 2021;21:142. [PMID: 33552261 DOI: 10.3892/ol.2020.12403] [Reference Citation Analysis]
96 Kirouac DC, Du J, Lahdenranta J, Onsum MD, Nielsen UB, Schoeberl B, McDonagh CF. HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B. PLoS Comput Biol 2016;12:e1004827. [PMID: 27035903 DOI: 10.1371/journal.pcbi.1004827] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
97 Amato M, Perrone G, Righi D, Pellegrini C, Rabitti C, Di Matteo F, Crucitti P, Caputo D, Coppola R, Tonini G, Santini D, Onetti Muda A. HER2 Status in Gastric Cancer: Comparison between Primary and Distant Metastatic Disease. Pathol Oncol Res 2017;23:55-61. [PMID: 27363700 DOI: 10.1007/s12253-016-0082-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
98 Liang H, Kim YH. Identifying molecular drivers of gastric cancer through next-generation sequencing. Cancer Lett 2013;340:241-6. [PMID: 23178814 DOI: 10.1016/j.canlet.2012.11.029] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
99 Huang JX, Zhao K, Lin M, Wang Q, Xiao W, Lin MS, Yu H, Chen P, Qian RY. HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma. Oncol Lett 2013;6:13-8. [PMID: 23946770 DOI: 10.3892/ol.2013.1348] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
100 Yoo C, Park YS. Companion diagnostics for the targeted therapy of gastric cancer. World J Gastroenterol 2015; 21(39): 10948-10955 [PMID: 26494953 DOI: 10.3748/wjg.v21.i39.10948] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
101 Shitara K. RAINFALL before RAINBOW-an illusion or reality? Transl Gastroenterol Hepatol 2017;2:26. [PMID: 28447061 DOI: 10.21037/tgh.2017.03.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
102 Matsumoto K, Arao T, Hamaguchi T, Shimada Y, Kato K, Oda I, Taniguchi H, Koizumi F, Yanagihara K, Sasaki H, Nishio K, Yamada Y. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer. 2012;106:727-732. [PMID: 22240789 DOI: 10.1038/bjc.2011.603] [Cited by in Crossref: 109] [Cited by in F6Publishing: 101] [Article Influence: 10.9] [Reference Citation Analysis]
103 Satake H, Iwatsuki M, Uenosono Y, Shiraishi T, Tanioka H, Saeki H, Sugimachi K, Kitagawa D, Shimokawa M, Oki E, Emi Y, Kakeji Y, Tsuji A, Akagi Y, Natsugoe S, Baba H, Maehara Y; Kyushu Study Group of Clinical Cancer. Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104). Cancer Chemother Pharmacol 2017;79:147-53. [PMID: 27942930 DOI: 10.1007/s00280-016-3204-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
104 Guo X, Zhao F, Ma X, Shen G, Ren D, Zheng F, Du F, Wang Z, Ahmad R, Yuan X, Zhao J, Zhao J. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer 2019;19:1125. [PMID: 31747911 DOI: 10.1186/s12885-019-6294-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
105 Lordick F, Al-Batran SE, Dietel M, Gaiser T, Hofheinz RD, Kirchner T, Kreipe HH, Lorenzen S, Möhler M, Quaas A, Röcken C, Rüschoff J, Tannapfel A, Thuss-Patience P, Baretton G. HER2 testing in gastric cancer: results of a German expert meeting. J Cancer Res Clin Oncol 2017;143:835-41. [PMID: 28285403 DOI: 10.1007/s00432-017-2374-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
106 Wu G, Zhang DY, Duan YH, Zhang YQ, Cui XN, Luo Z. Correlations of Hemoglobin Level and Perioperative Blood Transfusion with the Prognosis of Gastric Cancer: A Retrospective Study. Med Sci Monit 2017;23:2470-8. [PMID: 28535151 DOI: 10.12659/msm.900907] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
107 Huang LT, Ma JT, Zhang SL, Li XH, Sun L, Jing W, Zhao JZ, Wang YR, Han CB. Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report. Front Oncol 2019;9:1453. [PMID: 31956604 DOI: 10.3389/fonc.2019.01453] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
108 Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol 2012;30:3932-8. [PMID: 22987085 DOI: 10.1200/JCO.2012.43.1890] [Cited by in Crossref: 66] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
109 Hasina R, Surati M, Kawada I, Arif Q, Carey GB, Kanteti R, Husain AN, Ferguson MK, Vokes EE, Villaflor VM. O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer. J Carcinog. 2013;12:20. [PMID: 24319345 DOI: 10.4103/1477-3163.120632] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
110 Baykara M, Benekli M, Ekinci O, Irkkan SC, Karaca H, Demirci U, Akinci MB, Unal OU, Dane F, Turkoz FP. Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers. J Gastrointest Surg. 2015;19:1565-1571. [PMID: 26179664 DOI: 10.1007/s11605-015-2888-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
111 Ma MZ, Yuan SQ, Chen YM, Zhou ZW. Preoperative apolipoprotein B/apolipoprotein A1 ratio: a novel prognostic factor for gastric cancer. Onco Targets Ther 2018;11:2169-76. [PMID: 29713185 DOI: 10.2147/OTT.S156690] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
112 Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3:251-261. [PMID: 22943016 DOI: 10.3978/j.issn.2078-6891.2012.021] [Cited by in F6Publishing: 160] [Reference Citation Analysis]
113 Chen W, Zhang J, Fu H, Hou X, Su Q, He Y, Yang D. KLF5 Is Activated by Gene Amplification in Gastric Cancer and Is Essential for Gastric Cell Proliferation. Cells 2021;10:1002. [PMID: 33923166 DOI: 10.3390/cells10051002] [Reference Citation Analysis]
114 Shitara K, Ikeda J, Yokota T, Takahari D, Ura T, Muro K, Matsuo K. Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials. Invest New Drugs 2012;30:1224-31. [PMID: 21350803 DOI: 10.1007/s10637-011-9648-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
115 Feng J, Qin S. The synergistic effects of Apatinib combined with cytotoxic chemotherapeutic agents on gastric cancer cells and in a fluorescence imaging gastric cancer xenograft model. Onco Targets Ther 2018;11:3047-57. [PMID: 29872316 DOI: 10.2147/OTT.S159935] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
116 Wang J, Qu J, Li Z, Che X, Liu J, Teng Y, Jin B, Zhao M, Liu Y, Qu X. Pretreatment platelet-to-lymphocyte ratio is associated with the response to first-line chemotherapy and survival in patients with metastatic gastric cancer. J Clin Lab Anal 2018;32. [PMID: 28238215 DOI: 10.1002/jcla.22185] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
117 Chang WC, Cheng WC, Cheng BH, Chen L, Ju LJ, Ou YJ, Jeng LB, Yang MD, Hung YC, Ma WL. Mitochondrial Acetyl-CoA Synthetase 3 is Biosignature of Gastric Cancer Progression. Cancer Med 2018;7:1240-52. [PMID: 29493120 DOI: 10.1002/cam4.1295] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
118 Yue T, Zuo S, Zhu J, Guo S, Huang Z, Li J, Wang X, Liu Y, Chen S, Wang P. Two Similar Signatures for Predicting the Prognosis and Immunotherapy Efficacy of Stomach Adenocarcinoma Patients. Front Cell Dev Biol 2021;9:704242. [PMID: 34414187 DOI: 10.3389/fcell.2021.704242] [Reference Citation Analysis]
119 Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, Leiserson MDM, Sethi G, Lu C, Ryan M, Su X, Cherniack AD, Robertson G, Akbani R, Spellman P, Weinstein JN, Hayes DN, Raphael B, Lichtenberg T, Leraas K, Zenklusen JC, Fujimoto J, Scapulatempo-Neto C, Moreira AL, Hwang D, Huang J, Marino M, Korst R, Giaccone G, Gokmen-Polar Y, Badve S, Rajan A, Ströbel P, Girard N, Tsao MS, Marx A, Tsao AS, Loehrer PJ; Cancer Genome Atlas Network. The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell 2018;33:244-258.e10. [PMID: 29438696 DOI: 10.1016/j.ccell.2018.01.003] [Cited by in Crossref: 96] [Cited by in F6Publishing: 94] [Article Influence: 24.0] [Reference Citation Analysis]
120 Higashihara Y, Kato J, Nagahara A, Izumi K, Konishi M, Kodani T, Serizawa N, Osada T, Watanabe S. Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer. Int J Oncol. 2014;44:662-668. [PMID: 24398900 DOI: 10.3892/ijo.2013.2242] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
121 Riquelme I, Saavedra K, Espinoza JA, Weber H, García P, Nervi B, Garrido M, Corvalán AH, Roa JC, Bizama C. Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget 2015;6:24750-79. [PMID: 26267324 DOI: 10.18632/oncotarget.4990] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 13.0] [Reference Citation Analysis]
122 Seo AN, Kwak Y, Kim DW, Kang SB, Choe G, Kim WH, Lee HS. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS One. 2014;9:e98528. [PMID: 24879338 DOI: 10.1371/journal.pone.0098528] [Cited by in Crossref: 91] [Cited by in F6Publishing: 87] [Article Influence: 11.4] [Reference Citation Analysis]
123 Remon J, Dienstmann R. Precision oncology: separating the wheat from the chaff. ESMO Open 2018;3:e000446. [PMID: 30425845 DOI: 10.1136/esmoopen-2018-000446] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
124 Walters S, Benitez-Majano S, Muller P, Coleman MP, Allemani C, Butler J, Peake M, Guren MG, Glimelius B, Bergström S, Påhlman L, Rachet B. Is England closing the international gap in cancer survival? Br J Cancer 2015;113:848-60. [PMID: 26241817 DOI: 10.1038/bjc.2015.265] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 10.3] [Reference Citation Analysis]
125 Dong Z, Kong L, Wan Z, Zhu F, Zhong M, Lv Y, Zhao P, Shi H. Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients. Sci Rep 2019;9:16894. [PMID: 31729406 DOI: 10.1038/s41598-019-53039-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
126 Carrasco-Garcia E, García-Puga M, Arevalo S, Matheu A. Towards precision medicine: linking genetic and cellular heterogeneity in gastric cancer. Ther Adv Med Oncol 2018;10:1758835918794628. [PMID: 30181784 DOI: 10.1177/1758835918794628] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
127 Molefe PF, Masamba P, Oyinloye BE, Mbatha LS, Meyer M, Kappo AP. Molecular Application of Aptamers in the Diagnosis and Treatment of Cancer and Communicable Diseases. Pharmaceuticals (Basel) 2018;11:E93. [PMID: 30274155 DOI: 10.3390/ph11040093] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
128 Chmielecki J, Ross JS, Wang K, Frampton GM, Palmer GA, Ali SM, Palma N, Morosini D, Miller VA, Yelensky R. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. Oncologist. 2015;20:7-12. [PMID: 25480824 DOI: 10.1634./theoncologist.2014-0234] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
129 Yang Y, Pang Z, Ding N, Dong W, Ma W, Li Y, Du J, Liu Q. The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis. Oncotarget 2016;7:74350-61. [PMID: 27542277 DOI: 10.18632/oncotarget.11291] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
130 Spackman E, Rice S, Norman G, Suh DC, Eastwood A, Palmer S. Trastuzumab for the treatment of HER2-positive metastatic gastric cancer : a NICE single technology appraisal. Pharmacoeconomics 2013;31:185-94. [PMID: 23371465 DOI: 10.1007/s40273-013-0023-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
131 Ji J, Zhou C, Wu J, Cai Q, Shi M, Zhang H, Yu Y, Zhu Z, Zhang J. Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8+ cell density and CCL12 expression. Int J Med Sci 2019;16:1142-8. [PMID: 31523177 DOI: 10.7150/ijms.34541] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
132 Yoshida H, Yamamoto N, Taniguchi H, Oda I, Katai H, Kushima R, Tsuda H. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. Virchows Arch. 2014;465:145-154. [PMID: 24889042 DOI: 10.1007/s00428-014-1597-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
133 Morishita A, Gong J, Masaki T. Targeting receptor tyrosine kinases in gastric cancer. World J Gastroenterol 2014; 20(16): 4536-4545 [PMID: 24782606 DOI: 10.3748/wjg.v20.i16.4536] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
134 Lopez A, Harada K, Mizrak Kaya D, Ajani JA. Current therapeutic landscape for advanced gastroesophageal cancers. Ann Transl Med 2018;6:78. [PMID: 29666801 DOI: 10.21037/atm.2017.10.29] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
135 Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 2018;554:189-94. [PMID: 29420467 DOI: 10.1038/nature25475] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
136 AlDeghaither D, Smaglo BG, Weiner LM. Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs. J Clin Pharmacol 2015;55 Suppl 3:S4-20. [PMID: 25707963 DOI: 10.1002/jcph.407] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
137 Kankeu Fonkoua LA, Yoon HH. Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data. Onco Targets Ther 2021;14:4361-81. [PMID: 34385820 DOI: 10.2147/OTT.S216047] [Reference Citation Analysis]
138 Shiraishi K, Mimura K, Izawa S, Inoue A, Shiba S, Maruyama T, Watanabe M, Kawaguchi Y, Inoue M, Fujii H. Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity. Gastric Cancer. 2013;16:571-580. [PMID: 23187882 DOI: 10.1007/s10120-012-0219-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
139 Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, Chou JF, Segal MF, Simmons MZ, Momtaz P, Shcherba M, Ku GY, Zervoudakis A, Won ES, Kelsen DP, Ilson DH, Nagy RJ, Lanman RB, Ptashkin RN, Donoghue MTA, Capanu M, Taylor BS, Solit DB, Schultz N, Hechtman JF. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol 2020;21:821-31. [PMID: 32437664 DOI: 10.1016/S1470-2045(20)30169-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 23.0] [Reference Citation Analysis]
140 Han M, Deng HY, Jiang R. Effect of Trastuzumab on Notch-1 Signaling Pathway in Breast Cancer SK-BR3 Cells. Chin J Cancer Res 2012;24:213-9. [PMID: 23358465 DOI: 10.1007/s11670-012-0213-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
141 Xu N, Redfern CH, Gordon M, Eppler S, Lum BL, Trudeau C. Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study. Cancer Chemother Pharmacol 2014;74:1251-60. [PMID: 25344761 DOI: 10.1007/s00280-014-2603-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
142 Qiao YM, Zhang Y. Immunotherapy for esophageal cancer: Current studies and future perspectives. Shijie Huaren Xiaohua Zazhi 2016; 24(36): 4739-4751 [DOI: 10.11569/wcjd.v24.i36.4739] [Reference Citation Analysis]
143 Hayashi K, Suzuki S, Ikehara H, Okuno H, Irie A, Esaki M, Kusano C, Gotoda T, Moriyama M. Endoscopic resection for residual lesion of metastatic gastric cancer: A case report. World J Clin Cases 2019; 7(4): 482-488 [PMID: 30842959 DOI: 10.12998/wjcc.v7.i4.482] [Reference Citation Analysis]
144 Ross JS, Mulcahy M. HER2 Testing in Gastric/Gastroesophageal Junction Adenocarcinomas: Unique Features of a Familiar Test. Gastrointest Cancer Res 2011;4:62-6. [PMID: 21673877 DOI: 10.1152/ajpcell.00650.2009] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
145 Kim HJ, Oh SC. Novel Systemic Therapies for Advanced Gastric Cancer. J Gastric Cancer 2018;18:1-19. [PMID: 29629216 DOI: 10.5230/jgc.2018.18.e3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
146 Shen X, Li P, Xu Y, Chen X, Sun H, Zhao Y, Liu M, Zhang W. Association of sirtuins with clinicopathological parameters and overall survival in gastric cancer. Oncotarget 2017;8:74359-70. [PMID: 29088792 DOI: 10.18632/oncotarget.20799] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
147 Li L, Jin XJ, Li JW, Li CH, Zhou SY, Li JJ, Feng CQ, Liu DL, Liu YQ. Systematic insight into the active constituents and mechanism of Guiqi Baizhu for the treatment of gastric cancer. Cancer Sci 2021;112:1772-84. [PMID: 33682294 DOI: 10.1111/cas.14851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Zhu Z, Gong YB, Xu HM. Neoadjuvant therapy strategies for advanced gastric cancer: Current innovations and future challenges. Chronic Dis Transl Med 2020;6:147-57. [PMID: 32908968 DOI: 10.1016/j.cdtm.2020.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
149 Ishido K, Higuchi K, Azuma M, Sasaki T, Tanabe S, Katada C, Yano T, Wada T, Koizumi W; Kitasato Digestive Disease & Oncology Group. Aprepitant, granisetron, and dexamethasone versus palonosetron and dexamethasone for prophylaxis of cisplatin-induced nausea and vomiting in patients with upper gastrointestinal cancer: a randomized crossover phase II trial (KDOG 1002). Anticancer Drugs 2016;27:884-90. [PMID: 27254283 DOI: 10.1097/CAD.0000000000000385] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
150 Magalhães H, Fontes-Sousa M, Machado M. Immunotherapy in Advanced Gastric Cancer: An Overview of the Emerging Strategies. Can J Gastroenterol Hepatol 2018;2018:2732408. [PMID: 30027089 DOI: 10.1155/2018/2732408] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
151 Song J, Li Z, Chen P, Yu J, Wang F, Yang Z, Wang X. A 18FDG PET/CT-based volume parameter is a predictor of overall survival in patients with local advanced gastric cancer. Chin J Cancer Res 2019;31:632-40. [PMID: 31564806 DOI: 10.21147/j.issn.1000-9604.2019.04.07] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
152 Zhang T, Zhang L, Fan S, Zhang M, Fu H, Liu Y, Yin X, Chen H, Xie L, Zhang J, Gavine PR, Gu Y, Ni X, Su X. Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity. PLoS One 2015;10:e0134493. [PMID: 26217940 DOI: 10.1371/journal.pone.0134493] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
153 Hwang JE, Kim SH, Jin J, Hong JY, Kim MJ, Jung SH, Shim HJ, Bae WK, Hwang EC, Kim JW. Combination of percutaneous radiofrequency ablation and systemic chemotherapy are effective treatment modalities for metachronous liver metastases from gastric cancer. Clin Exp Metastasis. 2014;31:25-32. [PMID: 23975154 DOI: 10.1007/s10585-013-9606-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
154 Fontana E, Sclafani F, Cunningham D. Anti-angiogenic therapies for advanced esophago-gastric cancer. Indian J Med Paediatr Oncol 2014;35:253-62. [PMID: 25538401 DOI: 10.4103/0971-5851.144985] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
155 Nakayama I, Takahari D, Wakatsuki T, Osumi H, Chin K, Ogura M, Sato T, Suzuki T, Kamiimabeppu D, Ooki A, Suenaga M, Shinozaki E, Yamaguchi K. Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting. ESMO Open 2020;5:e000595. [PMID: 32273288 DOI: 10.1136/esmoopen-2019-000595] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Kordbacheh F, Farah CS. Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. Cancers (Basel) 2021;13:5471. [PMID: 34771633 DOI: 10.3390/cancers13215471] [Reference Citation Analysis]
157 Oroujeni M, Rinne SS, Vorobyeva A, Loftenius A, Feldwisch J, Jonasson P, Chernov V, Orlova A, Frejd FY, Tolmachev V. Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake. Int J Mol Sci 2021;22:2770. [PMID: 33803361 DOI: 10.3390/ijms22052770] [Reference Citation Analysis]
158 Ahn S, Hong M, Van Vrancken M, Lyou YJ, Kim ST, Park SH, Kang WK, Park YS, Jung SH, Woo M, Lee J, Kim KM. A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer. Mol Diagn Ther 2016;20:375-83. [PMID: 27179810 DOI: 10.1007/s40291-016-0205-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
159 Sperduto PW, Fang P, Li J, Breen W, Brown PD, Cagney D, Aizer A, Yu J, Chiang V, Jain S, Gaspar LE, Myrehaug S, Sahgal A, Braunstein S, Sneed P, Cameron B, Attia A, Molitoris J, Wu CC, Wang TJC, Lockney N, Beal K, Parkhurst J, Buatti JM, Shanley R, Lou E, Tandberg DD, Kirkpatrick JP, Shi D, Shih HA, Chuong M, Saito H, Aoyama H, Masucci L, Roberge D, Mehta MP. Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress? Transl Res 2019;208:63-72. [PMID: 30885538 DOI: 10.1016/j.trsl.2019.02.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
160 Christenson ES, James T, Agrawal V, Park BH. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin Biochem. 2015;48:223-235. [PMID: 25445234 DOI: 10.1016/j.clinbiochem.2014.10.013] [Cited by in Crossref: 65] [Cited by in F6Publishing: 49] [Article Influence: 8.1] [Reference Citation Analysis]
161 Gertsen EC, Brenkman HJF, van Hillegersberg R, van Sandick JW, van Berge Henegouwen MI, Gisbertz SS, Luyer MDP, Nieuwenhuijzen GAP, van Lanschot JJB, Lagarde SM, Wijnhoven BPL, de Steur WO, Hartgrink HH, Stoot JHMB, Hulsewe KWE, Spillenaar Bilgen EJ, van Det MJ, Kouwenhoven EA, van der Peet DL, Daams F, van Grieken NCT, Heisterkamp J, van Etten B, van den Berg JW, Pierie JP, Eker HH, Thijssen AY, Belt EJT, van Duijvendijk P, Wassenaar E, van Laarhoven HWM, Wevers KP, Hol L, Wessels FJ, Haj Mohammad N, van der Meulen MP, Frederix GWJ, Vegt E, Siersema PD, Ruurda JP; PLASTIC Study Group. 18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer: A Multicenter Prospective Dutch Cohort Study (PLASTIC). JAMA Surg 2021;:e215340. [PMID: 34705049 DOI: 10.1001/jamasurg.2021.5340] [Reference Citation Analysis]
162 Johnston FM, Beckman M. Updates on Management of Gastric Cancer. Curr Oncol Rep 2019;21:67. [PMID: 31236716 DOI: 10.1007/s11912-019-0820-4] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 14.0] [Reference Citation Analysis]
163 Dong CX, Fu JF, Ye XY, Li XF, Zhong X, Yuan Y. Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy. World J Gastroenterol 2014; 20(34): 12355-12358 [PMID: 25232273 DOI: 10.3748/wjg.v20.i34.12355] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
164 El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biol Ther 2015;16:1726-37. [PMID: 26553611 DOI: 10.1080/15384047.2015.1113356] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 7.7] [Reference Citation Analysis]
165 Vogl UM, Vormittag L, Winkler T, Kafka A, Weiser-Jasch O, Heinrich B, Roider-Schur S, Andalibi H, Autzinger E, Schima W, Klaus A, Zacherl J, Wimberger GM, Öhler L. Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma-experience at two centres. J Gastrointest Oncol 2020;11:366-75. [PMID: 32399277 DOI: 10.21037/jgo.2020.03.10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
166 Kim SW, Roh J, Lee HS, Ryu MH, Park YS, Park CS. Expression of the immune checkpoint molecule V-set immunoglobulin domain-containing 4 is associated with poor prognosis in patients with advanced gastric cancer. Gastric Cancer 2021;24:327-40. [PMID: 32924090 DOI: 10.1007/s10120-020-01120-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
167 Au TH, Wang K, Stenehjem D, Garrido-Laguna I. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. J Gastrointest Oncol 2017;8:387-404. [PMID: 28736627 DOI: 10.21037/jgo.2017.01.04] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
168 Wang SE, Lin RJ. MicroRNA and HER2-overexpressing cancer. Microrna 2013;2:137-47. [PMID: 25070783 DOI: 10.2174/22115366113029990011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
169 Du Y, Cao Q, Jiang C, Liang H, Ning Z, Ji C, Wang J, Zhou C, Jiang Z, Yu C, Li L, Zhao Y, Xu Y, Xu T, Hu W, Wang D, Cheng H, Wang G, Zhou J, Wang S, Zhang Y, Hu Z, Li X, Lu D, Zhang J, Xie H, Sun G. Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study. Cancer Med 2020;9:5008-14. [PMID: 32441892 DOI: 10.1002/cam4.3105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
170 Parisi A, Porzio G, Ficorella C. Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future. Cancers (Basel) 2020;12:E2598. [PMID: 32932914 DOI: 10.3390/cancers12092598] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
171 Nishikawa K, Takahashi T, Takaishi H, Miki A, Noshiro H, Yoshikawa T, Nishida Y, Iwasa S, Miwa H, Masuishi T, Boku N, Yamada Y, Kodera Y, Yoshida K, Morita S, Sakamoto J, Saji S, Kitagawa Y. Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102). Int J Cancer 2017;140:188-96. [PMID: 27521503 DOI: 10.1002/ijc.30383] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
172 Kobayashi D, Kodera Y. Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Gastric Cancer 2017;20:111-21. [PMID: 27803990 DOI: 10.1007/s10120-016-0662-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
173 Porta C, Cosmai L, Gallieni M, Pedrazzoli P, Malberti F. Renal effects of targeted anticancer therapies. Nat Rev Nephrol 2015;11:354-70. [PMID: 25734768 DOI: 10.1038/nrneph.2015.15] [Cited by in Crossref: 61] [Cited by in F6Publishing: 43] [Article Influence: 8.7] [Reference Citation Analysis]
174 Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Chen LT, Kang YK. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol. 2019;30:250-258. [PMID: 30566590 DOI: 10.1093/annonc/mdy540] [Cited by in Crossref: 69] [Cited by in F6Publishing: 76] [Article Influence: 34.5] [Reference Citation Analysis]
175 Fujitani K, Kurokawa Y, Takeno A, Kawabata R, Omori T, Imamura H, Hirao M, Endo S, Kawada J, Moon JH, Kobayashi N, Takahashi T, Yamasaki M, Takiguchi S, Mori M, Eguchi H, Doki Y; Osaka University Clinical Research Group for Gastroenterological Surgery. Prospective Multicenter Interventional Study of Surgical Resection for Liver Metastasis from Gastric Cancer: R0 Resection Rate, and Operative Morbidity and Mortality. Ann Surg Oncol 2021. [PMID: 34480277 DOI: 10.1245/s10434-021-10750-3] [Reference Citation Analysis]
176 Jørgensen JT. Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects. World J Gastroenterol 2014; 20(16): 4526-4535 [PMID: 24782605 DOI: 10.3748/wjg.v20.i16.4526] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
177 Bonanno L, Pavan A, Ferro A, Calvetti L, Frega S, Pasello G, Aprile G, Guarneri V, Conte P; Rete Oncologica Veneta (ROV). Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience. Oncologist 2020;25:e1996-2005. [PMID: 32557976 DOI: 10.1634/theoncologist.2020-0148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
178 Bain GH, Collie-Duguid E, Murray GI, Gilbert FJ, Denison A, McKiddie F, Ahearn T, Fleming I, Leeds J, Phull P. Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas. Br J Cancer. 2014;110:1525-1534. [PMID: 24569475 DOI: 10.1038/bjc.2014.45] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
179 Jiang H, Li Q, Yu S, Yu Y, Wang Y, Li W, Cui Y, Liu T. Impact of HER2 expression on outcome in gastric cancer patients with liver metastasis. Clin Transl Oncol 2017;19:197-203. [PMID: 27324991 DOI: 10.1007/s12094-016-1523-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
180 Zhao D, Klempner SJ, Chao J. Progress and challenges in HER2-positive gastroesophageal adenocarcinoma. J Hematol Oncol 2019;12:50. [PMID: 31101074 DOI: 10.1186/s13045-019-0737-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
181 Watrowski R, Castillo-Tong DC, Schuster E, Fischer MB, Speiser P, Zeillinger R. Association of HER2 codon 655 polymorphism with ovarian cancer. Tumour Biol 2016;37:7239-44. [PMID: 26666819 DOI: 10.1007/s13277-015-4609-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
182 Yamashita-kashima Y, Yoshimura Y, Fujimura T, Shu S, Yanagisawa M, Yorozu K, Furugaki K, Higuchi R, Shoda J, Harada N. Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody–cytotoxic drug conjugate. Cancer Chemother Pharmacol 2019;83:659-71. [DOI: 10.1007/s00280-019-03768-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
183 Chen W, Zhou Y, Wu G, Sun P. CCNI2 promotes the progression of human gastric cancer through HDGF. Cancer Cell Int 2021;21:661. [PMID: 34895232 DOI: 10.1186/s12935-021-02352-6] [Reference Citation Analysis]
184 Klameth L, Rath B, Hamilton G. In vitro Cytotoxic Activities of the Oral Platinum(IV) Prodrug Oxoplatin and HSP90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines. J Cancer 2017;8:1733-43. [PMID: 28819369 DOI: 10.7150/jca.17816] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
185 Wang J, Li Z, Qu J, Song N, Chen Y, Cheng Y, Zhang S, Qu X, Liu Y. Clinical outcomes of capecitabine-based versus S-1-based regimens as first-line chemotherapy in patients with unresectable or metastatic gastric cancer: a propensity score matched single-center comparison. J Gastrointest Oncol 2020;11:674-84. [PMID: 32953151 DOI: 10.21037/jgo-20-52] [Reference Citation Analysis]
186 Deng JY, Liang H. Adenocarcinoma of esophagogastric junction. Chin J Cancer Res 2014;26:362-3. [PMID: 25232205 DOI: 10.3978/j.issn.1000-9604.2014.07.03] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
187 Lago NM, Villar MV, Ponte RV, Nallib IA, Alvarez JJC, López JRA, López RL, Iruegas MEP. Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population. Ecancermedicalscience 2020;14:1020. [PMID: 32256703 DOI: 10.3332/ecancer.2020.1020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
188 Kim JG. Molecular targeted therapy for advanced gastric cancer. Korean J Intern Med. 2013;28:149-155. [PMID: 23525404 DOI: 10.3904/kjim.2013.28.2.149] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
189 Lee KW, Maeng CH, Kim TY, Zang DY, Kim YH, Hwang IG, Oh SC, Chung JS, Song HS, Kim JW, Jeong SJ, Cho JY. A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01). Oncologist 2019;24:18-e24. [PMID: 30126861 DOI: 10.1634/theoncologist.2018-0142] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
190 Cao GD, Chen K, Xiong MM, Chen B. HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis. PLoS One 2016;11:e0161219. [PMID: 27536774 DOI: 10.1371/journal.pone.0161219] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
191 Shaikh H, Kamran A, Monga DK. Immunotherapy in gastroesophageal cancers: Current state and future directions. J Oncol Pharm Pract 2021;27:395-404. [PMID: 33050805 DOI: 10.1177/1078155220963538] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
192 Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8:CD004064. [PMID: 28850174 DOI: 10.1002/14651858.cd004064.pub4] [Cited by in Crossref: 77] [Cited by in F6Publishing: 166] [Article Influence: 15.4] [Reference Citation Analysis]
193 Lordick F. HER2 in gastric cancer: a biomarker with clinical impact, but not without translational challenges. Clin Transl Oncol 2011;13:597-8. [PMID: 21865130 DOI: 10.1007/s12094-011-0704-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
194 Gürbüz M, Akkuş E, Sakin A, Urvay S, Demiray AG, Şahin S, Şakalar T, Erol C, Şendur MAN, Şahin AB, Çubukçu E, Güven DC, Kılıçkap S, Ergün Y, Uncu D, Turhal NS, Üskent N, Çınkır HY, Demir A, Acar R, Karadurmuş N, Türker S, Altınbaş M, Karaoğlan M, Şenler FÇ. Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group. J Gastrointest Cancer 2021. [PMID: 33538958 DOI: 10.1007/s12029-021-00594-1] [Reference Citation Analysis]
195 Puhr HC, Preusser M, Prager G, Ilhan-Mutlu A. New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice? Cancers (Basel) 2020;12:E301. [PMID: 32012895 DOI: 10.3390/cancers12020301] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
196 Zahoor H, Luketich JD, Levy RM, Awais O, Winger DG, Gibson MK, Nason KS. A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma. J Thorac Cardiovasc Surg 2015;149:538-47. [PMID: 25454907 DOI: 10.1016/j.jtcvs.2014.10.044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
197 Chen LT, Oh DY, Ryu MH, Yeh KH, Yeo W, Carlesi R, Cheng R, Kim J, Orlando M, Kang YK. Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. Cancer Res Treat 2017;49:851-68. [PMID: 28052652 DOI: 10.4143/crt.2016.176] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
198 Jiao XD, Ding C, Zang YS, Yu G. Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report. BMC Cancer 2018;18:206. [PMID: 29463236 DOI: 10.1186/s12885-018-4116-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
199 Cocco E, Lopez S, Santin AD, Scaltriti M. Prevalence and role of HER2 mutations in cancer. Pharmacol Ther 2019;199:188-96. [PMID: 30951733 DOI: 10.1016/j.pharmthera.2019.03.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
200 Taghizadeh H, Mader RM, Müllauer L, Erhart F, Kautzky-Willer A, Prager GW. Precision Medicine for the Management of Therapy Refractory Colorectal Cancer. J Pers Med 2020;10:E272. [PMID: 33322358 DOI: 10.3390/jpm10040272] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
201 Yang Y, Zhang W, Yao J, Liu J, Qin S, Wu Q. First-line treatment of apatinib in elderly patient of advanced gastric carcinoma: A case report of NGS-driven targeted therapy. Cancer Biol Ther 2018;19:355-8. [PMID: 29336669 DOI: 10.1080/15384047.2018.1423917] [Reference Citation Analysis]
202 Dahle-Smith Å, Stevenson D, Massie D, Murray GI, Dutton SJ, Roberts C, Ferry D, Osborne A, Clark C, Petty RD. Epidermal Growth Factor (EGFR) copy number aberrations in esophageal and gastro-esophageal junctional carcinoma. Mol Cytogenet. 2015;8:78. [PMID: 26478746 DOI: 10.1186/s13039-015-0181-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
203 Kawazoe A, Shitara K, Fukuoka S, Noguchi M, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yoshino T, Ohtsu A, Doi T. Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience. Invest New Drugs 2015;33:664-70. [PMID: 25773493 DOI: 10.1007/s10637-015-0231-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
204 Marrelli D, Polom K, de Manzoni G, Morgagni P, Baiocchi GL, Roviello F. Multimodal treatment of gastric cancer in the west: Where are we going? World J Gastroenterol 2015; 21(26): 7954-7969 [PMID: 26185368 DOI: 10.3748/wjg.v21.i26.7954] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
205 Ratosa I, Oblak I, Anderluh F, Velenik V, But-Hadzic J, Ermenc AS, Jeromen A. Preoperative treatment with radiochemotherapy for locally advanced gastroesophageal junction cancer and unresectable locally advanced gastric cancer. Radiol Oncol. 2015;49:163-172. [PMID: 26029028 DOI: 10.2478/raon-2014-0027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
206 Kim JH, Eom HJ, Lim G, Park S, Lee J, Nam S, Kim YH, Jeong JH. Differential effects, on oncogenic pathway signalling, by derivatives of the HNF4 α inhibitor BI6015. Br J Cancer 2019;120:488-98. [PMID: 30792535 DOI: 10.1038/s41416-018-0374-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
207 Mingol F, Gallego J, Orduña A, Martinez-Blasco A, Sola-Vera J, Moya P, Morcillo MA, Ruiz JA, Calpena R, Lacueva FJ. Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction. BMC Surg 2015;15:66. [PMID: 25997454 DOI: 10.1186/s12893-015-0054-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
208 Chen CK, Lee MY, Lin WL, Wang YT, Han CP, Yu CP, Chao WR. A qualitative study comparing the assay performance characteristics between the 2007 and the 2013 American Society for Clinical Oncology and College of American Pathologists HER2 scoring methods in mucinous epithelial ovarian cancer. Medicine (Baltimore) 2014;93:e171. [PMID: 25501060 DOI: 10.1097/MD.0000000000000171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
209 Yi JH, Kang JH, Hwang IG, Ahn HK, Baek HJ, Lee SI, Lim DH, Won YW, Ji JH, Kim HS, Rha SY, Oh SY, Lee KE, Lim T, Maeng CH, Kim MJ, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH. A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. Cancer Res Treat 2016;48:553-60. [PMID: 26323641 DOI: 10.4143/crt.2015.155] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
210 Wang J, Li L, Jiang M, Li Y. MicroRNA-195 inhibits human gastric cancer by directly targeting basic fibroblast growth factor. Clin Transl Oncol 2017;19:1320-8. [PMID: 28500362 DOI: 10.1007/s12094-017-1668-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
211 Grade M, Difilippantonio MJ, Camps J. Patterns of Chromosomal Aberrations in Solid Tumors. Recent Results Cancer Res 2015;200:115-42. [PMID: 26376875 DOI: 10.1007/978-3-319-20291-4_6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
212 Kong L, Zhong D. [Research Progress of Targeted Therapy for HER2 Gene 
in Advanced Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2020;23:1108-12. [PMID: 33357319 DOI: 10.3779/j.issn.1009-3419.2020.101.49] [Reference Citation Analysis]
213 Gómez-Martin C, Garralda E, Echarri MJ, Ballesteros A, Arcediano A, Rodríguez-Peralto JL, Hidalgo M, López-Ríos F. HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J Clin Pathol. 2012;65:751-757. [PMID: 22569536 DOI: 10.1136/jclinpath-2012-200774.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
214 Schwarz RE. Current status of management of malignant disease: current management of gastric cancer. J Gastrointest Surg. 2015;19:782-788. [PMID: 25591828 DOI: 10.1007/s11605-014-2707-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
215 Chia CS, Seshadri RA, Kepenekian V, Vaudoyer D, Passot G, Glehen O. Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review. Pleura Peritoneum. 2016;1:65-77. [PMID: 30911610 DOI: 10.1515/pp-2016-0010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
216 Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2017;66:794-801. [PMID: 26801886 DOI: 10.1136/gutjnl-2015-310839] [Cited by in Crossref: 206] [Cited by in F6Publishing: 217] [Article Influence: 34.3] [Reference Citation Analysis]
217 Li J, Han S, Qian Z, Su X, Fan S, Fu J, Liu Y, Yin X, Gao Z, Zhang J, Yu DH, Ji Q. Genetic amplification of PPME1 in gastric and lung cancer and its potential as a novel therapeutic target. Cancer Biol Ther. 2014;15:128-134. [PMID: 24253382 DOI: 10.4161/cbt.27146] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
218 Takashima A, Shitara K, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Kimura Y, Amagai K, Fujii H, Muro K, Esaki T, Choda Y, Takano T, Chin K, Sato A, Goto M, Fukushima N, Hara T, Machida N, Ohta M, Boku N, Shimura M, Morita S, Koizumi W. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial. Gastric Cancer 2019;22:155-63. [PMID: 29855738 DOI: 10.1007/s10120-018-0838-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
219 Zheng S, Wang J, Ding N, Chen W, Chen H, Xue M, Chen F, Ni J, Wang Z, Lin Z, Jiang H, Liu X, Wang L. Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer. J Nanobiotechnology 2021;19:381. [PMID: 34802453 DOI: 10.1186/s12951-021-01127-5] [Reference Citation Analysis]
220 McCoach CE, Doebele RC. The minority report: targeting the rare oncogenes in NSCLC. Curr Treat Options Oncol 2014;15:644-57. [PMID: 25228144 DOI: 10.1007/s11864-014-0310-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
221 Carlomagno N, Incollingo P, Tammaro V, Peluso G, Rupealta N, Chiacchio G, Sandoval Sotelo ML, Minieri G, Pisani A, Riccio E, Sabbatini M, Bracale UM, Calogero A, Dodaro CA, Santangelo M. Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer. Biomed Res Int. 2017;2017:7869802. [PMID: 29094049 DOI: 10.1155/2017/7869802] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 7.6] [Reference Citation Analysis]
222 Gómez-Martin C, Garralda E, Echarri MJ, Ballesteros A, Arcediano A, Rodríguez-Peralto JL, Hidalgo M, López-Ríos F. HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J Clin Pathol 2012;65:751-7. [PMID: 22569536 DOI: 10.1136/jclinpath-2012-200774] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 5.4] [Reference Citation Analysis]
223 Gaur P, Hunt CR, Pandita TK. Emerging therapeutic targets in esophageal adenocarcinoma. Oncotarget 2016;7:48644-55. [PMID: 27102294 DOI: 10.18632/oncotarget.8777] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
224 Su B, Huang T, Jin Y, Yin H, Qiu H, Yuan X. Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways. Gastric Cancer 2021;24:352-67. [PMID: 33030616 DOI: 10.1007/s10120-020-01126-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
225 Lv J, Yao YS, Zhou F, Zhuang LK, Yao RY, Liang J, Qiu WS, Yue L. Prognosis significance of HER2 status and TACC1 expression in patients with gastric carcinoma. Med Oncol 2014;31:280. [PMID: 25297519 DOI: 10.1007/s12032-014-0280-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
226 Nishibeppu K, Komatsu S, Ichikawa D, Imamura T, Kosuga T, Okamoto K, Konishi H, Shiozaki A, Fujiwara H, Otsuji E. Venous invasion as a risk factor for recurrence after gastrectomy followed by chemotherapy for stage III gastric cancer. BMC Cancer 2018;18:108. [PMID: 29382310 DOI: 10.1186/s12885-018-4052-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
227 Pernot S, Dubreuil O, Aparicio T, Le Malicot K, Tougeron D, Lepère C, Lecaille C, Marthey L, Palle J, Bachet JB, Zaanan A, Taieb J. Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study. Br J Cancer 2018;119:424-8. [PMID: 29872148 DOI: 10.1038/s41416-018-0133-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
228 Collins IM, King F, O'Byrne K. Cost impact of trastuzumab prescribing in the treatment of advanced Her2 positive gastric cancer in Ireland. Ir J Med Sci 2012;181:451-2. [PMID: 22012551 DOI: 10.1007/s11845-011-0772-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
229 Taghizadeh H, Unseld M, Spalt M, Mader RM, Müllauer L, Fuereder T, Raderer M, Sibilia M, Hoda MA, Aust S, Polterauer S, Lamm W, Bartsch R, Preusser M, A KW, Prager GW. Targeted Therapy Recommendations for Therapy Refractory Solid Tumors-Data from the Real-World Precision Medicine Platform MONDTI. J Pers Med 2020;10:E188. [PMID: 33114048 DOI: 10.3390/jpm10040188] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
230 Cho CJ, Jung J, Jiang L, Lee EJ, Kim DS, Kim BS, Kim HS, Jung HY, Song HJ, Hwang SW, Park Y, Jung MK, Pack CG, Myung SJ, Chang S. Combinatory RNA-Sequencing Analyses Reveal a Dual Mode of Gene Regulation by ADAR1 in Gastric Cancer. Dig Dis Sci 2018;63:1835-50. [PMID: 29691780 DOI: 10.1007/s10620-018-5081-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
231 Coccolini F, Fugazzola P, Ansaloni L, Sartelli M, Cicuttin E, Leandro G, De' Angelis GL, Gaiani F, Di Mario F, Tomasoni M, Catena F. Advanced gastric cancer: the value of systemic and intraperitoneal chemotherapy. Acta Biomed 2018;89:104-9. [PMID: 30561427 DOI: 10.23750/abm.v89i8-S.7904] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
232 Lordick F, Hoffmeister A. [Treatment of gastric cancer]. Internist (Berl) 2014;55:15-6, 18-22. [PMID: 24154498 DOI: 10.1007/s00108-013-3317-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
233 Koopman T, Smits MM, Louwen M, Hage M, Boot H, Imholz AL. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison. J Cancer Res Clin Oncol. 2015;141:1343-1351. [PMID: 25544671 DOI: 10.1007/s00432-014-1900-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
234 Hendlisz A, Charette N, Awada A, Deleporte A. Academic versus industry-driven research in upper gastrointestinal cancer: sinners and saints. Curr Opin Oncol 2013;25:407-8. [PMID: 23673411 DOI: 10.1097/CCO.0b013e3283622c9e] [Reference Citation Analysis]
235 Kim HK, Hwang HL, Park SY, Lee KM, Park WC, Kim HS, Um TH, Hong YJ, Lee JK, Joo SY, Seoh JY, Song YW, Kim SY, Kim YN, Hong KM. Simple and versatile molecular method of copy-number measurement using cloned competitors. PLoS One 2013;8:e69414. [PMID: 23936009 DOI: 10.1371/journal.pone.0069414] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
236 Chan E, Duckworth LV, Alkhasawneh A, Toro TZ, Lu X, Ben-David K, Hughes SJ, Rossidis G, Zlotecki R, Lightsey J, Daily KC, Dang L, Allegra CJ, King B, George TJ Jr. Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma. J Gastrointest Oncol 2016;7:173-80. [PMID: 27034783 DOI: 10.3978/j.issn.2078-6891.2015.071] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
237 Inokuchi M1, Murayama T, Hayashi M, Takagi Y, Kato K, Enjoji M, Kojima K, Kumagai J, Sugihara K. Prognostic value of co-expression of STAT3, mTOR and EGFR in gastric cancer. Exp Ther Med. 2011;2:251-256. [PMID: 22977493 DOI: 10.3892/etm.2011.187] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
238 Won E, Janjigian YJ, Ilson DH. HER2 directed therapy for gastric/esophageal cancers. Curr Treat Options Oncol. 2014;15:395-404. [PMID: 24811128 DOI: 10.1007/s11864-014-0292-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
239 Park CK, Park JS, Kim HS, Rha SY, Hyung WJ, Cheong JH, Noh SH, Lee SK, Lee YC, Huh YM, Kim H. Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm. Oncotarget 2016;7:72099-112. [PMID: 27765925 DOI: 10.18632/oncotarget.12291] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
240 Bordry N, Astaras C, Ongaro M, Goossens N, Frossard JL, Koessler T. Recent advances in gastrointestinal cancers. World J Gastroenterol 2021; 27(28): 4493-4503 [PMID: 34366620 DOI: 10.3748/wjg.v27.i28.4493] [Reference Citation Analysis]
241 Wang LJ, Bai L, Jiao SC. The rugged road to targeted therapy for gastric cancer. Shijie Huaren Xiaohua Zazhi 2013; 21(24): 2385-2396 [DOI: 10.11569/wcjd.v21.i24.2385] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
242 Desai AM, Lichtman SM. Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly. Cancer Biol Med. 2015;12:284-291. [PMID: 26779365 DOI: 10.7497/j.issn.2095-3941.2015.0078] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
243 Zhang YW, Zhao XX, Tan C, Zhang ZG, Jiang Y, Chen JN, Wei HB, Xue L, Li HG, Du H, Shao CK. Epstein-Barr virus latent membrane protein 2A suppresses the expression of HER2 via a pathway involving TWIST and YB-1 in Epstein-Barr virus-associated gastric carcinomas. Oncotarget 2015;6:207-20. [PMID: 25402957 DOI: 10.18632/oncotarget.2702] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
244 Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, Vittadini G, Desiderio DM. EPMA position paper in cancer: current overview and future perspectives. EPMA J 2015;6:9. [PMID: 25908947 DOI: 10.1186/s13167-015-0030-6] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
245 Song R, Hou G, Yang J, Yuan J, Wang C, Chai T, Liu Z. Effects of PLK1 on proliferation, invasion and metastasis of gastric cancer cells through epithelial-mesenchymal transition. Oncol Lett 2018;16:5739-44. [PMID: 30405751 DOI: 10.3892/ol.2018.9406] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
246 Kahraman S, Yalcin S. Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer. Onco Targets Ther 2021;14:4149-62. [PMID: 34285507 DOI: 10.2147/OTT.S315252] [Reference Citation Analysis]
247 Barok M, Puhka M, Yazdi N, Joensuu H. Extracellular vesicles as modifiers of antibody-drug conjugate efficacy. J Extracell Vesicles 2021;10:e12070. [PMID: 33613875 DOI: 10.1002/jev2.12070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
248 Warneke VS, Behrens HM, Böger C, Becker T, Lordick F, Ebert MP, Röcken C. Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol 2013;24:725-33. [PMID: 23139264 DOI: 10.1093/annonc/mds528] [Cited by in Crossref: 87] [Cited by in F6Publishing: 75] [Article Influence: 8.7] [Reference Citation Analysis]
249 Niu J, Gelbspan D, Weitz D, Markman M, Quan W. HER2-positive, trastuzumab-resistant metastatic esophageal cancer presenting with brain metastasis after durable response to dual HER2 blockade: a case report. J Gastrointest Oncol. 2014;5:E103-E108. [PMID: 25436131 DOI: 10.3978/j.issn.2078-6891.2014.045] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
250 Lastraioli E, Romoli MR, Arcangeli A. Immunohistochemical biomarkers in gastric cancer research and management. Int J Surg Oncol 2012;2012:868645. [PMID: 22778942 DOI: 10.1155/2012/868645] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
251 Wiedmann MW, Mössner J. New and emerging combination therapies for esophageal cancer. Cancer Manag Res 2013;5:133-46. [PMID: 23869177 DOI: 10.2147/CMAR.S32199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
252 Yoon SH, Kim YH, Lee YJ, Park J, Kim JW, Lee HS, Kim B. Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment. PLoS One. 2016;11:e0161278. [PMID: 27517841 DOI: 10.1371/journal.pone.0161278] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
253 Zhu YB, Zhao AG. Application of conversion therapy in advanced gastric cancer. Shijie Huaren Xiaohua Zazhi 2016; 24(18): 2830-2837 [DOI: 10.11569/wcjd.v24.i18.2830] [Reference Citation Analysis]
254 Jung HS, Lee SI, Kang SH, Wang JS, Yang EH, Jeon B, Myung J, Baek JY, Park SK. Monoclonal antibodies against autocrine motility factor suppress gastric cancer. Oncol Lett 2017;13:4925-32. [PMID: 28599497 DOI: 10.3892/ol.2017.6037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
255 Kang BW, Lee D, Chung HY, Han JH, Kim YB. Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer. J Cancer Res Clin Oncol 2013;139:1835-43. [PMID: 24005419 DOI: 10.1007/s00432-013-1503-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
256 Shen L. Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer. Cancer Commun (Lond). 2018;38:72. [PMID: 30563572 DOI: 10.1186/s40880-018-0344-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
257 Ocana A, Vera-Badillo F, Al-Mubarak M, Templeton AJ, Corrales-Sanchez V, Diez-Gonzalez L, Cuenca-Lopez MD, Seruga B, Pandiella A, Amir E. Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis. PLoS One. 2014;9:e95219. [PMID: 24777052 DOI: 10.1371/journal.pone.0095219] [Cited by in Crossref: 97] [Cited by in F6Publishing: 100] [Article Influence: 12.1] [Reference Citation Analysis]
258 Yamaguchi T, Iwasa S, Shoji H, Honma Y, Takashima A, Kato K, Hamaguchi T, Higuchi K, Boku N. Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer. Gastric Cancer 2019;22:778-84. [PMID: 30603911 DOI: 10.1007/s10120-018-00917-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
259 Yoo C, Ryu MH, Na YS, Ryoo BY, Lee CW, Kang YK. Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis. Br J Cancer 2016;114:1185-90. [PMID: 27172248 DOI: 10.1038/bjc.2016.125] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
260 Shi HZ, Wang YN, Huang XH, Zhang KC, Xi HQ, Cui JX, Liu GX, Liang WT, Wei B, Chen L. Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer. World J Gastroenterol 2017; 23(10): 1836-1842 [PMID: 28348489 DOI: 10.3748/wjg.v23.i10.1836] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
261 Okines AF, Reynolds AR, Cunningham D. Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist. 2011;16:844-858. [PMID: 21632459 DOI: 10.1634/theoncologist.2010-0387] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
262 Wang Z, Chen JQ, Liu JL, Tian L. Issues on peritoneal metastasis of gastric cancer: an update. World J Surg Oncol 2019;17:215. [PMID: 31829265 DOI: 10.1186/s12957-019-1761-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
263 Takahashi T, Saikawa Y, Kitagawa Y. Gastric cancer: current status of diagnosis and treatment. Cancers (Basel). 2013;5:48-63. [PMID: 24216698 DOI: 10.3390/cancers5010048] [Cited by in Crossref: 102] [Cited by in F6Publishing: 105] [Article Influence: 11.3] [Reference Citation Analysis]
264 D'Souza JW, Robinson MK. Oligoclonal antibodies to target the ErbB family. Expert Opin Biol Ther 2015;15:1015-21. [PMID: 25936923 DOI: 10.1517/14712598.2015.1042362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
265 Shan YS, Hsu HP, Lai MD, Hung YH, Wang CY, Yen MC, Chen YL. Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer. Oncol Lett 2017;14:4517-26. [PMID: 28943959 DOI: 10.3892/ol.2017.6736] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
266 Corso S, Cargnelutti M, Durando S, Menegon S, Apicella M, Migliore C, Capeloa T, Ughetto S, Isella C, Medico E, Bertotti A, Sassi F, Sarotto I, Casorzo L, Pisacane A, Mangioni M, Sottile A, Degiuli M, Fumagalli U, Sgroi G, Molfino S, De Manzoni G, Rosati R, De Simone M, Marrelli D, Saragoni L, Rausei S, Pallabazzer G, Roviello F, Cassoni P, Sapino A, Bass A, Giordano S. Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts. Neoplasia 2018;20:443-55. [PMID: 29574251 DOI: 10.1016/j.neo.2018.02.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
267 Quéro L, Guillerm S, Hennequin C. Neoadjuvant or adjuvant therapy for gastric cancer. World J Gastrointest Oncol 2015; 7(8): 102-110 [PMID: 26306142 DOI: 10.4251/wjgo.v7.i8.102] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
268 Keller S, Zwingenberger G, Ebert K, Hasenauer J, Wasmuth J, Maier D, Haffner I, Schierle K, Weirich G, Luber B. Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines. Mol Oncol 2018;12:441-62. [PMID: 29325228 DOI: 10.1002/1878-0261.12170] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
269 Lee JY, Hong M, Kim ST, Park SH, Kang WK, Kim KM, Lee J. The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer. Sci Rep. 2015;5:9289. [PMID: 25786580 DOI: 10.1038/srep09289] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
270 Yang M, Fang X, Li J, Xu D, Xiao Q, Yu S, Hu H, Weng S, Ding K, Yuan Y. Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing. Cancer Biol Ther 2019;20:391-6. [PMID: 30307354 DOI: 10.1080/15384047.2018.1529120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
271 Komatsu S, Otsuji E. Essential updates 2017/2018: Recent topics in the treatment and research of gastric cancer in Japan. Ann Gastroenterol Surg 2019;3:581-91. [PMID: 31788646 DOI: 10.1002/ags3.12284] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
272 Meulendijks D, Beerepoot LV, Boot H, de Groot JW, Los M, Boers JE, Vanhoutvin SA, Polee MB, Beeker A, Portielje JE. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study. Invest New Drugs. 2016;34:119-128. [PMID: 26643663 DOI: 10.1007/s10637-015-0309-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
273 De Manzoni G, Marrelli D, Baiocchi GL, Morgagni P, Saragoni L, Degiuli M, Donini A, Fumagalli U, Mazzei MA, Pacelli F, Tomezzoli A, Berselli M, Catalano F, Di Leo A, Framarini M, Giacopuzzi S, Graziosi L, Marchet A, Marini M, Milandri C, Mura G, Orsenigo E, Quagliuolo V, Rausei S, Ricci R, Rosa F, Roviello G, Sansonetti A, Sgroi G, Tiberio GA, Verlato G, Vindigni C, Rosati R, Roviello F. The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. Gastric Cancer 2017;20:20-30. [PMID: 27255288 DOI: 10.1007/s10120-016-0615-3] [Cited by in Crossref: 71] [Cited by in F6Publishing: 73] [Article Influence: 11.8] [Reference Citation Analysis]
274 Woo J, Cohen SA, Grim JE. Targeted therapy in gastroesophageal cancers: past, present and future. Gastroenterol Rep (Oxf). 2015;3:316-329. [PMID: 26510453 DOI: 10.1093/gastro/gov052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
275 Sharma A, Radhakrishnan V. Gastric cancer in India. Indian J Med Paediatr Oncol 2021;32:12-6. [DOI: 10.4103/0971-5851.81884] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
276 Ren Z, Sun J, Sun X, Hou H, Li K, Ge Q. Efficacy and safety of different molecular targeted agents based on chemotherapy for gastric cancer patients treatment: a network meta-analysis. Oncotarget 2017;8:48253-62. [PMID: 28477027 DOI: 10.18632/oncotarget.17192] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
277 Lv H, Zhang J, Sun K, Nie C, Chen B, Wang J, Xu W, Wang S, Liu Y, Chen X. Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer. Front Oncol 2020;10:580045. [PMID: 33598422 DOI: 10.3389/fonc.2020.580045] [Reference Citation Analysis]
278 Bonelli P, Borrelli A, Tuccillo FM, Silvestro L, Palaia R, Buonaguro FM. Precision medicine in gastric cancer. World J Gastrointest Oncol 2019; 11(10): 804-829 [PMID: 31662821 DOI: 10.4251/wjgo.v11.i10.804] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 34] [Article Influence: 9.7] [Reference Citation Analysis]
279 Duan S, Gong B, Wang P, Huang H, Luo L, Liu F. Novel prognostic biomarkers of gastric cancer based on gene expression microarray: COL12A1, GSTA3, FGA and FGG. Mol Med Rep 2018;18:3727-36. [PMID: 30106150 DOI: 10.3892/mmr.2018.9368] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
280 Kumagai S, Koyama S, Nishikawa H. Antitumour immunity regulated by aberrant ERBB family signalling. Nat Rev Cancer 2021;21:181-97. [PMID: 33462501 DOI: 10.1038/s41568-020-00322-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
281 Razavi ZS, Asgarpour K, Mahjoubin-Tehran M, Rasouli S, Khan H, Shahrzad MK, Hamblin MR, Mirzaei H. Angiogenesis-related non-coding RNAs and gastrointestinal cancer. Mol Ther Oncolytics 2021;21:220-41. [PMID: 34095461 DOI: 10.1016/j.omto.2021.04.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
282 Takeda M, Sakai K, Takahama T, Fukuoka K, Nakagawa K, Nishio K. New Era for Next-Generation Sequencing in Japan. Cancers (Basel) 2019;11:E742. [PMID: 31142054 DOI: 10.3390/cancers11060742] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
283 Yu P, Zhang Y, Ye Z, Chen X, Huang L, Du Y, Cheng X. Treatment of Synchronous Liver Metastases from Gastric Cancer: A Single-Center Study. Cancer Manag Res 2020;12:7905-11. [PMID: 32904676 DOI: 10.2147/CMAR.S261353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
284 Davidson M, Chau I, Cunningham D, Khabra K, Iveson T, Hickish T, Seymour M, Starling N. Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. World J Gastrointest Oncol 2017; 9(8): 333-340 [PMID: 28868114 DOI: 10.4251/wjgo.v9.i8.333] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
285 Mori Y, Kataoka H, Ebi M, Adachi K, Yamaguchi Y, Hayashi N, Hirata Y, Sobue S, Ishihara R, Suzuki Y, Mizushima T, Inoue Y, Hasegawa I, Ono S, Hirano A, Kimura Y, Seno K, Ozeki K, Shimura T, Kubota E. Phase II Prospective Study of Trastuzumab in Combination with S-1 and Oxaliplatin (SOX100) Therapy for HER2-Positive Advanced Gastric Cancer. J Gastrointest Cancer 2021. [PMID: 34550548 DOI: 10.1007/s12029-021-00711-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
286 Tomasello G, Ghidini M, Liguigli W, Ratti M, Toppo L, Passalacqua R. Targeted therapies in gastric cancer treatment: where we are and where we are going. Invest New Drugs. 2016;34:378-393. [PMID: 26873643 DOI: 10.1007/s10637-016-0330-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
287 Kim DW, Jee YS, Kim CH, Kim JJ, Park S, Choi SI, Park JM, Kim JH; PIPS-GC (Perioperative Intra-Peritoneal & Systemic Chemotherapy for Gastric Cancer) study group. Multicenter Retrospective Analysis of Intraperitoneal Paclitaxel and Systemic Chemotherapy for Advanced Gastric Cancer with Peritoneal Metastasis. J Gastric Cancer 2020;20:50-9. [PMID: 32269844 DOI: 10.5230/jgc.2020.20.e6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
288 Koldby KM, Mortensen MB, Detlefsen S, Pfeiffer P, Thomassen M, Kruse TA. Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients. J Gastroenterol 2019;54:108-21. [PMID: 30242476 DOI: 10.1007/s00535-018-1508-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
289 Barth I, Schneider U, Grimm T, Karl A, Horst D, Gaisa NT, Knüchel R, Garczyk S. Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications. Virchows Arch 2018;472:749-58. [PMID: 29654370 DOI: 10.1007/s00428-018-2354-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
290 Zhou WH, Tang F, Xu J, Wu X, Feng ZY, Li HG, Lin DJ, Shao CK, Liu Q. Aberrant upregulation of 14-3-3ơ expression serves as an inferior prognostic biomarker for gastric cancer. BMC Cancer 2011;11:397. [PMID: 21933426 DOI: 10.1186/1471-2407-11-397] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
291 Aoyagi K, Kouhuji K, Kizaki J, Isobe T, Hashimoto K, Shirouzu K. Molecular targeting to treat gastric cancer. World J Gastroenterol 2014; 20(38): 13741-13755 [PMID: 25320512 DOI: 10.3748/wjg.v20.i38.13741] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
292 Kadowaki S, Yatabe Y, Nitta S, Ito Y, Muro K. Durable response of human epidermal growth factor receptor-2-positive gastric adenosquamous carcinoma to trastuzumab-based chemotherapy. Case Rep Oncol 2014;7:210-6. [PMID: 24803897 DOI: 10.1159/000362088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
293 Radovich M, Kiel PJ, Nance SM, Niland EE, Parsley ME, Ferguson ME, Jiang G, Ammakkanavar NR, Einhorn LH, Cheng L, Nassiri M, Davidson DD, Rushing DA, Loehrer PJ, Pili R, Hanna N, Callaghan JT, Skaar TC, Helft PR, Shahda S, O'Neil BH, Schneider BP. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. Oncotarget 2016;7:56491-500. [PMID: 27447854 DOI: 10.18632/oncotarget.10606] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 12.8] [Reference Citation Analysis]
294 Li XK, Fan QX. Progress in medication treatment of esophageal cancer. Shijie Huaren Xiaohua Zazhi 2012; 20(35): 3482-3487 [DOI: 10.11569/wcjd.v20.i35.3482] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
295 Bradley NA, Wilson C, Graham J, Evans J, Fullarton G, Mackay CK, Craig C, McIntosh D, MacDonald A, Grose D, Forshaw M. The downstaging approach to irresectable oesophageal and gastric cancer: a single centre experience. J Gastrointest Oncol 2019;10:499-505. [PMID: 31183200 DOI: 10.21037/jgo.2019.01.32] [Reference Citation Analysis]
296 Coveler AL, Ko AH, Catenacci DV, Von Hoff D, Becerra C, Whiting NC, Yang J, Wolpin B. A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. Invest New Drugs 2016;34:319-28. [PMID: 26994014 DOI: 10.1007/s10637-016-0343-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
297 Zhang Y, Xu J, Yu Y, Shang W, Ye A. Anti-Cancer Drug Sensitivity Assay with Quantitative Heterogeneity Testing Using Single-Cell Raman Spectroscopy. Molecules 2018;23:E2903. [PMID: 30405051 DOI: 10.3390/molecules23112903] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
298 Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20:518-530. [PMID: 30857956 DOI: 10.1016/s1470-2045(18)30904-5] [Cited by in Crossref: 121] [Cited by in F6Publishing: 65] [Article Influence: 40.3] [Reference Citation Analysis]
299 Caggiari L, Miolo G, Buonadonna A, Basile D, Santeufemia DA, Cossu A, Palmieri G, De Zorzi M, Fornasarig M, Alessandrini L, Canzonieri V, Lo Re G, Puglisi F, Steffan A, Cannizzaro R, De Re V. Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype. Int J Mol Sci 2017;19:E47. [PMID: 29295527 DOI: 10.3390/ijms19010047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
300 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs. 2011;71:541-555. [PMID: 21443280 DOI: 10.2165/11585460-000000000-000003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
301 An E, Ock CY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Liao WL, Cecchi F, Blackler A, Thyparambil S, Kim WH, Burrows J, Hembrough T, Catenacci DVT, Oh DY, Bang YJ. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment. Ann Oncol 2017;28:110-5. [PMID: 27687309 DOI: 10.1093/annonc/mdw442] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
302 Liu F, Ren C, Jin Y, Xi S, He C, Wang F, Wang Z, Xu RH, Wang F. Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer. Virchows Arch 2020;476:391-8. [PMID: 31720832 DOI: 10.1007/s00428-019-02668-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
303 Ahn S, Brant R, Sharpe A, Dry JR, Hodgson DR, Kilgour E, Kim K, Kim ST, Park SH, Kang WK, Kim KM, Lee J. Correlation between MEK signature and Ras gene alteration in advanced gastric cancer. Oncotarget 2017;8:107492-9. [PMID: 29296181 DOI: 10.18632/oncotarget.18182] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
304 Jin Z, Holubek M, Sukov WR, Sattler CA, Wiktor AE, Jenkins RB, Wu TT, Yoon HH. Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma. Am J Clin Oncol 2019;42:190-5. [PMID: 30516569 DOI: 10.1097/COC.0000000000000495] [Reference Citation Analysis]
305 Lim S, Koh MJ, Jeong HJ, Cho NH, Choi YD, Cho do Y, Lee HY, Rha SY. Fibroblast Growth Factor Receptor 1 Overexpression Is Associated with Poor Survival in Patients with Resected Muscle Invasive Urothelial Carcinoma. Yonsei Med J 2016;57:831-9. [PMID: 27189274 DOI: 10.3349/ymj.2016.57.4.831] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
306 Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Borger DR, Godfrey JT, Jessop NA, Clark JW, Blaszkowsky LS, Ryan DP, Lennerz JK, Iafrate AJ, Bardelli A, Hong TS, Corcoran RB. Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. Cancer Discov. 2015;5:1271-1281. [PMID: 26432108 DOI: 10.1158/2159-8290.cd-15-0748] [Cited by in Crossref: 113] [Cited by in F6Publishing: 66] [Article Influence: 16.1] [Reference Citation Analysis]
307 Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H, Kobayashi K, Yokoyama Y, Shaker MN, Takiguchi S, Mori M, Doki Y. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer. 2015;18:691-697. [PMID: 25224659 DOI: 10.1007/s10120-014-0430-7] [Cited by in Crossref: 45] [Cited by in F6Publishing: 53] [Article Influence: 5.6] [Reference Citation Analysis]
308 Nowara E, Boratyn-Nowicka A, Polakiewicz-Gilowska A, Drosik A, Kustra M, Huszno J. Chemotherapy for gastric cancer patients - time for personalization in medicine? Contemp Oncol (Pozn) 2012;16:86-9. [PMID: 23788860 DOI: 10.5114/wo.2012.27342] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
309 Mittal SK, Abdo J, Adrien MP, Bayu BA, Kline JR, Sullivan MM, Agrawal DK. Current state of prognostication, therapy and prospective innovations for Barrett's-related esophageal adenocarcinoma: a literature review. J Gastrointest Oncol 2021;12:1197-214. [PMID: 34532080 DOI: 10.21037/jgo-21-117] [Reference Citation Analysis]
310 Shi J, Qu YP, Hou P. Pathogenetic mechanisms in gastric cancer. World J Gastroenterol 2014; 20(38): 13804-13819 [PMID: 25320518 DOI: 10.3748/wjg.v20.i38.13804] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
311 Zhang Y, Hu Y, Ma C, Sun H, Wei X, Li M, Wei W, Zhang F, Yang F, Wang H, Gu K. Diagnostic, Therapeutic Predictive, and Prognostic Value of Neutrophil Extracellular Traps in Patients With Gastric Adenocarcinoma.Front Oncol. 2020;10:1036. [PMID: 32714865 DOI: 10.3389/fonc.2020.01036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
312 Fornaro L, Lucchesi M, Caparello C, Vasile E, Caponi S, Ginocchi L, Masi G, Falcone A. Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev Gastroenterol Hepatol. 2011;8:369-383. [PMID: 21647199 DOI: 10.1038/nrgastro.2011.81.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
313 Lau-Min KS, Li Y, Eads JR, Wang X, Meropol NJ, Mamtani R, Getz KD. Adherence to and determinants of guideline-recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: Insights from routine practice. Cancer 2021;127:2562-70. [PMID: 33730386 DOI: 10.1002/cncr.33514] [Reference Citation Analysis]
314 Hong Y, Chen H, Rao Z, Peng B, Hu H, Lin S, Xu Z. In vitro study on the role of SOX9 in trastuzumab resistance of adenocarcinoma of the esophagogastric junction. Exp Ther Med 2018;15:3103-7. [PMID: 29456713 DOI: 10.3892/etm.2018.5744] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
315 de Vos-Geelen J, Geurts SM, van Putten M, Valkenburg-van Iersel LB, Grabsch HI, Haj Mohammad N, Hoebers FJ, Hoge CV, Jeene PM, de Jong EJ, van Laarhoven HW, Rozema T, Slingerland M, Tjan-Heijnen VC, Nieuwenhuijzen GA, Lemmens VE. Trends in treatment and overall survival among patients with proximal esophageal cancer. World J Gastroenterol 2019; 25(47): 6835-6846 [PMID: 31885424 DOI: 10.3748/wjg.v25.i47.6835] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
316 Kobayashi T, Kubota M, Kinoshita Y, Arai Y, Oyama T, Yokota N, Saito K, Matsuda Y, Osawa M. Epidermal growth factor receptor/heme oxygenase-1 axis is involved in chemoresistance to cisplatin and pirarubicin in HepG2 cell lines and hepatoblastoma specimens. Pediatr Surg Int 2019;35:1369-78. [PMID: 31559456 DOI: 10.1007/s00383-019-04563-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
317 Zhang JN, Liu Y, Gao JB, Xie XL, Guo DD, Li JY. Correlation between PET-CT maximum standardized uptake value and HER2 expression in gastric carcinoma. Shijie Huaren Xiaohua Zazhi 2016; 24(15): 2312-2318 [DOI: 10.11569/wcjd.v24.i15.2312] [Reference Citation Analysis]
318 Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol Cancer Ther. 2012;11:660-669. [PMID: 22238368 DOI: 10.1158/1535-7163.mct-11-0754] [Cited by in Crossref: 118] [Cited by in F6Publishing: 84] [Article Influence: 11.8] [Reference Citation Analysis]
319 Stroes CI, Schokker S, Creemers A, Molenaar RJ, Hulshof MCCM, van der Woude SO, Bennink RJ, Mathôt RAA, Krishnadath KK, Punt CJA, Verhoeven RHA, van Oijen MGH, Creemers GJ, Nieuwenhuijzen GAP, van der Sangen MJC, Beerepoot LV, Heisterkamp J, Los M, Slingerland M, Cats A, Hospers GAP, Bijlsma MF, van Berge Henegouwen MI, Meijer SL, van Laarhoven HWM. Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study. J Clin Oncol 2020;38:462-71. [PMID: 31809243 DOI: 10.1200/JCO.19.01814] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
320 Aizawa M, Nagatsuma AK, Kitada K, Kuwata T, Fujii S, Kinoshita T, Ochiai A. Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer. 2014;17:34-42. [PMID: 23430266 DOI: 10.1007/s10120-013-0239-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 4.2] [Reference Citation Analysis]
321 Rahman R, Asombang AW, Ibdah JA. Characteristics of gastric cancer in Asia. World J Gastroenterol 2014; 20(16): 4483-4490 [PMID: 24782601 DOI: 10.3748/wjg.v20.i16.4483] [Cited by in CrossRef: 202] [Cited by in F6Publishing: 196] [Article Influence: 25.3] [Reference Citation Analysis]
322 Cho JH, Lim JY, Cho JY. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer. World J Gastroenterol 2017; 23(41): 7407-7414 [PMID: 29151694 DOI: 10.3748/wjg.v23.i41.7407] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
323 Lim SW, Kim HR, Kim HY, Huh JW, Kim YJ, Shin JH, Suh SP, Ryang DW, Kim HR, Shin MG. Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor. Cell Oncol (Dordr). 2013;36:311-321. [PMID: 23722824 DOI: 10.1007/s13402-013-0136-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
324 Hadi AA, Hindawi AE, Hareedy A, Khalil H, Ashiry RA, Elia S, Sadek A, Magdy M, Atta R, Anas A, Bakr H, Hammam O. Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients. Open Access Maced J Med Sci 2016;4:535-42. [PMID: 28028387 DOI: 10.3889/oamjms.2016.104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
325 Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One 2013;8:e54014. [PMID: 23516391 DOI: 10.1371/journal.pone.0054014] [Cited by in Crossref: 124] [Cited by in F6Publishing: 131] [Article Influence: 13.8] [Reference Citation Analysis]
326 Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, Wyrwicz LS, Xu J, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shah S, Bhagia P, Chung HC. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021;600:727-30. [PMID: 34912120 DOI: 10.1038/s41586-021-04161-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
327 Yu DH, Tang L, Dong H, Dong Z, Zhang L, Fu J, Su X, Zhang T, Fu H, Han L, Xie L, Chen H, Qian Z, Zhu G, Wang J, Ye Q, Zhang J, Yin X, Zhang X, Ji J, Ji Q. Oncogenic HER2 fusions in gastric cancer. J Transl Med 2015;13:116. [PMID: 25889497 DOI: 10.1186/s12967-015-0476-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
328 Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014;3:e29030. [PMID: 25083328 DOI: 10.4161/onci.29030] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
329 Singh P, Toom S, Huang Y. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J Hematol Oncol 2017;10:105. [PMID: 28494772 DOI: 10.1186/s13045-017-0473-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 9.8] [Reference Citation Analysis]
330 Jomrich G, Schoppmann SF. Targeted therapy in gastric cancer. Eur Surg 2016;48:278-84. [PMID: 27795701 DOI: 10.1007/s10353-016-0389-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
331 Mongan AM, Kalachand R, King S, O'Farrell NJ, Power D, Ravi N, Muldoon C, O'Byrne K, Reynolds JV. Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery. Ir J Med Sci. 2015;184:417-423. [PMID: 24879337 DOI: 10.1007/s11845-014-1135-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
332 Nishibeppu K, Komatsu S, Kiuchi J, Kishimoto T, Takashima Y, Shoda K, Arita T, Kosuga T, Konishi H, Shiozaki A, Kubota T, Okamoto K, Fujiwara H, Tsuda H, Otsuji E. TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer. J Cancer 2021;12:316-25. [PMID: 33391428 DOI: 10.7150/jca.47577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
333 Paris L, Podo F, Spadaro F, Abalsamo L, Pisanu ME, Ricci A, Cecchetti S, Altabella L, Buoncervello M, Lozneanu L, Bagnoli M, Ramoni C, Canevari S, Mezzanzanica D, Iorio E, Canese R. Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and in vivo tumor growth in a highly tumorigenic ovarian cancer model. Oncotarget 2017;8:55022-38. [PMID: 28903399 DOI: 10.18632/oncotarget.18992] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
334 Beg S, Ragunath K, Wyman A, Banks M, Trudgill N, Pritchard DM, Riley S, Anderson J, Griffiths H, Bhandari P, Kaye P, Veitch A. Quality standards in upper gastrointestinal endoscopy: a position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS). Gut. 2017;66:1886-1899. [PMID: 28821598 DOI: 10.1136/gutjnl-2017-314109] [Cited by in Crossref: 84] [Cited by in F6Publishing: 63] [Article Influence: 16.8] [Reference Citation Analysis]
335 Burney IA, Lakhtakia R. Precision Medicine: Where have we reached and where are we headed? Sultan Qaboos Univ Med J 2017;17:e255-8. [PMID: 29062546 DOI: 10.18295/squmj.2017.17.03.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
336 Nishikawa S, Konno M, Hamabe A, Hasegawa S, Kano Y, Fukusumi T, Satoh T, Takiguchi S, Mori M, Doki Y, Ishii H. Surgically resected human tumors reveal the biological significance of the gastric cancer stem cell markers CD44 and CD26. Oncol Lett 2015;9:2361-7. [PMID: 26137071 DOI: 10.3892/ol.2015.3063] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
337 Shitara K, Ikeda J, Kondo C, Takahari D, Ura T, Muro K, Matsuo K. Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer. Gastric Cancer 2012;15:137-43. [PMID: 21842172 DOI: 10.1007/s10120-011-0083-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
338 Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, Li H, Ciccarone V, Zhang T, Stavenhagen J, Koenig S, Stewart SJ, Moore PA, Johnson S, Bonvini E. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res 2011;13:R123. [PMID: 22129105 DOI: 10.1186/bcr3069] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 9.5] [Reference Citation Analysis]
339 Takemura N, Saiura A, Koga R, Yoshioka R, Yamamoto J, Kokudo N. Repeat hepatectomy for recurrent liver metastasis from gastric carcinoma. World J Surg. 2013;37:2664-2670. [PMID: 23963347 DOI: 10.1007/s00268-013-2190-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
340 Long HD, Lin YE, Zhang JJ, Zhong WZ, Zheng RN. Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis. Oncologist 2016;21:547-54. [PMID: 27026675 DOI: 10.1634/theoncologist.2015-0424] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
341 Heim D, Montavon G, Hufnagl P, Müller KR, Klauschen F. Computational analysis reveals histotype-dependent molecular profile and actionable mutation effects across cancers. Genome Med 2018;10:83. [PMID: 30442178 DOI: 10.1186/s13073-018-0591-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
342 Xia R, Zhou Y, Wang Y, Yuan J, Ma X. Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments. Front Oncol 2021;11:633916. [PMID: 33912455 DOI: 10.3389/fonc.2021.633916] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
343 Erickson KE, Rukhlenko OS, Posner RG, Hlavacek WS, Kholodenko BN. New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling. Semin Cancer Biol 2019;54:162-73. [PMID: 29518522 DOI: 10.1016/j.semcancer.2018.02.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
344 Zhang HP, Li SY, Wang JP, Lin J. Clinical significance and biological roles of cyclins in gastric cancer. Onco Targets Ther 2018;11:6673-85. [PMID: 30349301 DOI: 10.2147/OTT.S171716] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
345 Tajima JY, Futamura M, Gaowa S, Mori R, Tanahashi T, Tanaka Y, Matsuhashi N, Takahashi T, Yamaguchi K, Miyazaki T, Yoshida K. Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer. J Cancer 2018;9:358-66. [PMID: 29344282 DOI: 10.7150/jca.20266] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
346 Aratani K, Komatsu S, Ichikawa D, Ohashi T, Miyamae M, Okajima W, Imamura T, Kiuchi J, Nishibeppu K, Kosuga T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Tsuda H, Otsuji E. Overexpression of CTEN relates to tumor malignant potential and poor outcomes of adenocarcinoma of the esophagogastric junction. Oncotarget 2017;8:84112-22. [PMID: 29137409 DOI: 10.18632/oncotarget.21109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
347 Ni C, Yang P, Guo J, Ye M. Role of DiGeorge syndrome critical region gene 9, a long noncoding RNA, in gastric cancer. Onco Targets Ther 2018;11:2259-67. [PMID: 29719408 DOI: 10.2147/OTT.S162253] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
348 Inagaki-Ohara K. Gastric Leptin and Tumorigenesis: Beyond Obesity. Int J Mol Sci 2019;20:E2622. [PMID: 31141984 DOI: 10.3390/ijms20112622] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
349 Kim IH. Current status of adjuvant chemotherapy for gastric cancer. World J Gastrointest Oncol 2019; 11(9): 679-685 [PMID: 31558973 DOI: 10.4251/wjgo.v11.i9.679] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
350 Yazici O, Sendur MAN, Ozdemir N, Aksoy S. Targeted therapies in gastric cancer and future perspectives. World J Gastroenterol 2016; 22(2): 471-489 [PMID: 26811601 DOI: 10.3748/wjg.v22.i2.471] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
351 Harada K, Lopez A, Shanbhag N, Badgwell B, Baba H, Ajani J. Recent advances in the management of gastric adenocarcinoma patients. F1000Res 2018;7:F1000 Faculty Rev-1365. [PMID: 30228868 DOI: 10.12688/f1000research.15133.1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
352 Haag GM, Stocker G, Quidde J, Jaeger D, Lordick F. Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer - the multinational MATEO study. BMC Cancer 2017;17:509. [PMID: 28760152 DOI: 10.1186/s12885-017-3497-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
353 Kiuchi J, Komatsu S, Ichikawa D, Kosuga T, Okamoto K, Konishi H, Shiozaki A, Fujiwara H, Yasuda T, Otsuji E. Putative risk factors for postoperative pneumonia which affects poor prognosis in patients with gastric cancer. Int J Clin Oncol 2016;21:920-6. [PMID: 27173949 DOI: 10.1007/s10147-016-0987-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
354 Liao YY, Peng NF, Long D, Yu PC, Zhang S, Zhong JH, Li LQ. Hepatectomy for liver metastases from gastric cancer: a systematic review. BMC Surg. 2017;17:14. [PMID: 28193210 DOI: 10.1186/s12893-017-0215-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
355 Jácome AA, Wohnrath DR, Scapulatempo Neto C, Carneseca EC, Serrano SV, Viana LS, Nunes JS, Martinez EZ, Santos JS. Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors. Gastric Cancer. 2014;17:76-86. [PMID: 23455716 DOI: 10.1007/s10120-013-0236-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
356 Watanabe M, Kuwata T, Setsuda A, Tokunaga M, Kaito A, Sugita S, Tonouchi A, Kinoshita T, Nagino M. Molecular and pathological analyses of gastric stump cancer by next-generation sequencing and immunohistochemistry. Sci Rep 2021;11:4165. [PMID: 33603111 DOI: 10.1038/s41598-021-83711-1] [Reference Citation Analysis]
357 Li Z, Zou X, Xie L, Dong H, Chen Y, Liu Q, Wu X, Zhou D, Tan D, Zhang H. Prognostic importance and therapeutic implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma. PLoS One 2013;8:e80665. [PMID: 24236193 DOI: 10.1371/journal.pone.0080665] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
358 Shao Q, Wang F, Xu Y, Zhang X, Tang W, Feng Y, Li Y. CDKL2 Is Associated with HER2 Status and Overall Survival in Gastric Cancer: Comparative Analysis of CDKL2 Protein Expression and Gene Copy Number. Biomed Res Int 2020;2020:1712723. [PMID: 33178818 DOI: 10.1155/2020/1712723] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
359 Turgeman I, Ben-Aharon I. Evolving treatment paradigms in esophageal cancer. Ann Transl Med 2021;9:903. [PMID: 34164537 DOI: 10.21037/atm.2020.03.110] [Reference Citation Analysis]
360 Roy A, Cunningham D, Hawkins R, Sörbye H, Adenis A, Barcelo JR, Lopez-Vivanco G, Adler G, Canon JL, Lofts F, Castanon C, Fonseca E, Rixe O, Aparicio J, Cassinello J, Nicolson M, Mousseau M, Schalhorn A, D'Hondt L, Kerger J, Hossfeld DK, Garcia Giron C, Rodriguez R, Schoffski P, Misset JL. Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. Br J Cancer 2012;107:435-41. [PMID: 22767144 DOI: 10.1038/bjc.2012.286] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
361 Hallet J, Davis LE, Mahar AL, Liu Y, Zuk V, Gupta V, Earle CC, Coburn NG. Variation in receipt of therapy and survival with provider volume for medical oncology in non-curative esophago-gastric cancer: a population-based analysis. Gastric Cancer 2020;23:300-9. [PMID: 31628561 DOI: 10.1007/s10120-019-01012-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
362 Nakamura Y, Shitara K. Development of circulating tumour DNA analysis for gastrointestinal cancers. ESMO Open 2020;5:e000600. [PMID: 32830648 DOI: 10.1136/esmoopen-2019-000600] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
363 Kanda M, Kodera Y. Molecular mechanisms of peritoneal dissemination in gastric cancer. World J Gastroenterol 2016; 22(30): 6829-6840 [PMID: 27570420 DOI: 10.3748/wjg.v22.i30.6829] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 59] [Article Influence: 11.3] [Reference Citation Analysis]
364 Alhames S, Hsu A, Rustam F, Kassar R, Shihade MB, Almhanna K. Esophageal cancer in Aleppo, Syria 2010-2020: a rare cancer in a war zone. Ann Transl Med 2020;8:1105. [PMID: 33145324 DOI: 10.21037/atm-20-4474] [Reference Citation Analysis]
365 Friedlaender A, Subbiah V, Russo A, Banna GL, Malapelle U, Rolfo C, Addeo A. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nat Rev Clin Oncol 2021. [PMID: 34561632 DOI: 10.1038/s41571-021-00558-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
366 Canale M, Casadei-Gardini A, Ulivi P, Arechederra M, Berasain C, Lollini PL, Fernández-Barrena MG, Avila MA. Epigenetic Mechanisms in Gastric Cancer: Potential New Therapeutic Opportunities. Int J Mol Sci 2020;21:E5500. [PMID: 32752096 DOI: 10.3390/ijms21155500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
367 Wang S, Chen Y, Zhang H, Liang Z, Bu J. The Value of Predicting Human Epidermal Growth Factor Receptor 2 Status in Adenocarcinoma of the Esophagogastric Junction on CT-Based Radiomics Nomogram. Front Oncol 2021;11:707686. [PMID: 34722254 DOI: 10.3389/fonc.2021.707686] [Reference Citation Analysis]
368 Zimmer K, Kocher F, Spizzo G, Salem M, Gastl G, Seeber A. Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies. Comput Struct Biotechnol J 2019;17:447-53. [PMID: 31007870 DOI: 10.1016/j.csbj.2019.03.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
369 Mackenzie M, Spithoff K, Jonker D. Systemic therapy for advanced gastric cancer: a clinical practice guideline. Curr Oncol 2011;18:e202-9. [PMID: 21874111 DOI: 10.3747/co.v18i4.737] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
370 Aoki M, Shoji H, Nagashima K, Imazeki H, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Higuchi K, Boku N. Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer. ESMO Open. 2019;4:e000488. [PMID: 31231567 DOI: 10.1136/esmoopen-2019-000488] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
371 Accordino G, Lettieri S, Bortolotto C, Benvenuti S, Gallotti A, Gattoni E, Agustoni F, Pozzi E, Rinaldi P, Primiceri C, Morbini P, Lancia A, Stella GM. From Interconnection between Genes and Microenvironment to Novel Immunotherapeutic Approaches in Upper Gastro-Intestinal Cancers-A Multidisciplinary Perspective. Cancers (Basel) 2020;12:E2105. [PMID: 32751137 DOI: 10.3390/cancers12082105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
372 Jiang D, Xu Y, Chen Y, Jiang J, Wang M, Yang M, Chen Z, Yang L. Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review. Front Pharmacol 2020;11:1027. [PMID: 32765260 DOI: 10.3389/fphar.2020.01027] [Reference Citation Analysis]
373 Minarikova P, Benesova L, Halkova T, Belsanova B, Tuckova I, Belina F, Dusek L, Zavoral M, Minarik M. Prognostic Importance of Cell Cycle Regulators Cyclin D1 (CCND1) and Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B/p27) in Sporadic Gastric Cancers. Gastroenterol Res Pract 2016;2016:9408190. [PMID: 27781065 DOI: 10.1155/2016/9408190] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
374 Li K, Li J. Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application. Gastroenterol Res Pract. 2016;2016:4105615. [PMID: 26880889 DOI: 10.1155/2016/4105615] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
375 Nshizirungu JP, Bennis S, Mellouki I, Sekal M, Benajah DA, Lahmidani N, El Bouhaddouti H, Ibn Majdoub K, Ibrahimi SA, Celeiro SP, Viana-Pereira M, Munari FF, Ribeiro GG, Duval V, Santana I, Reis RM. Reproduction of the Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG) Gastric Cancer Molecular Classifications and Their Association with Clinicopathological Characteristics and Overall Survival in Moroccan Patients. Dis Markers 2021;2021:9980410. [PMID: 34367379 DOI: 10.1155/2021/9980410] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
376 Omari J, Drewes R, Orthmer M, Hass P, Pech M, Powerski M. Treatment of metastatic gastric adenocarcinoma with image-guided high-dose rate, interstitial brachytherapy as second-line or salvage therapy. Diagn Interv Radiol 2019;25:360-7. [PMID: 31348004 DOI: 10.5152/dir.2019.18390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
377 Yoon C, Park DJ, Schmidt B, Thomas NJ, Lee HJ, Kim TS, Janjigian YY, Cohen DJ, Yoon SS. CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res. 2014;20:3974-3988. [PMID: 24947926 DOI: 10.1158/1078-0432.ccr-14-0011] [Cited by in Crossref: 111] [Cited by in F6Publishing: 77] [Article Influence: 13.9] [Reference Citation Analysis]
378 Namikawa T, Yatabe T, Inoue K, Shuin T, Hanazaki K. Clinical applications of 5-aminolevulinic acid-mediated fluorescence for gastric cancer. World J Gastroenterol 2015; 21(29): 8769-8775 [PMID: 26269666 DOI: 10.3748/wjg.v21.i29.8769] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
379 Shum H, Rajdev L. Multimodality management of resectable gastric cancer: A review. World J Gastrointest Oncol 2014; 6(10): 393-402 [PMID: 25320655 DOI: 10.4251/wjgo.v6.i10.393] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
380 Chan HT, Chin YM, Low SK. The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics. Oncol Ther 2019;7:1-32. [PMID: 32700193 DOI: 10.1007/s40487-018-0090-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
381 Cordts Filho RM, Kassab P, Claro LC, Fracassi MT, Colombo-Souza P, Fukuhara DK, Thuler FR, de Freitas Junior WR, Ilias EJ, Malheiros CA. Evaluation of the Expression of the Human Epithelial Receptor 2 (HER2) in Gastric Carcinoma. ScientificWorldJournal 2016;2016:7951365. [PMID: 28105465 DOI: 10.1155/2016/7951365] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
382 Cazet A, Charest J, Bennett DC, Sambrooks CL, Contessa JN. Mannose phosphate isomerase regulates fibroblast growth factor receptor family signaling and glioma radiosensitivity. PLoS One 2014;9:e110345. [PMID: 25314669 DOI: 10.1371/journal.pone.0110345] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
383 Genitsch V, Novotny A, Seiler CA, Kröll D, Walch A, Langer R. Epstein-barr virus in gastro-esophageal adenocarcinomas - single center experiences in the context of current literature. Front Oncol 2015;5:73. [PMID: 25859432 DOI: 10.3389/fonc.2015.00073] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
384 Wen F, Zheng H, Wu Y, Wheeler J, Zeng X, Fu P, Li Q. Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma. Sci Rep 2016;6:36060. [PMID: 27824060 DOI: 10.1038/srep36060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
385 Adelstein DJ, Rodriguez CP, Rybicki LA, Ives DI, Rice TW. A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction. Invest New Drugs. 2012;30:1684-1689. [PMID: 21863238 DOI: 10.1007/s10637-011-9736-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
386 Aoyama T, Yoshikawa T, Miyagi Y, Kameda Y, Shirai J, Hayashi T, Cho H, Oshima T, Yukawa N, Rino Y, Masuda M, Tsuburaya A. Human epidermal growth factor receptor 2 (Her-2) and S-1 adjuvant chemotherapy in stage 2/3 gastric cancer patients who underwent D2 gastrectomy. Surg Today 2013;43:1390-7. [PMID: 23512532 DOI: 10.1007/s00595-013-0544-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
387 Kobayashi H, Komatsu S, Ichikawa D, Kawaguchi T, Hirajima S, Miyamae M, Okajima W, Ohashi T, Kosuga T, Konishi H. Overexpression of denticleless E3 ubiquitin protein ligase homolog (DTL) is related to poor outcome in gastric carcinoma. Oncotarget. 2015;6:36615-36624. [PMID: 26472028 DOI: 10.18632/oncotarget.5620] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
388 Huynh JC, Schwab E, Ji J, Kim E, Joseph A, Hendifar A, Cho M, Gong J. Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies. Cancers (Basel). 2020;12. [PMID: 32384640 DOI: 10.3390/cancers12051168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
389 Chen M, Li Y, Ming Z, Biao A, Zheng LX. Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer. Contemp Oncol (Pozn) 2014;18:95-9. [PMID: 24966791 DOI: 10.5114/wo.2014.41383] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
390 Li Q, Zhang L, Li X, Yan H, Yang L, Li Y, Li T, Wang J, Cao B. The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer : HER1-4 protein expression and prognosis in pancreatic cancer. BMC Cancer 2016;16:910. [PMID: 27871278 DOI: 10.1186/s12885-016-2889-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
391 Fushida S, Kaji M, Oyama K, Hirono Y, Nezuka H, Takeda T, Tsukada T, Fujimoto D, Ohyama S, Fujimura T, Ohta T. Randomized Phase II trial of paclitaxel plus valproic acid vs paclitaxel alone as second-line therapy for patients with advanced gastric cancer. Onco Targets Ther 2015;8:939-41. [PMID: 25960665 DOI: 10.2147/OTT.S83114] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
392 Pirrelli M, Caruso ML, Di Maggio M, Armentano R, Valentini AM. Are biopsy specimens predictive of HER2 status in gastric cancer patients? Dig Dis Sci. 2013;58:397-404. [PMID: 22918687 DOI: 10.1007/s10620-012-2357-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 17] [Article Influence: 0.4] [Reference Citation Analysis]
393 Cotes Sanchís A, Gallego J, Hernandez R, Arrazubi V, Custodio A, Cano JM, Aguado G, Macias I, Lopez C, López F, Visa L, Garrido M, Martínez Lago N, Fernández Montes A, Limón ML, Azkárate A, Pimentel P, Reguera P, Ramchandani A, Cacho JD, Martín Carnicero A, Granja M, Martín Richard M, Hernández Pérez C, Hurtado A, Serra O, Buxo E, Vidal Tocino R, Jimenez-Fonseca P, Carmona-Bayonas A. Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. PLoS One 2020;15:e0235848. [PMID: 32735623 DOI: 10.1371/journal.pone.0235848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
394 Kavaliauskas P, Maziukas R, Samalavicius NE, Kuliavas J, Lunevicius R. Subtotal gastrectomy with conventional D2 lymphadenectomy for carcinoma of the distal gastric portion: A retrospective cohort study on clinical outcomes. Ann Med Surg (Lond) 2016;6:36-41. [PMID: 27141301 DOI: 10.1016/j.amsu.2016.01.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
395 Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol 2019;3:PO. [PMID: 32923865 DOI: 10.1200/PO.18.00345] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
396 Reddavid R, Corso S, Moya-Rull D, Giordano S, Degiuli M. Patient-Derived Orthotopic Xenograft models in gastric cancer: a systematic review. Updates Surg 2020;72:951-66. [PMID: 32253687 DOI: 10.1007/s13304-020-00751-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
397 Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S. Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2014;20:4210-4217. [PMID: 25125258 DOI: 10.1158/1078-0432.ccr-14-0521] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
398 Yoshida K, Tsuda M, Matsumoto R, Semba S, Wang L, Sugino H, Tanino M, Kondo T, Tanabe K, Tanaka S. Exosomes containing ErbB2/CRK induce vascular growth in premetastatic niches and promote metastasis of bladder cancer. Cancer Sci 2019;110:2119-32. [PMID: 31141251 DOI: 10.1111/cas.14080] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
399 Shimura T, Yoshida M, Fukuda S, Ebi M, Hirata Y, Mizoshita T, Tanida S, Kataoka H, Kamiya T, Higashiyama S, Joh T. Nuclear translocation of the cytoplasmic domain of HB-EGF induces gastric cancer invasion. BMC Cancer 2012;12:205. [PMID: 22646534 DOI: 10.1186/1471-2407-12-205] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
400 Said R, Banchs J, Wheler J, Hess KR, Falchook G, Fu S, Naing A, Hong D, Piha-Paul S, Ye Y, Yeh E, Wolff RA, Tsimberidou AM. The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials. Ann Oncol 2014;25:276-82. [PMID: 24356639 DOI: 10.1093/annonc/mdt524] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
401 Lee SY. Tailored Therapy Based on Molecular Characteristics in Endometrial Cancer. Biomed Res Int 2021;2021:2068023. [PMID: 34036097 DOI: 10.1155/2021/2068023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
402 Sihag S, Nussenzweig SC, Walch HS, Hsu M, Tan KS, Sanchez-Vega F, Chatila WK, De La Torre SA, Patel A, Janjigian YY, Maron S, Ku GY, Tang LH, Hechtman J, Shah PM, Wu AJ, Jones DR, Molena D, Solit DB, Schultz N, Berger MF. Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways. Clin Cancer Res 2021;27:3491-8. [PMID: 33795256 DOI: 10.1158/1078-0432.CCR-20-4707] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
403 Arora N, Gupta A, Singh PP. Biological agents in gastrointestinal cancers: adverse effects and their management. J Gastrointest Oncol. 2017;8:485-498. [PMID: 28736636 DOI: 10.21037/jgo.2017.01.07] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
404 Hempel L, de Oliveira JV, Gaumann A, Milani V, Schweneker K, Schenck K, Fleischmann B, Philipp P, Mederle S, Garg A, Piehler A, Gandorfer B, Schick C, Kleespies A, Sellmann L, Bartels M, Goetze TO, Stein A, Goekkurt E, Pfitzner L, Robert S, Hempel D. Landscape of Biomarkers and Actionable Gene Alterations in Adenocarcinoma of GEJ and Stomach-A Real World Data Analysis. Cancers (Basel) 2021;13:4453. [PMID: 34503263 DOI: 10.3390/cancers13174453] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
405 He J, Shi H, Zhou Z, Chen J, Guan W, Wang H, Yu H, Liu S, Zhou Z, Yang X, Liu T. Correlation between apparent diffusion coefficients and HER2 status in gastric cancers: pilot study. BMC Cancer 2015;15:749. [PMID: 26487555 DOI: 10.1186/s12885-015-1726-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
406 Bittoni A, Del Prete M, Scartozzi M, Pistelli M, Giampieri R, Faloppi L, Bianconi M, Cascinu S. Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis. Springerplus 2015;4:743. [PMID: 26693102 DOI: 10.1186/s40064-015-1545-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
407 Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643-655. [PMID: 24061039 DOI: 10.1038/nrclinonc.2013.170] [Cited by in Crossref: 249] [Cited by in F6Publishing: 243] [Article Influence: 27.7] [Reference Citation Analysis]
408 Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, Lacouture ME, Capanu M, Mattar M, Qeriqi B, Cecchi F, Tian Y, Hembrough T, Nagy RJ, Lanman RB, Larson SM, Pandit-Taskar N, Schöder H, Iacobuzio-Donahue CA, Ilson DH, Weber WA, Berger MF, de Stanchina E, Taylor BS, Lewis JS, Solit DB, Carrasquillo JA, Scaltriti M, Schultz N, Janjigian YY. EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer Discov 2019;9:199-209. [PMID: 30463996 DOI: 10.1158/2159-8290.CD-18-0598] [Cited by in Crossref: 54] [Cited by in F6Publishing: 38] [Article Influence: 13.5] [Reference Citation Analysis]
409 Laboissiere RS, Buzelin MA, Balabram D, De Brot M, Nunes CB, Rocha RM, Cabral MM, Gobbi H. Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections. BMC Gastroenterol 2015;15:157. [PMID: 26530403 DOI: 10.1186/s12876-015-0384-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
410 Oue N, Sentani K, Sakamoto N, Uraoka N, Yasui W. Molecular carcinogenesis of gastric cancer: Lauren classification, mucin phenotype expression, and cancer stem cells. Int J Clin Oncol 2019;24:771-8. [PMID: 30980196 DOI: 10.1007/s10147-019-01443-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
411 Kim SY, Yoon MJ, Park YI, Kim MJ, Nam BH, Park SR. Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment. Gastric Cancer. 2018;21:453-463. [PMID: 28828688 DOI: 10.1007/s10120-017-0756-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
412 Lin S, Yan Z, Tang Q, Zhang S. Ubiquitin-associated protein 2 like (UBAP2L) enhances growth and metastasis of gastric cancer cells. Bioengineered 2021;12:10232-45. [PMID: 34823423 DOI: 10.1080/21655979.2021.1982308] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
413 Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29:4803-4810. [PMID: 22042947 DOI: 10.1200/jco.2011.35.4928] [Cited by in Crossref: 313] [Cited by in F6Publishing: 184] [Article Influence: 28.5] [Reference Citation Analysis]
414 Sharma MR, Schilsky RL. GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy. Nat Rev Clin Oncol 2011;8:70-2. [PMID: 21278772 DOI: 10.1038/nrclinonc.2010.219] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
415 Matsuoka T, Yashiro M. Molecular-targeted therapy toward precision medicine for gastrointestinal cancer: Current progress and challenges. World J Gastrointest Oncol 2021; 13(5): 366-390 [PMID: 34040699 DOI: 10.4251/wjgo.v13.i5.366] [Reference Citation Analysis]
416 Alvarez RH, Hortobagyi GN. Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer. Breast Cancer 2013;20:103-10. [PMID: 23377763 DOI: 10.1007/s12282-013-0446-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
417 Barchi LC, Ramos MFKP, Dias AR, Forones NM, Carvalho MP, Castro OAP, Kassab P, Costa-Júnior WLD, Weston AC, Zilberstein B, Ferraz ÁAB, ZeideCharruf A, Brandalise A, Silva AMD, Alves B, Marins CAM, Malheiros CA, Leite CV, Bresciani CJC, Szor D, Mucerino DR, Wohnrath DR, JirjossIlias E, Martins Filho ED, PinatelLopasso F, Coimbra FJF, Felippe FEC, Tomasisch FDS, Takeda FR, Ishak G, Laporte GA, Silva HJT, Cecconello I, Rodrigues JJG, Grande JCD, Lourenço LG, Motta LMD, Ferraz LR, Moreira LF, Lopes LR, Toneto MG, Mester M, Rodrigues MAG, Franciss MY, AdamiAndreollo N, Corletta OC, Yagi OK, Malafaia O, Assumpção PP, Savassi-Rocha PR, Colleoni Neto R, Oliveira RJ, AissarSallun RA, Weschenfelder R, Oliveira SCV, Abreu TB, Castria TB, Ribeiro Junior U, Barra W, Freitas Júnior WR; Consenso. BRAZILIAN GASTRIC CANCER ASSOCIATION GUIDELINES (PART 2): UPDATE ON TREATMENT. Arq Bras Cir Dig 2021;34:e1563. [PMID: 34008707 DOI: 10.1590/0102-672020210001e1563] [Reference Citation Analysis]
418 Zhang J, Quadri S, Wolfgang CL, Zheng L. New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. Biomedicines 2018;6:E87. [PMID: 30104497 DOI: 10.3390/biomedicines6030087] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
419 Kalinka-Warzocha E, Plazas JG, Mineur L, Salek T, Hendlisz A, DeCosta L, Vogl FD, Passalacqua R. Chemotherapy treatment patterns and neutropenia management in gastric cancer. Gastric Cancer 2015;18:360-7. [PMID: 24792482 DOI: 10.1007/s10120-014-0375-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
420 Bekaii-Saab T, El-Rayes B. Taking aim at the genomic diversity of gastrointestinal cancers: a changing landscape. J Gastrointest Oncol 2016;7:673-4. [PMID: 27747081 DOI: 10.21037/jgo.2016.09.09] [Reference Citation Analysis]
421 Openshaw MR, Mohamed AA, Ottolini B, Fernandez-Garcia D, Richards CJ, Page K, Guttery DS, Thomas AL, Shaw JA. Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma. Br J Cancer 2020;123:1271-9. [PMID: 32719550 DOI: 10.1038/s41416-020-1002-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
422 Iqbal M, Roberts A, Starr J, Mody K, Kasi PM. Feasibility and clinical value of circulating tumor DNA testing in patients with gastric adenocarcinomas. J Gastrointest Oncol 2019;10:400-6. [PMID: 31183188 DOI: 10.21037/jgo.2019.01.14] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
423 Jeong H, Jeong JH, Kim KP, Lee SS, Oh DW, Park DH, Song TJ, Park Y, Hong SM, Ryoo BY, Yoo C. Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin. Cancers (Basel) 2021;13:E161. [PMID: 33418871 DOI: 10.3390/cancers13020161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
424 Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, Kelsen DP. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res. 2011;17:2693-2701. [PMID: 21430069 DOI: 10.1158/1078-0432.ccr-10-2203] [Cited by in Crossref: 195] [Cited by in F6Publishing: 122] [Article Influence: 17.7] [Reference Citation Analysis]
425 Kanda M, Tanaka H, Shimizu D, Miwa T, Umeda S, Tanaka C, Kobayashi D, Hattori N, Suenaga M, Hayashi M, Iwata N, Yamada S, Fujiwara M, Kodera Y. SYT7 acts as a driver of hepatic metastasis formation of gastric cancer cells. Oncogene. 2018;37:5355-5366. [PMID: 29858600 DOI: 10.1038/s41388-018-0335-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
426 Yagi S, Wakatsuki T, Yamamoto N, Chin K, Takahari D, Ogura M, Ichimura T, Nakayama I, Osumi H, Shinozaki E, Suenaga M, Fujisaki J, Ishikawa Y, Yamaguchi K, Namikawa K, Horiuchi Y. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer. Gastric Cancer. 2019;22:518-525. [PMID: 30328533 DOI: 10.1007/s10120-018-0887-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
427 Bateni SB, Gingrich AA, Kirane AR, Sauder CAM, Gholami S, Bold RJ, Meyers FJ, Canter RJ. Chemotherapy After Diagnosis of Malignant Bowel Obstruction is Associated with Superior Survival for Medicare Patients with Advanced Malignancy. Ann Surg Oncol 2021. [PMID: 33829359 DOI: 10.1245/s10434-021-09831-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
428 Smyth E, Zhang S, Cunningham D, Wotherspoon A, Soong R, Peckitt C, Valeri N, Fassan M, Rugge M, Okines A, Allum W, Stenning S, Nankivell M, Langley R, Tan P. Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy. Clin Cancer Res 2017;23:7543-9. [PMID: 28972045 DOI: 10.1158/1078-0432.CCR-16-3142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
429 Zang YF, Li FZ, Ji ZP, Ding YL. Application value of enhanced recovery after surgery for total laparoscopic uncut Roux-en-Y gastrojejunostomy after distal gastrectomy. World J Gastroenterol 2018; 24(4): 504-510 [PMID: 29398871 DOI: 10.3748/wjg.v24.i4.504] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
430 Chang HR, Park HS, Ahn YZ, Nam S, Jung HR, Park S, Lee SJ, Balch C, Powis G, Ku JL, Kim YH. Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems. BMC Cancer 2016;16:200. [PMID: 26955870 DOI: 10.1186/s12885-016-2232-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
431 Awasthi N, Schwarz MA, Zhang C, Schwarz RE. Augmentation of Nab-Paclitaxel Chemotherapy Response by Mechanistically Diverse Antiangiogenic Agents in Preclinical Gastric Cancer Models. Mol Cancer Ther 2018;17:2353-64. [PMID: 30166402 DOI: 10.1158/1535-7163.MCT-18-0489] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
432 Goff LW, Thakkar N, Du L, Chan E, Tan BR, Cardin DB, McLeod HL, Berlin JD, Zehnbauer B, Fournier C, Picus J, Wang-Gillam A, Lee W, Lockhart AC. Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers. PLoS One 2014;9:e107424. [PMID: 25232828 DOI: 10.1371/journal.pone.0107424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
433 Aydin K, Okutur SK, Bozkurt M, Turkmen I, Namal E, Pilanci K, Ozturk A, Akcali Z, Dogusoy G, Demir OG. Effect of epidermal growth factor receptor status on the outcomes of patients with metastatic gastric cancer: A pilot study. Oncol Lett 2014;7:255-9. [PMID: 24348859 DOI: 10.3892/ol.2013.1662] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
434 Jiao XD, Liu K, Wu Y, Zhou XC, Qin BD, Ling Y, Liu J, He X, Du H, Xiang J, Zang YS. HER2 Splice Site Mutation c.1899-1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2-Positive Gastric Adenocarcinoma. Oncologist 2021;26:717-21. [PMID: 33896090 DOI: 10.1002/onco.13799] [Reference Citation Analysis]
435 Ross DS, Zehir A, Cheng DT, Benayed R, Nafa K, Hechtman JF, Janjigian YY, Weigelt B, Razavi P, Hyman DM, Baselga J, Berger MF, Ladanyi M, Arcila ME. Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay. J Mol Diagn 2017;19:244-54. [PMID: 28027945 DOI: 10.1016/j.jmoldx.2016.09.010] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 8.8] [Reference Citation Analysis]
436 Aoki M, Iwasa S, Boku N. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective. Gastric Cancer 2021;24:567-76. [PMID: 33646464 DOI: 10.1007/s10120-021-01164-x] [Reference Citation Analysis]
437 Ieni A, Angelico G, Barresi V, Giuffrè G, Arena F, Caruso RA, Tuccari G. Human Epidermal Growth Factor Receptor 2 Status in Gastric Carcinomas with Distinctive Prevalent Cribriform Component. Dis Markers 2018;2018:1505428. [PMID: 29670669 DOI: 10.1155/2018/1505428] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
438 Moorcraft SY, Fontana E, Cunningham D, Peckitt C, Waddell T, Smyth EC, Allum W, Thompson J, Rao S, Watkins D, Starling N, Chau I. Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study. BMC Cancer 2016;16:112. [PMID: 26883815 DOI: 10.1186/s12885-016-2145-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
439 Spitzner M, Emons G, Schütz KB, Wolff HA, Rieken S, Ghadimi BM, Schneider G, Grade M. Inhibition of Wnt/β-Catenin Signaling Sensitizes Esophageal Cancer Cells to Chemoradiotherapy. Int J Mol Sci 2021;22:10301. [PMID: 34638639 DOI: 10.3390/ijms221910301] [Reference Citation Analysis]
440 Chen S, Ou-Yang LY, Nie RC, Li YF, Xiang J, Zhou ZW, Chen YB, Peng JS. Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T3-4aN0M0 Gastric Cancer Patients after D2 Gastrectomy. Gastroenterol Res Pract 2017;2017:4928736. [PMID: 28331491 DOI: 10.1155/2017/4928736] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
441 Ecker BL, Taylor L, Zhang PJ, Furth EE, Ginsberg GG, McMillan MT, Datta J, Czerniecki BJ, Roses RE. HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction. PLoS One 2016;11:e0161781. [PMID: 27559738 DOI: 10.1371/journal.pone.0161781] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
442 Findlay JM, Middleton MR, Tomlinson I. A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage. Ann Oncol. 2015;26:624-644. [PMID: 25214541 DOI: 10.1093/annonc/mdu449] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
443 Diessner J, Bruttel V, Stein RG, Horn E, Häusler SF, Dietl J, Hönig A, Wischhusen J. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Cell Death Dis 2014;5:e1149. [PMID: 24675467 DOI: 10.1038/cddis.2014.115] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
444 McGee SF, AlGhareeb W, Ahmad CH, Armstrong D, Babak S, Berry S, Biagi J, Booth C, Bossé D, Champion P, Colwell B, Finn N, Goel R, Gray S, Green J, Harb M, Hyde A, Jeyakumar A, Jonker D, Kanagaratnam S, Kavan P, MacMillan A, Muinuddin A, Patil N, Porter G, Powell E, Ramjeesingh R, Raza M, Rorke S, Seal M, Servidio-Italiano F, Siddiqui J, Simms J, Smithson L, Snow S, St-Hilaire E, Stuckless T, Tate A, Tehfe M, Thirlwell M, Tsvetkova E, Valdes M, Vickers M, Virik K, Welch S, Marginean C, Asmis T. Eastern Canadian Colorectal Cancer Consensus Conference 2017. Curr Oncol 2018;25:262-74. [PMID: 30111967 DOI: 10.3747/co.25.4083] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
445 D'Avino C, Paciello R, Riccio G, Coppola C, Laccetti P, Maurea N, Raines RT, De Lorenzo C. Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells. Protein Eng Des Sel 2014;27:83-8. [PMID: 24421342 DOI: 10.1093/protein/gzt065] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
446 Shibata W, Kinoshita H, Hikiba Y, Sato T, Ishii Y, Sue S, Sugimori M, Suzuki N, Sakitani K, Ijichi H, Mori R, Endo I, Maeda S. Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice. Sci Rep 2018;8:6150. [PMID: 29670173 DOI: 10.1038/s41598-018-24375-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
447 Wang F, Sun GP, Zou YF, Zhong F, Ma T, Li XQ, Wu D. Helicobacter pylori infection predicts favorable outcome in patients with gastric cancer. Curr Oncol. 2013;20:e388-e395. [PMID: 24155636 DOI: 10.3747/co.20.1417] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
448 Yuan SQ, Nie RC, Chen S, Chen XJ, Chen YM, Xu LP, Yang LF, Zhou ZW, Peng JS, Chen YB. Selective Gastric Cancer Patients with Peritoneal Seeding Benefit from Gastrectomy after Palliative Chemotherapy: A Propensity Score Matching Analysis. J Cancer 2017;8:2231-7. [PMID: 28819425 DOI: 10.7150/jca.18932] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
449 Lamarca A, Foster L, Valle JW, Satyadas T, Siriwardena A. FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out? ESMO Open 2020;5:e000633. [PMID: 33122352 DOI: 10.1136/esmoopen-2019-000633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
450 Anestis A, Zoi I, Karamouzis MV. Current advances of targeting HGF/c-Met pathway in gastric cancer. Ann Transl Med 2018;6:247. [PMID: 30069449 DOI: 10.21037/atm.2018.04.42] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
451 Ito M, Oshima Y, Yajima S, Suzuki T, Nanami T, Shiratori F, Funahashi K, Shimada H. Diagnostic impact of high serum midkine level in patients with gastric cancer. Ann Gastroenterol Surg 2019;3:195-201. [PMID: 30923789 DOI: 10.1002/ags3.12226] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
452 Shimura T. Novel Biomarkers of Gastrointestinal Cancer. Cancers (Basel) 2021;13:1501. [PMID: 33805858 DOI: 10.3390/cancers13071501] [Reference Citation Analysis]
453 Liu L, Yu H, Huang L, Shao F, Bai J, Lou D, Chen F. Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer. Onco Targets Ther 2015;8:921-8. [PMID: 25960663 DOI: 10.2147/OTT.S82365] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
454 Lee D, Yu EJ, Ham IH, Hur H, Kim YS. AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells. Onco Targets Ther 2017;10:4153-9. [PMID: 28860825 DOI: 10.2147/OTT.S139664] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 4.4] [Reference Citation Analysis]
455 Miyazaki K, Inokuchi M, Takagi Y, Kato K, Kojima K, Sugihara K. EphA4 is a prognostic factor in gastric cancer. BMC Clin Pathol. 2013;13:19. [PMID: 23738943 DOI: 10.1186/1472-6890-13-19] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
456 Sun Z, Yue L, Shen Z, Li Y, Sui A, Li T, Tang Q, Yao R, Sun Y. Downregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin. Oncol Lett 2017;13:2377-84. [PMID: 28454407 DOI: 10.3892/ol.2017.5722] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
457 Shi S, Yang ZZ, Liu S, Yang F, Lin H. PIWIL1 promotes gastric cancer via a piRNA-independent mechanism. Proc Natl Acad Sci U S A 2020;117:22390-401. [PMID: 32848063 DOI: 10.1073/pnas.2008724117] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
458 Xu B, Liu F, Liu Q, Shi T, Wang Z, Wu N, Xu X, Li L, Fan X, Yu L, Liu B, Wei J. Highly expressed Claudin18.2 as a potential therapeutic target in advanced gastric signet-ring cell carcinoma (SRCC). J Gastrointest Oncol 2020;11:1431-9. [PMID: 33457012 DOI: 10.21037/jgo-20-344] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
459 Komeda K, Hayashi M, Kubo S, Nagano H, Nakai T, Kaibori M, Wada H, Takemura S, Kinoshita M, Koga C, Matsumoto M, Sakaguchi T, Inoue Y, Hirokawa F, Kwon AH, Uchiyama K. High survival in patients operated for small isolated liver metastases from gastric cancer: a multi-institutional study. World J Surg. 2014;38:2692-2697. [PMID: 24803345 DOI: 10.1007/s00268-014-2608-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
460 Akutagawa T, Aoki S, Yamamoto-Rikitake M, Iwakiri R, Fujimoto K, Toda S. Cancer-adipose tissue interaction and fluid flow synergistically modulate cell kinetics, HER2 expression, and trastuzumab efficacy in gastric cancer. Gastric Cancer 2018;21:946-55. [PMID: 29696406 DOI: 10.1007/s10120-018-0829-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
461 van der Wilk BJ, Eyck BM, Lagarde SM, van der Gaast A, Nuyttens JJME, Wijnhoven BPL, van Lanschot JJB. The optimal neoadjuvant treatment of locally advanced esophageal cancer. J Thorac Dis 2019;11:S621-31. [PMID: 31080638 DOI: 10.21037/jtd.2018.11.143] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
462 Feilchenfeldt J, Varga Z, Siano M, Grabsch HI, Held U, Schuknecht B, Trip A, Hamaguchi T, Gut P, Balague O, Khanfir K, Diebold J, Jochum W, Shoji H, Kushima R, Wagner D, Shimada Y, Cats A, Knuth A, Moch H, Aebi S, Hofer S. Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). Br J Cancer 2015;113:716-21. [PMID: 26313663 DOI: 10.1038/bjc.2015.279] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
463 Volpi CC, Pietrantonio F, Gloghini A, Fucà G, Giordano S, Corso S, Pruneri G, Antista M, Cremolini C, Fasano E, Saggio S, Faraci S, Di Bartolomeo M, de Braud F, Di Nicola M, Tagliabue E, Pupa SM, Castagnoli L. The landscape of d16HER2 splice variant expression across HER2-positive cancers. Sci Rep 2019;9:3545. [PMID: 30837627 DOI: 10.1038/s41598-019-40310-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
464 Kimura A, Ogata K, Altan B, Yokobori T, Mochiki E, Yanai M, Kogure N, Yanoma T, Suzuki M, Bai T, Kuwano H. Nuclear heat shock protein 110 expression is associated with poor prognosis and hyperthermo-chemotherapy resistance in gastric cancer patients with peritoneal metastasis. World J Gastroenterol 2017; 23(42): 7541-7550 [PMID: 29204054 DOI: 10.3748/wjg.v23.i42.7541] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
465 Xu C, Liu Y, Ge X, Jiang D, Zhang Y, Ji Y, Hou J, Huang J, Su J, Zeng H, Qin J, Hou Y. Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer. Diagn Pathol 2017;12:41. [PMID: 28549444 DOI: 10.1186/s13000-017-0616-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
466 Carmona-Bayonas A, Jiménez-Fonseca P, Custodio A, Sánchez Cánovas M, Hernández R, Pericay C, Echavarria I, Lacalle A, Visa L, Rodríguez Palomo A, Mangas M, Cano JM, Buxo E, Álvarez-Manceñido F, García T, Lorenzo JE, Ferrer-Cardona M, Viudez A, Azkarate A, Ramchandani A, Arias D, Longo F, López C, Sánchez Bayona R, Limón ML, Díaz-Serrano A, Fernández Montes A, Sala P, Cerdá P, Rivera F, Gallego J; AGAMENON study group. Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry. Gastric Cancer 2018;21:96-105. [PMID: 28393278 DOI: 10.1007/s10120-017-0718-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
467 Zhang J, Dong R, Shen L. Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer. Chin J Cancer Res 2020;32:263-70. [PMID: 32410803 DOI: 10.21147/j.issn.1000-9604.2020.02.13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
468 Qin S, Ji J, Xu RH, Wang W, Tang Y, Bi F, Li J, Wang K, Xu JM, Fan Q, Su W, Shen L. Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE). Oncologist 2021;26:e1567-80. [PMID: 34003545 DOI: 10.1002/onco.13826] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
469 Jain S, Dhingra S. Pathology of esophageal cancer and Barrett's esophagus. Ann Cardiothorac Surg. 2017;6:99-109. [PMID: 28446998 DOI: 10.21037/acs.2017.03.06] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
470 Kneissl J, Hartmann A, Pfarr N, Erlmeier F, Lorber T, Keller S, Zwingenberger G, Weichert W, Luber B. Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines. J Cancer Res Clin Oncol. 2017;143:573-600. [PMID: 27933395 DOI: 10.1007/s00432-016-2308-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
471 Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643-655. [PMID: 24061039 DOI: 10.1038/nrclinonc] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
472 Garg PK, Brandl A, Rau B. Hyperthermic Intraperitoneal Chemotherapy - Fading Perspective in the Light of Modern Systemic Chemotherapy? Visc Med 2018;34:412-6. [PMID: 30675484 DOI: 10.1159/000493493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
473 Chen T, Xu XY, Zhou PH. Emerging molecular classifications and therapeutic implications for gastric cancer. Chin J Cancer. 2016;35:49. [PMID: 27233623 DOI: 10.1186/s40880-016-0111-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
474 Shitara K, Sawaki A, Matsuo K, Kondo C, Takahari D, Ura T, Tajika M, Niwa Y, Muro K. A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer. Int J Clin Oncol. 2013;18:539-546. [PMID: 22552360 DOI: 10.1007/s10147-012-0416-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
475 Kochi M, Fujii M, Masuda S, Kanamori N, Mihara Y, Funada T, Tamegai H, Watanabe M, Suda H, Takayama T. Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes. Diagn Pathol 2013;8:191. [PMID: 24261710 DOI: 10.1186/1746-1596-8-191] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
476 Seo S, Park SJ, Ryu MH, Park SR, Ryoo BY, Park YS, Na YS, Lee CW, Lee JK, Kang YK. Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers. Oncotarget 2017;8:33844-54. [PMID: 27802183 DOI: 10.18632/oncotarget.12953] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
477 Ock CY, Oh DY, Lee J, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ. Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer. Gastric Cancer 2016;19:597-606. [PMID: 25749718 DOI: 10.1007/s10120-015-0481-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
478 Lin JX, Xu YC, Lin W, Xue FQ, Ye JX, Zang WD, Cai LS, You J, Xu JH, Cai JC, Tang YH, Xie JW, Li P, Zheng CH, Huang CM. Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial. JAMA Netw Open 2021;4:e2116240. [PMID: 34241629 DOI: 10.1001/jamanetworkopen.2021.16240] [Reference Citation Analysis]
479 Wang S, Wang X, Gao Y, Peng Y, Dong N, Xie Q, Zhang X, Wu Y, Li M, Li JL. RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK-cyclin D1/CDK4 pathway. J Pathol 2019;248:204-16. [PMID: 30714150 DOI: 10.1002/path.5246] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
480 Minami T, Kijima T, Kohmo S, Arase H, Otani Y, Nagatomo I, Takahashi R, Miyake K, Higashiguchi M, Morimura O, Ihara S, Tsujino K, Hirata H, Inoue K, Takeda Y, Kida H, Tachibana I, Kumanogoh A. Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis. Sci Rep 2013;3:2669. [PMID: 24036898 DOI: 10.1038/srep02669] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
481 Liu GF, Tang D, Li P, Wang S, Xu YX, Long AH, Zhou NL, Zhang LL, Chen J, Xiang XX. S-1-based combination therapy vs S-1 monotherapy in advanced gastric cancer: A meta-analysis. World J Gastroenterol 2014; 20(1): 310-318 [PMID: 24415887 DOI: 10.3748/wjg.v20.i1.310] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
482 Marte G, Tufo A, Steccanella F, Marra E, Federico P, Petrillo A, Maida P. Efficacy of Surgery for the Treatment of Gastric Cancer Liver Metastases: A Systematic Review of the Literature and Meta-Analysis of Prognostic Factors. J Clin Med 2021;10:1141. [PMID: 33803135 DOI: 10.3390/jcm10051141] [Reference Citation Analysis]
483 Kataoka K, Kinoshita T, Moehler M, Mauer M, Shitara K, Wagner AD, Schrauwen S, Yoshikawa T, Roviello F, Tokunaga M, Boku N, Ducreux M, Terashima M, Lordick F; EORTC GITCG Group and JCOG SCGC Group. Current management of liver metastases from gastric cancer: what is common practice? Gastric Cancer. 2017;20:904-912. [PMID: 28150070 DOI: 10.1007/s10120-017-0696-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
484 Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell 2019;36:444-457.e7. [PMID: 31588020 DOI: 10.1016/j.ccell.2019.09.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 14.3] [Reference Citation Analysis]
485 Yi JH, Jang J, Cho J, Do IG, Hong M, Kim ST, Kim KM, Lee S, Park SH, Park JO, Park YS, Kang WK, Lim HY, Lee J. MerTK is a novel therapeutic target in gastric cancer. Oncotarget 2017;8:96656-67. [PMID: 29228560 DOI: 10.18632/oncotarget.3750] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
486 Lee KW, Park SR, Oh DY, Park YI, Khosravan R, Lin X, Lee SY, Roh EJ, Valota O, Lechuga MJ. Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. Invest New Drugs. 2013;31:1547-1558. [PMID: 24091982 DOI: 10.1007/s10637-013-0032-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
487 Kim SH, Lee HJ, Park JH, Choi JH, Park SH, Choe HN, Oh SY, Suh YS, Kong SH, Park DJ, Yang HK. Proposal of a New TNM Classification for Gastric Cancer: Focusing on pN3b and Cytology-Positive (CY1) Disease. J Gastric Cancer 2019;19:329-43. [PMID: 31598375 DOI: 10.5230/jgc.2019.19.e33] [Reference Citation Analysis]
488 Kinoshita J, Yamaguchi T, Moriyama H, Fushida S. Current status of conversion surgery for stage IV gastric cancer. Surg Today 2021. [PMID: 33486610 DOI: 10.1007/s00595-020-02222-0] [Reference Citation Analysis]
489 Satolli MA, Buffoni L, Spadi R, Roato I. Gastric cancer: The times they are a-changin’. World J Gastrointest Oncol 2015; 7(11): 303-316 [PMID: 26600930 DOI: 10.4251/wjgo.v7.i11.303] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
490 Sue S, Shibata W, Kameta E, Sato T, Ishii Y, Kaneko H, Miwa H, Sasaki T, Tamura T, Kondo M. Intestine-specific homeobox (ISX) induces intestinal metaplasia and cell proliferation to contribute to gastric carcinogenesis. J Gastroenterol. 2016; Epub ahead of print. [PMID: 26872890 DOI: 10.1007/s00535-016-1176-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
491 Shitara K, Matsuo K, Muro K, Doi T, Ohtsu A. Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer. Gastric Cancer 2014;17:362-70. [PMID: 23736742 DOI: 10.1007/s10120-013-0274-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
492 Yip C, Weeks A, Shaw K, Siddique M, Chang F, Landau DB, Cook GJ, Goh V. Magnetic Resonance Imaging (MRI) of Intratumoral Voxel Heterogeneity as a Potential Response Biomarker: Assessment in a HER2+ Esophageal Adenocarcinoma Xenograft Following Trastuzumab and/or Cisplatin Therapy. Transl Oncol 2017;10:459-67. [PMID: 28456115 DOI: 10.1016/j.tranon.2017.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
493 Qiu M, Zhou Y, Zhang X, Wang Z, Wang F, Shao J, Lu J, Jin Y, Wei X, Zhang D. Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. BMC Cancer. 2014;14:823. [PMID: 25380654 DOI: 10.1186/1471-2407-14-823] [Cited by in Crossref: 30] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
494 Takahashi S, Kobayashi T, Tomomatsu J, Ito Y, Oda H, Kajitani T, Kakizume T, Tajima T, Takeuchi H, Maacke H, Esaki T. LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer. Cancer Chemother Pharmacol 2017;79:131-8. [PMID: 27942917 DOI: 10.1007/s00280-016-3214-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
495 Ang C, Doyle E, Branch A. Bisphosphonates as potential adjuvants for patients with cancers of the digestive system. World J Gastroenterol 2016; 22(3): 906-916 [PMID: 26811636 DOI: 10.3748/wjg.v22.i3.906] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
496 Quadri HS, Smaglo BG, Morales SJ, Phillips AC, Martin AD, Chalhoub WM, Haddad NG, Unger KR, Levy AD, Al-Refaie WB. Gastric Adenocarcinoma: A Multimodal Approach.Front Surg. 2017;4:42. [PMID: 28824918 DOI: 10.3389/fsurg.2017.00042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
497 Wang L, Chang Y, Xu J, Zhang Q. Predictive Significance of Serum Level of Vascular Endothelial Growth Factor in Gastric Cancer Patients. Biomed Res Int 2016;2016:8103019. [PMID: 27597973 DOI: 10.1155/2016/8103019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
498 Chen C, Zhang F, Zhou N, Gu YM, Zhang YT, He YD, Wang L, Yang LX, Zhao Y, Li YM. Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. Oncoimmunology. 2019;8:e1581547. [PMID: 31069144 DOI: 10.1080/2162402x.2019.1581547] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
499 Overman MJ, Soifer HS, Schueneman AJ, Ensor J Jr, Adsay V, Saka B, Neishaboori N, Wolff RA, Wang H, Schnabel CA, Varadhachary G. Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma. BMC Cancer 2016;16:668. [PMID: 27549176 DOI: 10.1186/s12885-016-2677-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
500 Ter Veer E, van Oijen MGH, van Laarhoven HWM. The Use of (Network) Meta-Analysis in Clinical Oncology. Front Oncol 2019;9:822. [PMID: 31508373 DOI: 10.3389/fonc.2019.00822] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
501 Imamura T, Komatsu S, Ichikawa D, Miyamae M, Okajima W, Ohashi T, Kiuchi J, Nishibeppu K, Kosuga T, Konishi H, Shiozaki A, Okamoto K, Fujiwara H, Otsuji E. Low plasma levels of miR-101 are associated with tumor progression in gastric cancer. Oncotarget 2017;8:106538-50. [PMID: 29290969 DOI: 10.18632/oncotarget.20860] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
502 Matthiesen SH, Hansen CM. Fast and non-toxic in situ hybridization without blocking of repetitive sequences. PLoS One 2012;7:e40675. [PMID: 22911704 DOI: 10.1371/journal.pone.0040675] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 5.2] [Reference Citation Analysis]
503 Kawamoto Y, Komatsu Y, Yuki S, Sawada K, Muranaka T, Harada K, Nakatsumi H, Fukushima H, Ishiguro A, Dazai M, Hatanaka K, Nakamura M, Iwanaga I, Uebayashi M, Sogabe S, Kobayashi Y, Miyagishima T, Ono K, Sakamoto N, Sakata Y. Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer. BMC Cancer 2017;17:837. [PMID: 29221445 DOI: 10.1186/s12885-017-3850-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
504 Park J, Park E, Han SW, Im SA, Kim TY, Kim WH, Oh DY, Bang YJ. Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer. Invest New Drugs 2012;30:1404-12. [PMID: 21720740 DOI: 10.1007/s10637-011-9710-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
505 Wang K, Zhang X, Wei J, Xu Y, Liu Q, Xie J, Yuan L, Sun Z, Tan S, Zhang L, Liu B, Yang Y. Hepatic Arterial Infusion Oxaliplatin Plus Oral S-1 Chemotherapy in Gastric Cancer with Unresectable Liver Metastases: A Case Series and Literature Review. Cancer Manag Res 2020;12:863-70. [PMID: 32104068 DOI: 10.2147/CMAR.S233123] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
506 Pak KH, Kim DH, Kim H, Lee DH, Cheong JH. Differences in TGF-β1 signaling and clinicopathologic characteristics of histologic subtypes of gastric cancer. BMC Cancer 2016;16:60. [PMID: 26846663 DOI: 10.1186/s12885-016-2091-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
507 Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, Ajani JA. Translating genomic profiling to gastrointestinal cancer treatment. Future Oncol 2017;13:919-34. [PMID: 28067073 DOI: 10.2217/fon-2016-0422] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
508 Nishida Y, Kuwata T, Nitta H, Dennis E, Aizawa M, Kinoshita T, Ohtsu A, Ochiai A. A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity. Gastric Cancer 2015;18:458-66. [PMID: 24917219 DOI: 10.1007/s10120-014-0394-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
509 Lordick F, Janjigian YY. Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol. 2016;13:348-360. [PMID: 26925958 DOI: 10.1038/nrclinonc.2016.15] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 12.8] [Reference Citation Analysis]
510 Zou Q, Lv Y, Gan Z, Liao S, Liang Z. Identification and Validation of a Malignant Cell Subset Marker-Based Polygenic Risk Score in Stomach Adenocarcinoma Through Integrated Analysis of Bulk and Single-Cell RNA Sequencing Data. Front Cell Dev Biol 2021;9:720649. [PMID: 34733840 DOI: 10.3389/fcell.2021.720649] [Reference Citation Analysis]
511 Marqués-Lespier JM, González-Pons M, Cruz-Correa M. Current Perspectives on Gastric Cancer. Gastroenterol Clin North Am 2016;45:413-28. [PMID: 27546840 DOI: 10.1016/j.gtc.2016.04.002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 11.8] [Reference Citation Analysis]
512 Ahn DH, Bekaii-Saab T. Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. J Gastrointest Oncol 2017;8:293-301. [PMID: 28480068 DOI: 10.21037/jgo.2016.10.01] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
513 Xu Z, Huo X, Ye H, Tang C, Nandakumar V, Lou F, Zhang D, Dong H, Sun H, Jiang S, Zhang G, Liu Z, Dong Z, Guo B, He Y, Yan C, Wang L, Su Z, Li Y, Gu D, Zhang X, Wu X, Wei X, Hong L, Zhang Y, Yang J, Gong Y, Tang C, Jones L, Huang XF, Chen SY, Chen J. Genetic mutation analysis of human gastric adenocarcinomas using ion torrent sequencing platform. PLoS One 2014;9:e100442. [PMID: 25025766 DOI: 10.1371/journal.pone.0100442] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
514 Adashek JJ, Arroyo-Martinez Y, Menta AK, Kurzrock R, Kato S. Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer. Front Oncol 2020;10:1312. [PMID: 32850413 DOI: 10.3389/fonc.2020.01312] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
515 Tokumaru Y, Tajirika T, Sugito N, Kuranaga Y, Shinohara H, Tsujino T, Matsuhashi N, Futamura M, Akao Y, Yoshida K. Synthetic miR-143 Inhibits Growth of HER2-Positive Gastric Cancer Cells by Suppressing KRAS Networks Including DDX6 RNA Helicase. Int J Mol Sci 2019;20:E1697. [PMID: 30959742 DOI: 10.3390/ijms20071697] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
516 Rivera F, Grávalos C, García-Carbonero R. SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma. Clin Transl Oncol. 2012;14:528-535. [PMID: 22721798 DOI: 10.1007/s12094-012-0836-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
517 Lee H, Ross JS. The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer. Therap Adv Gastroenterol. 2017;10:507-520. [PMID: 28567120 DOI: 10.1177/1756283x17698090] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
518 Kobayakawa M, Kojima Y. Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. Onco Targets Ther. 2011;4:193-201. [PMID: 22162925 DOI: 10.2147/ott.s19059] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
519 Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology. 2011;58:383-394. [PMID: 21323962 DOI: 10.1111/j.1365-2559.2011.03760.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 5.1] [Reference Citation Analysis]
520 Qian J, Zhu W, Wang K, Ma L, Xu J, Xu T, Røe OD, Li A, Zhou J, Shu Y. JWA loss promotes cell migration and cytoskeletal rearrangement by affecting HER2 expression and identifies a high-risk subgroup of HER2-positive gastric carcinoma patients. Oncotarget 2016;7:36865-84. [PMID: 27167206 DOI: 10.18632/oncotarget.9211] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
521 Matsumoto T, Oda T, Yoshida Y, Kimura S, Himei H, Tsuduki T, Takagi S, Takatani M, Morishita H. Takotsubo cardiomyopathy caused by infusion reaction to trastuzumab. Int Cancer Conf J 2020;9:28-31. [PMID: 31950014 DOI: 10.1007/s13691-019-00396-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
522 Chen J, Wang J. Efficacy and safety assessment of apatinib in patients with advanced gastric cancer: a meta-analysis. Onco Targets Ther 2018;11:4149-58. [PMID: 30050306 DOI: 10.2147/OTT.S157466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
523 Shim HJ, Yun JY, Hwang JE, Bae WK, Cho SH, Chung IJ. Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer. Gastric Cancer 2011;14:249-56. [PMID: 21431297 DOI: 10.1007/s10120-011-0032-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
524 Wong H, Yau T. Molecular targeted therapies in advanced gastric cancer: does tumor histology matter? Therap Adv Gastroenterol. 2013;6:15-31. [PMID: 23320047 DOI: 10.1177/1756283x12453636] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
525 Bird-lieberman E, Ford H, Fitzgerald R. Barrett’s oesophagus and oesophageal adenocarcinoma. Medicine 2011;39:142-8. [DOI: 10.1016/j.mpmed.2010.12.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
526 Matsusaka S, Yoshida K. Letter in response to "Our HER2 is same as yours". Transl Gastroenterol Hepatol 2016;1:18. [PMID: 28138585 DOI: 10.21037/tgh.2016.03.01] [Reference Citation Analysis]
527 Nakamura Y, Kawazoe A, Lordick F, Janjigian YY, Shitara K. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat Rev Clin Oncol 2021;18:473-87. [PMID: 33790428 DOI: 10.1038/s41571-021-00492-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
528 Ko BK, Choi S, Cui LG, Lee YH, Hwang IS, Kim KT, Shim H, Lee JS. Affinity Maturation of Monoclonal Antibody 1E11 by Targeted Randomization in CDR3 Regions Optimizes Therapeutic Antibody Targeting of HER2-Positive Gastric Cancer. PLoS One 2015;10:e0134600. [PMID: 26225765 DOI: 10.1371/journal.pone.0134600] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
529 Qiu HB, Zhang LY, Ren C, Zeng ZL, Wu WJ, Luo HY, Zhou ZW, Xu RH. Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating Wnt/β-catenin signaling. PLoS One. 2013;8:e56959. [PMID: 23554857 DOI: 10.1371/journal.pone.0056959] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
530 Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014;6:377-387. [PMID: 24440717 DOI: 10.1016/j.celrep.2013.12.035] [Cited by in Crossref: 170] [Cited by in F6Publishing: 163] [Article Influence: 21.3] [Reference Citation Analysis]
531 Grossman R, Francis R. The Way to Man's Heart Is through the Stomach. Thorac Cardiovasc Surg 2021;69:2-7. [PMID: 31756748 DOI: 10.1055/s-0039-1700886] [Reference Citation Analysis]
532 Matzenauer M, Vrána D, Vlachová Z, Aujesky R, Vrba R, Neoral C, Melichar B. Stereotactic radiotherapy in the treatment of local recurrences of esophageal cancer. Oncol Lett 2017;13:1807-10. [PMID: 28454327 DOI: 10.3892/ol.2017.5605] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
533 Tamura S, Takeno A, Miki H. Lymph node dissection in curative gastrectomy for advanced gastric cancer. Int J Surg Oncol. 2011;2011:748745. [PMID: 22312521 DOI: 10.1155/2011/748745] [Cited by in Crossref: 9] [Cited by in F6Publishing: 21] [Article Influence: 0.8] [Reference Citation Analysis]
534 Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, Elimova E, Ajani JA, Psyrri A. Medical management of gastric cancer: a 2017 update. Cancer Med. 2018;7:123-133. [PMID: 29239137 DOI: 10.1002/cam4.1274] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 14.4] [Reference Citation Analysis]
535 Bupathi M, Ahn DH, Bekaii-Saab T. Therapeutic options for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017;6:91-100. [PMID: 28503556 DOI: 10.21037/hbsn.2016.12.12] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
536 Jhaveri TZ, Woo J, Shang X, Park BH, Gabrielson E. AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer. Oncotarget 2015;6:14754-65. [PMID: 26143491 DOI: 10.18632/oncotarget.4474] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
537 Biondi A, Lirosi MC, D’Ugo D, Fico V, Ricci R, Santullo F, Rizzuto A, Cananzi FC, Persiani R. Neo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectives. World J Gastrointest Oncol 2015; 7(12): 389-400 [PMID: 26690252 DOI: 10.4251/wjgo.v7.i12.389] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
538 Taghizadeh H, Mader RM, Müllauer L, Fuereder T, Kautzky-Willer A, Prager GW. Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers. Cancers (Basel) 2020;12:E3381. [PMID: 33203166 DOI: 10.3390/cancers12113381] [Reference Citation Analysis]
539 Jain VK, Cunningham D, Rao S. Chemotherapy for operable gastric cancer: current perspectives. Indian J Surg Oncol. 2011;2:334-342. [PMID: 23204792 DOI: 10.1007/s13193-012-0139-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
540 Nagatsuma AK, Aizawa M, Kuwata T, Doi T, Ohtsu A, Fujii H, Ochiai A. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer. 2015;18:227-238. [PMID: 24626858 DOI: 10.1007/s10120-014-0360-4] [Cited by in Crossref: 87] [Cited by in F6Publishing: 88] [Article Influence: 10.9] [Reference Citation Analysis]
541 Tang L, Hu H, He Y, Mcleod HL, Xiao D, Chen P, Shen L, Zeng S, Yin X, Ge J, Li L, Ma J, Chen Z, Huang J. The relationship between miR-302b and EphA2 and their clinical significance in gastric cancer. J Cancer 2018;9:3109-16. [PMID: 30210634 DOI: 10.7150/jca.25235] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
542 Clemons NJ, Phillips WA, Lord RV. Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction. Cancer Biol Ther. 2013;14:782-795. [PMID: 23792587 DOI: 10.4161/cbt.25362] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
543 Peng Z, Liu XY, Cheng Z, Kai W, Song Z. Comprehensive analysis of a new immune-related prognostic signature for esophageal cancer and its correlation with infiltrating immune cells and target genes. Ann Transl Med 2021;9:1576. [PMID: 34790782 DOI: 10.21037/atm-21-4756] [Reference Citation Analysis]
544 Patel KB, Arantes LH Jr, Tang WY, Fung S. The role of biosimilars in value-based oncology care. Cancer Manag Res 2018;10:4591-602. [PMID: 30410395 DOI: 10.2147/CMAR.S164201] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
545 Beggs AD, Dilworth MP. Surgery in the era of the 'omics revolution. Br J Surg 2015;102:e29-40. [PMID: 25627134 DOI: 10.1002/bjs.9722] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
546 Liu T, Qin Y, Li J, Xu R, Xu J, Yang S, Qin S, Bai Y, Wu C, Mao Y, Wu H, Ge Y, Shen L. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. Cancer Commun (Lond) 2019;39:38. [PMID: 31234927 DOI: 10.1186/s40880-019-0384-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
547 Teles SP, Oliveira P, Ferreira M, Carvalho J, Ferreira P, Oliveira C. Integrated Analysis of Structural Variation and RNA Expression of FGFR2 and Its Splicing Modulator ESRP1 Highlight the ESRP1amp-FGFR2norm-FGFR2-IIIchigh Axis in Diffuse Gastric Cancer. Cancers (Basel) 2019;12:E70. [PMID: 31881796 DOI: 10.3390/cancers12010070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
548 Chung HC, Bang YJ, S Fuchs C, Qin SK, Satoh T, Shitara K, Tabernero J, Van Cutsem E, Alsina M, Cao ZA, Lu J, Bhagia P, Shih CS, Janjigian YY. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol 2021;17:491-501. [PMID: 33167735 DOI: 10.2217/fon-2020-0737] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
549 Kim TH, Do Cho H, Choi YW, Lee HW, Kang SY, Jeong GS, Choi JH, Ahn MS, Sheen SS. Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data. BMC Cancer 2021;21:325. [PMID: 33771119 DOI: 10.1186/s12885-021-08058-2] [Reference Citation Analysis]
550 Raufi AG, Klempner SJ. Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol. 2015;6:561-569. [PMID: 26487950 DOI: 10.3978/j.issn.2078-6891.2015.037] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
551 Baek SK, Kim SY, Jeong JH, Cho KS, Yoon HJ. Second-line chemotherapy for advanced gastric cancer in Korea. Gastric Cancer 2012;15:345-54. [PMID: 22410800 DOI: 10.1007/s10120-011-0114-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
552 Purim O, Beny A, Inbar M, Shulman K, Brenner B, Dudnik E, Bokstein F, Temper M, Limon D, Matceyevsky D, Sarid D, Segal A, Semenisty V, Brenner R, Peretz T, Idelevich E, Pelles-Avraham S, Meirovitz A, Figer A, Russell K, Voss A, Dvir A, Soussan-Gutman L, Hubert A. Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience. Target Oncol 2018;13:217-26. [PMID: 29353436 DOI: 10.1007/s11523-017-0548-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
553 Oh DY, Lee KW, Cho JY, Kang WK, Im SA, Kim JW, Bang YJ. Phase II trial of dacomitinib in patients with HER2-positive gastric cancer. Gastric Cancer 2016;19:1095-103. [PMID: 26581547 DOI: 10.1007/s10120-015-0567-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
554 Press MF, Sauter G, Buyse M, Fourmanoir H, Quinaux E, Tsao-Wei DD, Eiermann W, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Mackey JR, Bee V, Ma Y, Villalobos I, Campeau A, Mirlacher M, Lindsay MA, Slamon DJ. HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. J Clin Oncol 2016;34:3518-28. [PMID: 27573653 DOI: 10.1200/JCO.2016.66.6693] [Cited by in Crossref: 82] [Cited by in F6Publishing: 30] [Article Influence: 16.4] [Reference Citation Analysis]
555 Yamaguchi K, Yoshida K, Tanahashi T, Takahashi T, Matsuhashi N, Tanaka Y, Tanabe K, Ohdan H. The long-term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer 2018;21:315-23. [PMID: 28616743 DOI: 10.1007/s10120-017-0738-1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 7.8] [Reference Citation Analysis]
556 Pasini FS, Zilberstein B, Snitcovsky I, Roela RA, Mangone FR, Ribeiro U Jr, Nonogaki S, Brito GC, Callegari GD, Cecconello I, Alves VA, Eluf-Neto J, Chammas R, Federico MH. A gene expression profile related to immune dampening in the tumor microenvironment is associated with poor prognosis in gastric adenocarcinoma. J Gastroenterol 2014;49:1453-66. [PMID: 24217965 DOI: 10.1007/s00535-013-0904-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
557 Rhode P, Mehdorn M, Lyros O, Kahlert C, Kurth T, Venus T, Schierle K, Estrela-Lopis I, Jansen-Winkeln B, Lordick F, Gockel I, Thieme R. Characterization of Total RNA, CD44, FASN, and PTEN mRNAs from Extracellular Vesicles as Biomarkers in Gastric Cancer Patients. Cancers (Basel) 2021;13:5975. [PMID: 34885085 DOI: 10.3390/cancers13235975] [Reference Citation Analysis]
558 Yu Y, Ma X, Zhang Y, Zhang Y, Ying J, Zhang W, Zhong Q, Zhou A, Zeng Y. Changes in Expression of Multiple Checkpoint Molecules and Infiltration of Tumor Immune Cells after Neoadjuvant Chemotherapy in Gastric Cancer. J Cancer 2019;10:2754-63. [PMID: 31258783 DOI: 10.7150/jca.31755] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
559 Saisana M, Griffin SM, May FE. Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation. Oncotarget 2016;7:54445-62. [PMID: 27437872 DOI: 10.18632/oncotarget.10642] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
560 Viúdez A, Carmona-Bayonas A, Gallego J, Lacalle A, Hernández R, Cano JM, Macías I, Custodio A, Martínez de Castro E, Sánchez A, Iglesia L, Reguera P, Visa L, Azkarate A, Sánchez-Cánovas M, Mangas M, Limón ML, Martínez-Torrón A, Asensio E, Ramchandani A, Martín-Carnicero A, Hurtado A, Cerdà P, Garrido M, Sánchez-Bayonas R, Serrano R, Jiménez-Fonseca P; AGAMENON Study Group. Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry. Clin Transl Oncol 2020;22:734-50. [PMID: 31385226 DOI: 10.1007/s12094-019-02183-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
561 Kollmann D, Ignatova D, Jedamzik J, Chang YT, Jomrich G, Paireder M, Kristo I, Kazakov D, Michal M, Cozzio A, Hoetzenecker W, Schatton T, Asari R, Preusser M, Guenova E, Schoppmann SF. Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma. Ann Surg Oncol 2017;24:2698-706. [PMID: 28429196 DOI: 10.1245/s10434-017-5858-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
562 Koh J, Lee KW, Nam SK, Seo AN, Kim JW, Kim JW, Park DJ, Kim HH, Kim WH, Lee HS. Development and Validation of an Easy-to-Implement, Practical Algorithm for the Identification of Molecular Subtypes of Gastric Cancer: Prognostic and Therapeutic Implications. Oncologist 2019;24:e1321-30. [PMID: 31371521 DOI: 10.1634/theoncologist.2019-0058] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
563 Mikhail S, Ciombor K, Noonan A, Wu C, Goldberg R, Zhao W, Wei L, Mathey K, Yereb M, Timmers C, Bekaii-Saab T. Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet? Oncotarget 2015;6:22206-13. [PMID: 26082439 DOI: 10.18632/oncotarget.4247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
564 Hu R, Liu W, Qiu X, Lin Z, Xie Y, Hong X, Paerhati R, Qi Z, Zhuang G, Liu Z. Expression of tumor necrosis factor-α-induced protein 8 in stage III gastric cancer and the correlation with DcR3 and ERK1/2. Oncol Lett 2016;11:1835-40. [PMID: 26998086 DOI: 10.3892/ol.2016.4133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
565 Kim HS, Lee H, Shin SJ, Beom SH, Jung M, Bae S, Lee EY, Park KH, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Park JC, Shin SK, Lee SK, Lee YC, Koom WS, Lim JS, Chung HC, Noh SH, Rha SY, Kim H, Paik S. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. Oncotarget 2017;8:38389-98. [PMID: 28418920 DOI: 10.18632/oncotarget.16409] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
566 Li S, Lan X, Gao H, Li Z, Chen L, Wang W, Song S, Wang Y, Li C, Zhang H, Xue Y. Systemic Inflammation Response Index (SIRI), cancer stem cells and survival of localised gastric adenocarcinoma after curative resection. J Cancer Res Clin Oncol 2017;143:2455-68. [PMID: 28828692 DOI: 10.1007/s00432-017-2506-3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 7.4] [Reference Citation Analysis]
567 Kanagavel D, Fedyanin M, Tryakin A, Tjulandin S. Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol 2015; 21(41): 11621-11635 [PMID: 26556991 DOI: 10.3748/wjg.v21.i41.11621] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
568 Wang W, Sun Z, Deng JY, Qi XL, Feng XY, Fang C, Ma XH, Wang ZN, Liang H, Xu HM, Zhou ZW. A novel nomogram individually predicting disease-specific survival after D2 gastrectomy for advanced gastric cancer. Cancer Commun (Lond). 2018;38:23. [PMID: 29764518 DOI: 10.1186/s40880-018-0293-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
569 Bang YJ, Ruiz EY, Van Cutsem E, Lee KW, Wyrwicz L, Schenker M, Alsina M, Ryu MH, Chung HC, Evesque L, Al-Batran SE, Park SH, Lichinitser M, Boku N, Moehler MH, Hong J, Xiong H, Hallwachs R, Conti I, Taieb J. Phase III, randomised trial of avelumab vs physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018;29:2052-2060. [PMID: 30052729 DOI: 10.1093/annonc/mdy264] [Cited by in Crossref: 169] [Cited by in F6Publishing: 175] [Article Influence: 56.3] [Reference Citation Analysis]
570 Zhu YH, Ye N, Tang XF, Khan MI, Liu HL, Shi N, Hang LF. Synergistic Effect of Retinoic Acid Polymeric Micelles and Prodrug for the Pharmacodynamic Evaluation of Tumor Suppression. Front Pharmacol 2019;10:447. [PMID: 31156425 DOI: 10.3389/fphar.2019.00447] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
571 Tokunaga M, Sato Y, Nakagawa M, Aburatani T, Matsuyama T, Nakajima Y, Kinugasa Y. Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives. Surg Today. 2020;50:30-37. [PMID: 31612329 DOI: 10.1007/s00595-019-01896-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
572 Su X, Zhan P, Gavine PR, Morgan S, Womack C, Ni X, Shen D, Bang YJ, Im SA, Ho Kim W, Jung EJ, Grabsch HI, Kilgour E. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cancer. 2014;110:967-975. [PMID: 24457912 DOI: 10.1038/bjc.2013.802] [Cited by in Crossref: 111] [Cited by in F6Publishing: 102] [Article Influence: 13.9] [Reference Citation Analysis]
573 Popa EC, Shah MA. Met, IGF1R, and other new targets in upper GI malignancies. Curr Treat Options Oncol. 2013;14:321-336. [PMID: 23873272 DOI: 10.1007/s11864-013-0245-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
574 Kim J, Hong JY, Kim ST, Park SH, Jekal SY, Choi JS, Chang DK, Kang WK, Seo SW, Lee J. Clinical scoring system for the prediction of survival of patients with advanced gastric cancer. ESMO Open 2020;5:e000670. [PMID: 32188716 DOI: 10.1136/esmoopen-2020-000670] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
575 Grupp K, Uzunoglu FG, Melling N, Hofmann B, El Gammal AT, Grotelüschen R, Heumann A, Bellon E, Reeh M, Wolters-Eisfeld G, Ghabdan T, Nentwich M, Bachmann K, Bockhorn M, Bogoevski D, Izbicki JR, Kutup A. FOXO1 overexpression and loss of pSerine256-FOXO1 expression predicts clinical outcome in esophageal adenocarcinomas. Sci Rep 2018;8:17370. [PMID: 30478420 DOI: 10.1038/s41598-018-35459-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
576 Atreya R, Goetz M. Molecular imaging in gastroenterology. Nat Rev Gastroenterol Hepatol. 2013;10:704-712. [PMID: 23856892 DOI: 10.1038/nrgastro.2013.125] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
577 Amedei A, Benagiano M, della Bella C, Niccolai E, D'Elios MM. Novel immunotherapeutic strategies of gastric cancer treatment. J Biomed Biotechnol 2011;2011:437348. [PMID: 22253528 DOI: 10.1155/2011/437348] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
578 Yoong J, Michael M, Leong T. Targeted therapies for gastric cancer: current status. Drugs. 2011;71:1367-1384. [PMID: 21812503 DOI: 10.2165/11592530-000000000-00000] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
579 Moik F, van Es N, Posch F, Di Nisio M, Fuereder T, Preusser M, Pabinger I, Ay C. Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study. Cancers (Basel) 2020;12:E2493. [PMID: 32899157 DOI: 10.3390/cancers12092493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
580 Hoppe S, Jonas C, Wenzel MC, Velazquez Camacho O, Arolt C, Zhao Y, Büttner R, Quaas A, Plum PS, Hillmer AM. Genomic and Transcriptomic Characteristics of Esophageal Adenocarcinoma. Cancers (Basel) 2021;13:4300. [PMID: 34503107 DOI: 10.3390/cancers13174300] [Reference Citation Analysis]
581 Wu B, Li T, Cai J, Xu Y, Zhao G. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer 2014;14:984. [PMID: 25526802 DOI: 10.1186/1471-2407-14-984] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
582 Parisi A, Cortellini A, Roberto M, Venditti O, Santini D, Dell'Aquila E, Stellato M, Marchetti P, Occhipinti MA, Zoratto F, Mazzuca F, Tinari N, De Tursi M, Iezzi L, Natoli C, Ratti M, Pizzo C, Ghidini M, Porzio G, Ficorella C, Cannita K. Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. J Cancer Res Clin Oncol 2019;145:2365-73. [PMID: 31280347 DOI: 10.1007/s00432-019-02971-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
583 Stewart C, Chao J, Chen YJ, Lin J, Sullivan MJ, Melstrom L, Hyung WJ, Fong Y, Paz IB, Woo Y. Multimodality management of locally advanced gastric cancer-the timing and extent of surgery. Transl Gastroenterol Hepatol 2019;4:42. [PMID: 31231709 DOI: 10.21037/tgh.2019.05.02] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
584 Choritz H, Büsche G, Kreipe H; Study Group HER2 Monitor. Quality assessment of HER2 testing by monitoring of positivity rates. Virchows Arch 2011;459:283-9. [PMID: 21809092 DOI: 10.1007/s00428-011-1132-8] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
585 Mackay HJ, Au HJ, McWhirter E, Alcindor T, Jarvi A, MacAlpine K, Wang L, Wright JJ, Oza AM. A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Invest New Drugs. 2012;30:1158-1163. [PMID: 21400081 DOI: 10.1007/s10637-011-9650-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
586 Jiménez-Fonseca P, Carmona-Bayonas A, Sánchez Lorenzo ML, Plazas JG, Custodio A, Hernández R, Garrido M, García T, Echavarría I, Cano JM, Rodríguez Palomo A, Mangas M, Macías Declara I, Ramchandani A, Visa L, Viudez A, Buxó E, Díaz-Serrano A, López C, Azkarate A, Longo F, Castañón E, Sánchez Bayona R, Pimentel P, Limón ML, Cerdá P, Álvarez Llosa R, Serrano R, Lobera MPF, Alsina M, Hurtado Nuño A, Gómez-Martin C. Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. Gastric Cancer 2017;20:465-74. [PMID: 27599830 DOI: 10.1007/s10120-016-0639-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
587 Ishii T, Kawazoe A, Shitara K. Dawn of precision medicine on gastric cancer. Int J Clin Oncol 2019;24:779-88. [PMID: 30976939 DOI: 10.1007/s10147-019-01441-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
588 Kano K, Aoyama T, Maezawa Y, Nakajima T, Ikeda K, Yamada T, Sato T, Oshima T, Rino Y, Masuda M, Ogata T, Cho H, Yoshikawa T. The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy. Int J Clin Oncol. 2017;22:887-896. [PMID: 28456896 DOI: 10.1007/s10147-017-1128-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
589 Iwatsuki M, Toyoshima K, Watanabe M, Hayashi N, Ishimoto T, Eto K, Iwagami S, Baba Y, Yoshida N, Hayashi A, Ohta Y, Baba H. Frequency of HER2 expression of circulating tumour cells in patients with metastatic or recurrent gastrointestinal cancer. Br J Cancer 2013;109:2829-32. [PMID: 24201755 DOI: 10.1038/bjc.2013.680] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
590 Li S, Cong X, Gao H, Lan X, Li Z, Wang W, Song S, Wang Y, Li C, Zhang H, Zhao Y, Xue Y. Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells. J Exp Clin Cancer Res 2019;38:6. [PMID: 30616627 DOI: 10.1186/s13046-018-1003-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 11.7] [Reference Citation Analysis]
591 Elimova E, Shiozaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, Blum MA, Badgwell B, Das P, Song S, Ajani JA. Medical management of gastric cancer: A 2014 update. World J Gastroenterol 2014; 20(38): 13637-13647 [PMID: 25320502 DOI: 10.3748/wjg.v20.i38.13637] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
592 Radpour R, Forouharkhou F. Single-cell analysis of tumors: Creating new value for molecular biomarker discovery of cancer stem cells and tumor-infiltrating immune cells. World J Stem Cells 2018; 10(11): 160-171 [PMID: 30631391 DOI: 10.4252/wjsc.v10.i11.160] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
593 Wu SG, Xie WH, Zhang ZQ, Sun JY, Li FY, Lin HX, Yong Bao, He ZY. Surgery Combined with Radiotherapy Improved Survival in Metastatic Esophageal Cancer in a Surveillance Epidemiology and End Results Population-based Study. Sci Rep 2016;6:28280. [PMID: 27323696 DOI: 10.1038/srep28280] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
594 Hamamoto Y, Piao Y, Makiyama A. Achieving sequential therapy in advanced gastric cancer: the importance of appropriate patient management for the elderly and/or those with ascites. Gastric Cancer 2020;23:363-72. [PMID: 32236760 DOI: 10.1007/s10120-020-01067-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
595 Kannangara DKS, Lokuhetty MDS, Subasinghe D, Gunawardene YINS, Dassanayake RS. Could quantitative real-time polymerase chain reaction assay serve as an alternative test method to evaluate human epidermal growth factor receptor 2 status of gastric carcinoma in the South Asian setting? Indian J Gastroenterol 2019;38:317-24. [PMID: 31401730 DOI: 10.1007/s12664-019-00955-6] [Reference Citation Analysis]
596 Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 310] [Article Influence: 28.2] [Reference Citation Analysis]
597 Mukherjee S, Hochwald SN. Pembrolizumab in advanced gastric cancer: pioneering or prosaic? Ann Transl Med 2019;7:S3. [PMID: 31032284 DOI: 10.21037/atm.2019.01.17] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
598 Nakamura K, Aimono E, Oba J, Hayashi H, Tanishima S, Hayashida T, Chiyoda T, Kosaka T, Hishida T, Kawakubo H, Kitago M, Okabayashi K, Funakoshi T, Okita H, Ikeda S, Takaishi H, Nishihara H. Estimating copy number using next-generation sequencing to determine ERBB2 amplification status. Med Oncol 2021;38:36. [PMID: 33710417 DOI: 10.1007/s12032-021-01482-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
599 Zhang W, Yu Y, Fang Y, Wang Y, Cui Y, Shen K, Liu T. Systemic chemotherapy as a main strategy for liver metastases from gastric cancer. Clin Transl Oncol. 2015;17:888-894. [PMID: 26108406 DOI: 10.1007/s12094-015-1321-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
600 Müller V, Clemens M, Jassem J, Al-Sakaff N, Auclair P, Nüesch E, Holloway D, Shing M, Bang YJ. Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer. BMC Cancer 2018;18:295. [PMID: 29544445 DOI: 10.1186/s12885-018-4183-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
601 Gao J, Wang H, Zang W, Li B, Rao G, Li L, Yu Y, Li Z, Dong B, Lu Z, Jiang Z, Shen L. Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer. Cancer Sci. 2017;108:1881-1887. [PMID: 28677165 DOI: 10.1111/cas.13314] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
602 Kurokawa Y, Sugimoto N, Miwa H, Tsuda M, Nishina S, Okuda H, Imamura H, Gamoh M, Sakai D, Shimokawa T, Komatsu Y, Doki Y, Tsujinaka T, Furukawa H. Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer. 2014;110:1163-1168. [PMID: 24473399 DOI: 10.1038/bjc.2014.18] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 10.6] [Reference Citation Analysis]
603 Tang D, Liu CY, Shen D, Fan S, Su X, Ye P, Gavine PR, Yin X. Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas. Onco Targets Ther. 2015;8:7-14. [PMID: 25565860 DOI: 10.2147/OTT.S70922] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
604 Park Y, Seo AN, Koh J, Nam SK, Kwak Y, Ahn SH, Park DJ, Kim HH, Lee HS. Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry. Oncoimmunology 2021;10:1954761. [PMID: 34367732 DOI: 10.1080/2162402X.2021.1954761] [Reference Citation Analysis]
605 Araújo TM, Seabra AD, Lima EM, Assumpção PP, Montenegro RC, Demachki S, Burbano RM, Khayat AS. Recurrent amplification of RTEL1 and ABCA13 and its synergistic effect associated with clinicopathological data of gastric adenocarcinoma. Mol Cytogenet 2016;9:52. [PMID: 27366209 DOI: 10.1186/s13039-016-0260-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
606 Izadi F, Sharpe BP, Breininger SP, Secrier M, Gibson J, Walker RC, Rahman S, Devonshire G, Lloyd MA, Walters ZS, Fitzgerald RC, Rose-Zerilli MJJ, Underwood TJ, On Behalf Of Occams. Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma. Cancers (Basel) 2021;13:3394. [PMID: 34298611 DOI: 10.3390/cancers13143394] [Reference Citation Analysis]
607 Takahashi K, Taki S, Yasui H, Nishinaga Y, Isobe Y, Matsui T, Shimizu M, Koike C, Sato K. HER2 targeting near-infrared photoimmunotherapy for a CDDP-resistant small-cell lung cancer. Cancer Med 2021. [PMID: 34729945 DOI: 10.1002/cam4.4381] [Reference Citation Analysis]
608 Desautels D, Harlos C, Czaykowski P. The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer. J Carcinog 2014;13:13. [PMID: 25525412 DOI: 10.4103/1477-3163.145609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
609 Orii T, Karasawa Y, Kitahara H, Yoshimura M, Okumura M. Long-term survival after sequential chemotherapy and surgery for advanced gastric cancer. Int J Surg Case Rep 2013;4:976-80. [PMID: 24070832 DOI: 10.1016/j.ijscr.2013.07.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
610 Li Q, Jiang H, Li H, Xu R, Shen L, Yu Y, Wang Y, Cui Y, Li W, Yu S, Liu T. Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study. Oncotarget 2016;7:50656-65. [PMID: 27409420 DOI: 10.18632/oncotarget.10456] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
611 Cummings D, Wong J, Palm R, Hoffe S, Almhanna K, Vignesh S. Epidemiology, Diagnosis, Staging and Multimodal Therapy of Esophageal and Gastric Tumors. Cancers (Basel) 2021;13:582. [PMID: 33540736 DOI: 10.3390/cancers13030582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
612 Ji C, Zhang Q, Guan W, Guo T, Chen L, Liu S, He J, Zhou Z. Role of intravoxel incoherent motion MR imaging in preoperative assessing HER2 status of gastric cancers. Oncotarget. 2017;8:49293-49302. [PMID: 28514733 DOI: 10.18632/oncotarget.17570] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
613 Grillo F, Fassan M, Sarocchi F, Fiocca R, Mastracci L. HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice. World J Gastroenterol 2016; 22(26): 5879-5887 [PMID: 27468182 DOI: 10.3748/wjg.v22.i26.5879] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 44] [Article Influence: 7.7] [Reference Citation Analysis]
614 Liu J, Liu F, Shi Y, Tan H, Zhou L. Identification of key miRNAs and genes associated with stomach adenocarcinoma from The Cancer Genome Atlas database. FEBS Open Bio 2018;8:279-94. [PMID: 29435418 DOI: 10.1002/2211-5463.12365] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
615 Schulenburg A, Blatt K, Cerny-Reiterer S, Sadovnik I, Herrmann H, Marian B, Grunt TW, Zielinski CC, Valent P. Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? J Hematol Oncol 2015;8:16. [PMID: 25886184 DOI: 10.1186/s13045-015-0113-9] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 7.9] [Reference Citation Analysis]
616 Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open. 2017;2:e000279. [PMID: 29209536 DOI: 10.1136/esmoopen-2017-000279] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 9.0] [Reference Citation Analysis]
617 Long D, Yu PC, Huang W, Luo YL, Zhang S. Systematic review of partial hepatic resection to treat hepatic metastases in patients with gastric cancer. Medicine (Baltimore) 2016;95:e5235. [PMID: 27858875 DOI: 10.1097/MD.0000000000005235] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
618 Sasaki Y, Miwa K, Yamashita K, Sunakawa Y, Shimada K, Ishida H, Hasegawa K, Fujiwara K, Kodaira M, Fujiwara Y, Namiki M, Matsuda M, Takeuchi Y, Katsumata N. A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors. Invest New Drugs 2015;33:332-40. [PMID: 25380636 DOI: 10.1007/s10637-014-0180-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
619 Zaanan A, Palle J, Soularue E, Leroy F, Louafi S, Tougeron D, Manfredi S, Artru P, Pozet A, Taieb J. Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study. Target Oncol 2018;13:107-12. [PMID: 29090377 DOI: 10.1007/s11523-017-0531-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
620 Park J, Choi Y, Ko YS, Kim Y, Pyo JS, Jang BG, Kim MA, Lee JS, Chang MS, Park JW, Lee BL. FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation. Cancer Res Treat 2018;50:239-54. [PMID: 28343375 DOI: 10.4143/crt.2016.580] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
621 Park KS, Hong YS, Choi J, Yoon S, Kang J, Kim D, Lee KP, Im HS, Lee CH, Seo S, Kim SW, Lee DH, Park SR. HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells. BMB Rep 2018;51:660-5. [PMID: 30591093 [PMID: 30591093 DOI: 10.5483/bmbrep.2018.51.12.259] [Cited by in Crossref: 8] [Article Influence: 2.7] [Reference Citation Analysis]
622 Lodhia KA, Hadley AM, Haluska P, Scott CL. Prioritizing therapeutic targets using patient-derived xenograft models. Biochim Biophys Acta 2015;1855:223-34. [PMID: 25783201 DOI: 10.1016/j.bbcan.2015.03.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
623 Takahashi N, Yamada Y, Taniguchi H, Fukahori M, Sasaki Y, Shoji H, Honma Y, Iwasa S, Takashima A, Kato K. Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer. BMC Res Notes. 2014;7:271. [PMID: 24774510 DOI: 10.1186/1756-0500-7-271] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
624 Nakayama N, Yamashita K, Tanaka T, Kawamata H, Ooki A, Sato T, Nakamura T, Watanabe M. Genomic gain of the PRL-3 gene may represent poor prognosis of primary colorectal cancer, and associate with liver metastasis. Clin Exp Metastasis 2016;33:3-13. [PMID: 26563151 DOI: 10.1007/s10585-015-9749-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
625 Li X, Tang D, Yao Y, Qi W, Liang J. Clinical significance and positive correlation of FoxM1 and Her-2 expression in gastric cancer. Clin Exp Med 2014;14:447-55. [PMID: 24101296 DOI: 10.1007/s10238-013-0261-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
626 Mitsuda Y, Morita K, Kashiwazaki G, Taniguchi J, Bando T, Obara M, Hirata M, Kataoka TR, Muto M, Kaneda Y, Nakahata T, Liu PP, Adachi S, Sugiyama H, Kamikubo Y. RUNX1 positively regulates the ErbB2/HER2 signaling pathway through modulating SOS1 expression in gastric cancer cells. Sci Rep 2018;8:6423. [PMID: 29686309 DOI: 10.1038/s41598-018-24969-w] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
627 Harada K, Mizrak Kaya D, Shimodaira Y, Ajani JA. Global chemotherapy development for gastric cancer. Gastric Cancer 2017;20:92-101. [PMID: 27718136 DOI: 10.1007/s10120-016-0655-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
628 Park KK, Yang SI, Seo KW, Yoon KY, Lee SH, Jang HK, Shin YM. Correlations of Human Epithelial Growth Factor Receptor 2 Overexpression with MUC2, MUC5AC, MUC6, p53, and Clinicopathological Characteristics in Gastric Cancer Patients with Curative Resection. Gastroenterol Res Pract. 2015;2015:946359. [PMID: 26060493 DOI: 10.1155/2015/946359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
629 Kan S, Koido S, Okamoto M, Hayashi K, Ito M, Kamata Y, Komita H, Nagasaki E, Homma S. Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. BMC Cancer. 2015;15:726. [PMID: 26475267 DOI: 10.1186/s12885-015-1772-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
630 Hirashita Y, Tsukamoto Y, Yanagihara K, Fumoto S, Hijiya N, Nakada C, Uchida T, Matsuura K, Kodama M, Okimoto T, Daa T, Seike M, Iha H, Shirao K, Murakami K, Moriyama M. Reduced phosphorylation of ribosomal protein S6 is associated with sensitivity to MEK inhibition in gastric cancer cells. Cancer Sci 2016;107:1919-28. [PMID: 27699948 DOI: 10.1111/cas.13094] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
631 Pericay C, Rivera F, Gomez-Martin C, Nuñez I, Cassinello A, Imedio ER. Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma. Cancer Med 2016;5:3464-74. [PMID: 27774774 DOI: 10.1002/cam4.941] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
632 Ebert K, Zwingenberger G, Barbaria E, Keller S, Heck C, Arnold R, Hollerieth V, Mattes J, Geffers R, Raimúndez E, Hasenauer J, Luber B. Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines. BMC Cancer 2020;20:1039. [PMID: 33115415 DOI: 10.1186/s12885-020-07540-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
633 Goode EF, Smyth EC. Immunotherapy for Gastroesophageal Cancer. J Clin Med. 2016;5. [PMID: 27669318 DOI: 10.3390/jcm5100084] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
634 Jin C, Lin JR, Ma L, Song Y, Shi YX, Jiang P, Dong Y, Li XS. Elevated spondin-2 expression correlates with progression and prognosis in gastric cancer. Oncotarget 2017;8:10416-24. [PMID: 28060752 DOI: 10.18632/oncotarget.14423] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
635 Kamitani N, Watanabe A, Kirihataya Y, Ko S. Metachronous skeletal muscle metastasis without any other organ metastases after curative gastrectomy: a case report. Surg Case Rep 2018;4:98. [PMID: 30120615 DOI: 10.1186/s40792-018-0507-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
636 Steffen JS, Simon E, Warneke V, Balschun K, Ebert M, Röcken C. LGR4 and LGR6 are differentially expressed and of putative tumor biological significance in gastric carcinoma. Virchows Arch 2012;461:355-65. [PMID: 22855134 DOI: 10.1007/s00428-012-1292-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
637 Tessier-Cloutier B, Cai E, Schaeffer DF. Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal. Diagn Pathol 2019;14:62. [PMID: 31221175 DOI: 10.1186/s13000-019-0843-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
638 Chiari D, Orsenigo E, Guarneri G, Baiocchi GL, Mazza E, Albarello L, Bissolati M, Molfino S, Staudacher C; Gruppo Italiano Ricerca Cancro Gastrico (GIRCG). Effect of neoadjuvant chemotherapy on HER-2 expression in surgically treated gastric and oesophagogastric junction carcinoma: a multicentre Italian study. Updates Surg 2017;69:35-43. [PMID: 28276033 DOI: 10.1007/s13304-017-0423-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
639 Rosenberg AJ, Rademaker A, Hochster HS, Ryan T, Hensing T, Shankaran V, Baddi L, Mahalingam D, Mulcahy MF, Benson AB 3rd. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up. Oncologist 2019;24:1039-e642. [PMID: 31138725 DOI: 10.1634/theoncologist.2019-0330] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
640 Müsri FY, Mutlu H, Karaağaç M, Eryilmaz MK, Gündüz Ş, Artaç M. Primary Tumor Resection and Survival in Patients with Stage IV Gastric Cancer. J Gastric Cancer 2016;16:78-84. [PMID: 27433392 DOI: 10.5230/jgc.2016.16.2.78] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
641 Fiedler W, Stoeger H, Perotti A, Gastl G, Weidmann J, Dietrich B, Baumeister H, Danielczyk A, Goletz S, Salzberg M, De Dosso S. Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours. ESMO Open 2018;3:e000381. [PMID: 30018811 DOI: 10.1136/esmoopen-2018-000381] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
642 Schildberg CW, Weidinger T, Hohenberger W, Wein A, Langheinrich M, Neurath M, Boxberger F. Metastatic adenocarcinomas of the stomach or esophagogastric junction (UICC stage IV) are not always a palliative situation: a retrospective analysis. World J Surg. 2014;38:419-425. [PMID: 24146196 DOI: 10.1007/s00268-013-2293-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
643 Phan DAT, Nguyen VT, Hua TNH, Ngo QD, Doan TPT, Nguyen ST, Thai AT, Nguyen VT. HER2 Status and Its Heterogeneity in Gastric Carcinoma of Vietnamese Patient. J Pathol Transl Med 2017;51:396-402. [PMID: 28625044 DOI: 10.4132/jptm.2017.04.24] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
644 Conley BA, Staudt L, Takebe N, Wheeler DA, Wang L, Cardenas MF, Korchina V, Zenklusen JC, McShane LM, Tricoli JV, Williams PM, Lubensky I, O'Sullivan-Coyne G, Kohn E, Little RF, White J, Malik S, Harris LN, Mann B, Weil C, Tarnuzzer R, Karlovich C, Rodgers B, Shankar L, Jacobs PM, Nolan T, Berryman SM, Gastier-Foster J, Bowen J, Leraas K, Shen H, Laird PW, Esteller M, Miller V, Johnson A, Edmondson EF, Giordano TJ, Kim B, Ivy SP. The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. J Natl Cancer Inst 2021;113:27-37. [PMID: 32339229 DOI: 10.1093/jnci/djaa061] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
645 Taghizadeh H, Müllauer L, Mader RM, Füreder T, Prager GW. Molecularly guided treatment of metastatic parotid gland carcinoma in adults. Wien Klin Wochenschr 2021;133:32-40. [PMID: 33296026 DOI: 10.1007/s00508-020-01778-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
646 Song KY, Park YG, Jeon HM, Park CH. A nomogram for predicting individual survival of patients with gastric cancer who underwent radical surgery with extended lymph node dissection. Gastric Cancer 2014;17:287-93. [PMID: 23712439 DOI: 10.1007/s10120-013-0270-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
647 Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, Wang C, Qiu MZ, Cai MY, Wu Q, Liu H, Guan WL, Zhou AP, Zhang YJ, Liu TS, Bi F, Yuan XL, Rao SX, Xin Y, Sheng WQ, Xu HM, Li GX, Ji JF, Zhou ZW, Liang H, Zhang YQ, Jin J, Shen L, Li J, Xu RH. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond) 2021;41:747-95. [PMID: 34197702 DOI: 10.1002/cac2.12193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
648 Luber B, Deplazes J, Keller G, Walch A, Rauser S, Eichmann M, Langer R, Höfler H, Hegewisch-Becker S, Folprecht G. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer. 2011;11:509. [PMID: 22152101 DOI: 10.1186/1471-2407-11-509] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
649 Goetze TO, Al-Batran SE, Berlth F, Hoelscher AH. Multimodal Treatment Strategies in Esophagogastric Junction Cancer: a Western Perspective. J Gastric Cancer 2019;19:148-56. [PMID: 31245159 DOI: 10.5230/jgc.2019.19.e19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
650 Miura Y, Sukawa Y, Hironaka S, Mori M, Nishikawa K, Tokunaga S, Okuda H, Sakamoto T, Taku K, Nishikawa K, Moriwaki T, Negoro Y, Kimura Y, Uchino K, Shinozaki K, Shinozaki H, Musha N, Yoshiyama H, Tsuda T, Miyata Y, Sugimoto N, Shirakawa T, Ito M, Yonesaka K, Yoshimura K, Boku N, Nosho K, Takano T, Hyodo I. Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G). Gastric Cancer 2018;21:84-95. [PMID: 28497176 DOI: 10.1007/s10120-017-0725-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
651 Sanford M. Trastuzumab: a review of its use in HER2-positive advanced gastric cancer. Drugs. 2013;73:1605-1615. [PMID: 24057416 DOI: 10.1007/s40265-013-0119-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
652 Goh XY, Newton R, Wernisch L, Fitzgerald R. Testing the utility of an integrated analysis of copy number and transcriptomics datasets for inferring gene regulatory relationships. PLoS One 2013;8:e63780. [PMID: 23737949 DOI: 10.1371/journal.pone.0063780] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
653 Lin Z, Zhang C, Zhang M, Xu D, Fang Y, Zhou Z, Chen X, Qin N, Zhang X. Targeting cadherin-17 inactivates Ras/Raf/MEK/ERK signaling and inhibits cell proliferation in gastric cancer. PLoS One. 2014;9:e85296. [PMID: 24465527 DOI: 10.1371/journal.pone.0085296] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
654 Xiao B, Zhang Z, Viennois E, Kang Y, Zhang M, Han MK, Chen J, Merlin D. Combination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve Inflammation. Theranostics 2016;6:2250-66. [PMID: 27924161 DOI: 10.7150/thno.15710] [Cited by in Crossref: 82] [Cited by in F6Publishing: 78] [Article Influence: 13.7] [Reference Citation Analysis]
655 Yang K, Zhang WH, Liu K, Chen XZ, Zhou ZG, Hu JK. Comparison of quality of life between Billroth-І and Roux-en-Y anastomosis after distal gastrectomy for gastric cancer: A randomized controlled trial. Sci Rep 2017;7:11245. [PMID: 28900096 DOI: 10.1038/s41598-017-09676-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
656 Ramanathan RK, McDonough SL, Kennecke HF, Iqbal S, Baranda JC, Seery TE, Lim HJ, Hezel AF, Vaccaro GM, Blanke CD. Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer. 2015;121:2193-2197. [PMID: 25827820 DOI: 10.1002/cncr.29363] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 7.1] [Reference Citation Analysis]
657 Nagahashi M, Shimada Y, Ichikawa H, Kameyama H, Takabe K, Okuda S, Wakai T. Next generation sequencing-based gene panel tests for the management of solid tumors. Cancer Sci 2019;110:6-15. [PMID: 30338623 DOI: 10.1111/cas.13837] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
658 Song H, Zhu J, Lu D. Molecular-targeted first-line therapy for advanced gastric cancer. Cochrane Database Syst Rev 2016;7:CD011461. [PMID: 27432490 DOI: 10.1002/14651858.CD011461.pub2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
659 Ghosn M, Kourie HR, Tabchi S. Gastrointestinal cancers in the era of theranostics: Updates and future perspectives. World J Gastroenterol 2015; 21(28): 8473-8477 [PMID: 26229391 DOI: 10.3748/wjg.v21.i28.8473] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
660 Chen H, Ye Q, Lv J, Ye P, Sun Y, Fan S, Su X, Gavine P, Yin X. Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models. Pathol Oncol Res 2015;21:947-55. [PMID: 25749810 DOI: 10.1007/s12253-015-9909-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
661 Cardoso R, Coburn NG, Seevaratnam R, Mahar A, Helyer L, Law C, Singh S. A systematic review of patient surveillance after curative gastrectomy for gastric cancer: a brief review. Gastric Cancer. 2012;15 Suppl 1:S164-S167. [PMID: 22382929 DOI: 10.1007/s10120-012-0142-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
662 Laterza MM, Ciaramella V, Facchini BA, Franzese E, Liguori C, De Falco S, Coppola P, Pompella L, Tirino G, Berretta M, Montella L, Facchini G, Ciardiello F, de Vita F. Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells. Cancers (Basel) 2021;13:2339. [PMID: 34066144 DOI: 10.3390/cancers13102339] [Reference Citation Analysis]
663 Peixoto RD, Rocha-Filho DR, Weschenfelder RF, Rego JFM, Riechelmann R, Coutinho AK, Fernandes GS, Jacome AA, Andrade AC, Murad AM, Mello CAL, Miguel DSCG, Gomes DBD, Racy DJ, Moraes ED, Akaishi EH, Carvalho ES, Mello ES, Filho FM, Coimbra FJF, Capareli FC, Arruda FF, Vieira FMAC, Takeda FR, Cotti GCC, Pereira GLS, Paulo GA, Ribeiro HSC, Lourenco LG, Crosara M, Toneto MG, Oliveira MB, de Lourdes Oliveira M, Begnami MD, Forones NM, Yagi O, Ashton-Prolla P, Aguillar PB, Amaral PCG, Hoff PM, Araujo RLC, Filho RPDP, Gansl RC, Gil RA, Pfiffer TEF, Souza T, Jr UR, Jesus VHF, Jr WLC, Prolla G. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of gastric cancer. Ecancermedicalscience 2020;14:1126. [PMID: 33209117 DOI: 10.3332/ecancer.2020.1126] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
664 Namikawa T, Kawanishi Y, Fujisawa K, Munekage E, Iwabu J, Munekage M, Maeda H, Kitagawa H, Kobayashi M, Hanazaki K. Serum carbohydrate antigen 125 is a significant prognostic marker in patients with unresectable advanced or recurrent gastric cancer. Surg Today. 2018;48:388-394. [PMID: 29043453 DOI: 10.1007/s00595-017-1598-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
665 Palle J, Rochand A, Pernot S, Gallois C, Taïeb J, Zaanan A. Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives. Drugs 2020;80:401-15. [PMID: 32077003 DOI: 10.1007/s40265-020-01272-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
666 Lan T, Xue X, Dunmall LC, Miao J, Wang Y. Patient-derived xenograft: a developing tool for screening biomarkers and potential therapeutic targets for human esophageal cancers. Aging (Albany NY) 2021;13:12273-93. [PMID: 33903283 DOI: 10.18632/aging.202934] [Reference Citation Analysis]
667 Velho S, Fernandes MS, Leite M, Figueiredo C, Seruca R. Causes and consequences of microsatellite instability in gastric carcinogenesis. World J Gastroenterol 2014; 20(44): 16433-16442 [PMID: 25469011 DOI: 10.3748/wjg.v20.i44.16433] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
668 Okumura Y, Yamashita H, Aikou S, Yagi K, Yamagata Y, Nishida M, Mori K, Nomura S, Kitayama J, Watanabe T, Seto Y. Palliative distal gastrectomy offers no survival benefit over gastrojejunostomy for gastric cancer with outlet obstruction: retrospective analysis of an 11-year experience. World J Surg Oncol 2014;12:364. [PMID: 25432703 DOI: 10.1186/1477-7819-12-364] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
669 Kawakami H, Okamoto I. MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. Gastric Cancer. 2016;19:687-695. [PMID: 26690587 DOI: 10.1007/s10120-015-0585-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
670 Rudno-Rudzinska J, Kielan W, Grzebieniak Z, Dziegiel P, Donizy P, Mazur G, Knakiewicz M, Frejlich E, Halon A. High density of peritumoral lymphatic vessels measured by D2-40/podoplanin and LYVE-1 expression in gastric cancer patients: an excellent prognostic indicator or a false friend? Gastric Cancer 2013;16:513-20. [PMID: 23238856 DOI: 10.1007/s10120-012-0216-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
671 Hescheler DA, Plum PS, Zander T, Quaas A, Korenkov M, Gassa A, Michel M, Bruns CJ, Alakus H. Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data. Gastric Cancer 2020;23:627-38. [PMID: 32107691 DOI: 10.1007/s10120-020-01045-9] [Reference Citation Analysis]
672 Mavroeidis VK, Gkegkes ID, Saffioti F, Kandilaris K, Alexiou K, Horti M, Economou N, Demonakou M. Parietal cell/oncocytic gastric carcinoma: systematic review and first-time assessment of HER2 status in two new cases. Ann R Coll Surg Engl 2020;102:300-7. [PMID: 31928359 DOI: 10.1308/rcsann.2019.0183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
673 Iimori M, Kitao H, Maehara Y. Mad2 and BubR1: chemotherapeutic coordinators in gastric cancer. Cell Cycle 2015;14:946. [PMID: